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    SUMMARY 
 
Oropharyngeal candidosis (OPC) is a common opportunistic yeast infection in 
elderly and immuno-compromised populations, caused by Candida albicans and 
other Candida spp. forming biofilms on the oral epithelium or artificial denture 
surfaces. Oral thrush (pseudomembranous candidosis) is the most common type 
of OPC occurring when a biofilm grows on oral mucosal surfaces, while growth 
on  dentures  commonly  causes  denture  stomatitis  in  denture-wearers.  OPC 
causes significant morbidity with symptoms including inflammation, pain, burning, 
eating  difficulties  and  alteration  of  taste  sensation.  Conventional  antifungal 
treatments  have  limited  success  due  to  biofilm  resistance  mechanisms,  with 
recurring infections promoting development of azole resistance. Other problems 
with current antifungal drugs include toxicity, drug interactions and unpleasant 
taste. Therefore, alternative methods for prophylactic or therapeutic management 
of Candida spp. biofilms are desirable.  
 
This  study  aimed  firstly  to  evaluate  the  efficacy  of  tea  tree  oil  (TTO)  and  its 
derivatives against biofilms formed by a clinically-diverse panel of C. albicans 
isolates; and secondly to assess the toxicological effects of TTO exposure using 
a clinically relevant oral cell line. Thirdly, this study aimed to further investigate 
previously reported anti-inflammatory effects of TTO.  
 
TTO is a complex mixture of essential oils; however, individual components of 
TTO are commercially available. TTO has broad spectrum antimicrobial activity 
and TTO oral products are currently available. However, evidence for antifungal 
efficacy is limited and there are concerns regarding safety of long-term use of 
TTO products.  
 
The data presented demonstrate TTO and its derivatives are effective antifungal 
agents. Minimal inhibitory concentrations (MIC) of TTO and seven components                                                                                                
   
  xiii 
were determined for planktonic C. albicans cells (PMIC) using the standard CLSI 
dilution technique. The PMIC50 value for TTO was 0.5%, with lower values for two 
components - 0.25% for both terpinen-4-ol (T4-ol) and α-terpineol. Growth of all 
100 strains was inhibited by 1% TTO, 0.5% terpinen-4-ol and 0.5% α-terpineol. A 
pilot  study  found  no  decrease  in  TTO  sensitivity  with  multiple  TTO  exposure. 
Sessile  susceptibilities  (SMFC)  were  determined  using  a  metabolic  assay  on     
C. albicans cells after 24 h treatment of pre-formed biofilms, to determine the 
most effective anti-biofilm components. T4-ol and α-terpineol were potent biofilm 
inhibitors,  which  could  inhibit  biofilm  metabolism  by  50%  at  PMIC50 
concentrations  (SMFC50  =  0.25%),  exhibiting  significantly  greater  anti-biofilm 
activity than TTO (SMFC50 = 1%). Strains isolated from different patient groups 
had similar biofilm susceptibilities. Other components tested had little effect on 
biofilm  metabolism  (SMFC50  of  2%  to  >4%).  Shorter  treatments  modelling  a 
‘mouthwash’ exposure time produced moderate inhibition (50%) of pre-formed 
biofilm metabolism after 2 min in 1% α-terpineol, while longer exposures with 1% 
T4-ol (15 min) and 2% TTO (60 min) were required to give this level of inhibition. 
A time-dependent treatment effect for TTO and the single components was also 
seen at these concentrations, with longer exposures giving better inhibition of 
biofilm metabolism.  
 
Inhibition of biofilm formation and morphogenesis was also investigated to define 
effective components, concentrations and exposure times for prophylactic use. 
Presence  of  TTO,  T4-ol  or  α-terpineol  could  prevent  morphogenesis  of                
C. albicans, and therefore block biofilm formation, if present within 2 hours of 
adherence of cells to a surface. One hour treatments with PMIC50 levels of TTO 
(0.5%) or the 2 components (0.25%) could effectively prevent biofilm formation. 
Pre-coating  a  plastic  well  with  1%  TTO  prior  to  inoculation  resulted  in  strong 
inhibition (>50%) of biofilm formation.  
                                                                                                
   
  xiv 
Cellular cytotoxicity studies demonstrated that antifungal concentrations of TTO 
and T4-ol were cytotoxic to human cells in vitro. Investigations using a human 
oral epithelial cell line (OKF6-TERT2) and primary oral fibroblasts indicated that 2 
min exposures to TTO and T4-ol showed cytotoxic effects at 0.25%, comparable 
with 0.12% chlorhexidine, with 0.125% TTO / T4-ol being non-toxic. Previously 
reported  immunomodulatory  effects  were  investigated  using  non-toxic 
concentrations of TTO / T4-ol (0.125%). The cytokine response of oral epithelial 
cells  following  TTO  /  T4-ol  treatment  was  monitored  using  quantitative  PCR, 
protein  arrays  and  an  IL-8  ELISA.  TTO  did  not  exhibit  any  clear 
immunomodulatory  effects,  but  T4-ol  pre-treatment  of  zymosan-activated  cells 
resulted in reduced IL-8 protein in ELISA assays, indicating a potential to reduce 
inflammation. Although inflammation is a major symptom of OPC infections, it is 
also an important part of the host response to control the yeast pathogen. An 
anti-inflammatory agent may help to control candidosis symptoms, but may cause 
problems in controlling the infection. 
 
These studies demonstrate that T4-ol could be suitable for use in prophylactic 
oral hygiene products such as mouthrinses and denture cleansers, and also as a 
novel  treatment  for  established  OPC  infections.  The  use  of  T4-ol,  a  single 
component from TTO, has advantages over the complete essential oil in terms of 
product safety and consistency. Preclinical and clinical trials of mouthwashes or 
denture cleansers, containing the range of T4-ol concentrations (0.125 - 0.5%) 
investigated in these studies, would be required to validate the clinical use of 
such a product.  
 
 In conclusion, TTO-derived mouthwashes and denture cleansers may offer both 
a suitable alternative to conventional azole treatment of OPC and also a safe 
prophylactic  alternative  for  inhibiting  microbial  biofilms,  as  they  exhibit  potent 
antifungal activity.                                                                                                Chapter 1: Introduction 
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A healthy oral cavity can normally be maintained by regular brushing of teeth and 
dentures  to  remove  microbial  biofilms.  Patient  non-compliance,  environmental 
and  genetic  factors  result  in  this  microbial  biofilm  causing  diseases  such  as 
caries,  periodontal  disease  and  candidosis.  The  oral  healthcare  sector  has 
produced  a  wide  range  of  antimicrobial  products  including  toothpastes, 
mouthwashes  and  denture  cleansers.  However,  many  of  these  products  have 
side-effects associated with them, such as tooth staining, unpleasant aftertaste, 
tissue  irritation  and  resistance  problems  (Choo  et  al.,  2001).  Antiseptic 
mouthwashes  do  not  kill  all  oral  micro-organisms,  but  those  containing 
chlorhexidine are considered the most effective (Adams & Addy, 1994). However, 
chlorhexidine  also  has  the  aforementioned  side-effects.  Yeasts,  particularly 
Candida  species,  are  commonly  isolated  from  the  oral  cavity,  and  given  the 
opportunity  can  form  biofilms  resulting  in  various  forms  of  oral  candidosis. 
Candida  biofilms  can  resist  current  antifungal  treatments,  so  development  of 
novel, more effective prophylactic measures, with fewer side-effects, would be of 
great  clinical  benefit.  This  is  particularly  true  for  immuno-compromised  and 
elderly individuals, who are more likely to develop serious oral candida infections. 
The following section describes the role of Candida yeasts in oral candidosis, 
their  ability  to  exist  within  complex  biofilm  communities  and  conventional  and 
novel methods of chemotherapeutic intervention.  
 
1.1 Oropharyngeal Candidosis 
When  the  hosts’  innate  and  adaptive  immunological  defences  are  weakened, 
Candida species (spp.) can become opportunistic fungal pathogens, resulting in 
yeast overgrowth and penetration of the oral tissues (Akpan & Morgan, 2002; 
Webb et al., 1998a). This results in significant morbidity including oral pain and 
burning,  altered  taste  sensation,  and  eating  difficulties,  leading  to  nutritional 
problems (Finlay & Davies, 2005; Rossie & Guggenheimer, 1997; Wray & Bagg,                                                                                               Chapter 1: Introduction 
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1997). Acute oropharyngeal candidosis (OPC) is rare in healthy adults but occurs 
in up to 5% of newborn infants, who become infected during birth from mothers 
with  vaginal  candidiasis,  and  are  susceptible  due  to  their  immature  immune 
system  (Epstein  &  Polsky,  1998).  Around  10%  of  the  elderly  population  are 
affected by OPC, often due to a poor immune system, but also because denture-
wearers  are  susceptible  to  denture  stomatitis,  one  of  the  major  types  of  oral 
candidosis. Immunological impairment also increases OPC rates in patients with 
diabetes  mellitus  (Soysa  et  al.,  2006),  malignancies  such  as  leukaemia  and 
lymphoma (Davies et al., 2008; Rodu et al., 1988), neutropenia, or HIV infection 
where  OPC  indicates  possible  clinical  progression  to  AIDS  (Vazquez,  2007). 
Ninety  percent  of  patients  with  advanced  AIDS  develop  oral  candidosis, 
demonstrating the crucial role that the immune system plays in controlling growth 
of Candida spp. (Akpan & Morgan, 2002). Genetic autoimmune diseases such as 
autoimmune  polyendocrinopathy-candidiasis-ectodermal  dystrophy  (APECED) 
also cause chronic candidosis which is implicated in development of oral cancer 
(Rautemaa  et  al.,  2007).  Immuno-suppressed  patients  develop  OPC  due  to 
compromised host recognition of the pathogen and problems with activation of 
antifungal  defence  mechanisms  (Villar  &  Dongari-Bagtzoglou,  2008).    Other 
causes  are  use  of  broad-spectrum  antibiotics  which  alter  the  normal  oral 
microbial  flora  allowing  overgrowth  of  yeast  (Soysa  et  al.,  2008),  immuno-
suppressive therapies (corticosteroids or cytotoxic drugs) and radiation therapy 
(Soysa et al., 2004).  
 
Saliva is important in helping to control yeast growth in the oral cavity (Epstein, 
1990;  Peterson,  1992).  Salivary  flow  helps  remove  organisms  from  the  oral 
mucosa and dilutes any organisms. Reduced saliva causes a decrease in the pH 
of the mouth, which encourages increased yeast proliferation (Lundstrom et al., 
1984).  Saliva  also  contains  antimicrobial  proteins  (lactoferrin,  sialoperoxidase,                                                                                               Chapter 1: Introduction 
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lysozyme), anti-candidal antibodies (Nikawa et al., 1994) and phagocytes which 
can  regulate  growth  of  Candida  spp..  Salivary  gland  hypofunction,  commonly 
known as xerostomia or ‘dry mouth’, reduces salivary flow and is therefore a risk 
factor  for  OPC  (Guggenheimer  &  Moore,  2003).  Xerostomia  is  a  common 
symptom in the elderly (Turner & Ship, 2007) and patients with diabetes (Davies 
et  al.,  2006),  Sjögren’s  syndrome  (Radfar  et  al.,  2003),  and  those  receiving 
head/neck radiation therapy or many medications (Peterson, 1992). Other risk 
factors  include  dentures,  smoking (Soysa  &  Ellepola,  2005)  and  a  high  sugar 
diet. Glucose in saliva enhances yeast growth, as it can be utilised as an energy 
source, and also improves the adherence of candida cells to oral epithelial cells 
(Ohman & Jontell, 1988). 
 
There  are  several  different  types  of  oral  candidosis,  illustrated  in  Figure  1.1 
(Akpan  &  Morgan,  2002;  Odds,  1988;  Samaranayake  et  al.,  2009).  These 
include: 
 
·  Pseudomembranous (thrush) 
·  Atrophic and denture-induced stomatitis (erythematous) 
·  Angular cheilitis (stomatitis) ( 
·  Chronic hyperplastic (candidal leukoplakia) 
·  Median rhomboid glossitis 
 
The  commonest  form  of  acute  candidosis  is  pseudomembranous  candidosis, 
characterised  by  yellowish-white  plaques  on  the  surface  of  buccal  and  labial 
mucosa and also sometimes on the tongue, gums, palate or pharynx. This is 
commonly known as oral thrush. These plaques are composed of desquamated 
epithelial cells, fibrin and fungal hyphae. They can normally be scraped away to 
leave red or bleeding sites (Wray & Bagg, 1997). Symptoms, if present, include 
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erythematous candidosis normally gives a burning sensation in the mouth, with a 
bright  red  tongue  and  patchy  red  changes  on  the  palate.  The  erythematous 
mucosa  is  sensitive  and  painful,  and  can  be  difficult  to  diagnose.  It  often 
develops in patients taking antibiotics or steroid inhalers, and also in HIV-infected 
patients (Lewis et al., 1991).  
 
Chronic candidosis, including denture-induced candidosis, or denture stomatitis, 
occurs  when  the  yeast  grows  as  a  biofilm  on  the  denture  surface,  often  co-
aggregating with oral streptococci between the denture surface and the palatal 
mucosa,  causing  inflammation  and  pain  (Budtz-Jorgensen,  1990a;  Douglas, 
2003).  Movement  of  poorly-fitting  dentures  can  irritate  and  damage  the  oral 
mucosa,  allowing  access  of  the  yeast  to  the  mucosa  and  subsequent 
inflammation from the host response. Colonisation with C. albicans can be very 
high in denture-wearers, 78% compared to 37% for dentate patients (Abu-Elteen 
& Abu-Alteen, 1998), and denture stomatitis incidence rates of up to 65% have 
been reported in denture wearers (Dreizen, 1984). With over 15 million people in 
the UK wearing dentures (Coulthwaite & Verran, 2007), the problem is certainly 
significant. Rates can also be underestimated since patients often experience no 
symptoms  and  diagnosis  requires  removal  of  dentures  and  careful  inspection. 
Regular  cleaning  of  dentures  and  good  oral  hygiene  are  the  main  ways  to 
prevent denture stomatitis. Treatment includes correcting denture faults, cleaning 
dentures carefully and antifungal therapy (Jose et al., 2010; Samaranayake et al., 
2009).  
 
Denture wearers are also susceptible to angular cheilitis, which presents as an 
erythematous fissuring at one or both corners of the mouth (Budtz-Jorgensen, 
1990b; Cross & Short, 2008; MacFarlane & Helnarska, 1976). This inflammatory 
reaction is often caused by C. albicans, but may also involve bacteria, particularly                                                                                               Chapter 1: Introduction 
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Staphylococcus aureus and streptococci (Ohman et al., 1986). These infections 
can  become  severe  in  immuno-compromised  individuals  (Epstein  &  Polsky, 
1998). 
 
Chronic  hyperplastic  candidosis,  or  leukoplakia,  presents  as  bilateral  white 
lesions on the buccal mucosa, tongue and floor of the oral cavity. Candida spp. 
are often cultured from these lesions, but it is not clear if the yeast is the cause or 
simply  an  opportunistic  invader  of  damaged  tissue.  A  small  proportion  of  the 
lesions  are  pre-malignant  and  will  develop  into  cancer  (van  der  Waal  et  al., 
1997). The main risk factor for leukoplakia is smoking (Freitas et al., 2006).   
 
Median  rhomboid  glossitis  is  a  fairly  rare  condition  presenting  as  a  chronic 
symmetrical lesion on the tongue. It is linked with smoking and inhaled steroids, 
and  candida  can  be  isolated  from  around  85%  of  cases  (Budtz-Jorgenson, 
1990a).  There  are  a  number  of  excellent  reviews  on  the  causes,  types  and 
treatment  of  oral  candidosis  (Epstein  &  Polsky,  1998;  Pappas  et  al.,  2009; 
Samaranayake et al., 2009; Webb et al., 1998a, b, and c). 
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Figure 1.1:  Types of oral candidosis:   
(1)  pseudomembranous (thrush),   (2)  erythematous,   (3)  denture stomatitis,   
(4)  angular  cheilitis,    (5)  median  rhomboid  glossitis,    (6)  chronic  hyperplastic   
(leukoplakia)   [Akpan & Morgan, 2002; Samaranayake et al., 2009]. 
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1.2 Secondary effects of oral candidosis 
1.2.1 Oral cancer 
Consumption of high quantities of alcohol is known to increase oral cancer rates.  
Certain  yeast  and  bacterial  species  in  the  oral  flora  possess  alcohol 
dehydrogenase  enzyme  activity  (Meurman  &  Uittamo,  2008).  This  results  in 
production of acetaldehyde, a known carcinogen (Yokoyama et al., 2007). Many 
Candida  spp.  (Nieminen  et  al.,  2009)  and  oral  streptococci  (Kurkivuori  et  al., 
2007)  can  produce  acetaldehyde  from  ethanol  metabolism.  C.  albicans  and       
C. glabrata can also produce acetaldehyde from glucose fermentation (Nieminen 
et al., 2009; Uittamo et al., 2009). Patients with poor oral health status have been 
shown to have higher salivary acetaldehyde concentrations than those with better 
oral health (Homann et al., 1997; Homann et al., 2001). Therefore, it is plausible 
that poor oral hygiene may contribute to an increased risk of oral cancers. In 
contrast,  improving  oral  hygiene  with  alcohol-containing  mouthrinse  may  also 
have associated problems, as it has been shown that these mouthwashes can 
raise  localised  salivary  acetaldehyde  to  concentrations  associated  with 
carcinogenic effects (Lachenmeier et al., 2009). However, the evidence for this 
link is inconclusive at present.  
 
A recent study in Finland found high levels of oral cancer in a group of APECED 
patients,  a  rare  genetic  autoimmune  disorder  (Rautemaa  et  al.,  2007).  These 
patients  experience  recurring  oral  candidosis  which  has  to  be  controlled  with 
repeated  antifungal  drug  therapy.  10%  of  the  patients  over  25  years  of  age 
developed  oral  or  oesophageal  squamous  cell  carcinoma.  The  production  of 
acetaldehyde  by  the  yeast  was  suggested  to  be  the  cause  of  the  cancer 
(Uittamo, 2009). 
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1.2.2 Systemic candidiasis (candidaemia) 
A major concern is for the haematogenous spreading potential of Candida spp. 
from the oral cavity through the bloodstream to distal organ sites, resulting in 
severe systemic disease. This is a particular problem in immuno-compromised 
patients, where systemic candidiasis is associated with mortality rates in excess 
of 70% (Fraser et al., 1992; Migliorati & Madrid, 2007). The increased use of 
indwelling  biomaterials,  such  as  catheters,  has  inadvertently  assisted  in 
candidaemias  by  providing  substrates  on  which  Candida  spp.  can  grow  and 
proliferate as biofilm structures (Ramage et al., 2006b). A recent Scottish survey 
of candidaemia patients found a rate of 4.8 candidaemia cases per 100,000 of 
the population per year, which was higher than many other European countries 
(Odds et al., 2007). The prevalence of each species isolated is shown in Table 
1.1. The two predominant species were C. albicans and C. glabrata, representing 
75% of all isolates. 
 
Table 1.1: Candida species isolated from blood cultures in Scotland  
Adapted from Odds and colleagues (Odds et al., 2007) 
 
 
     Species 
 
Total no. of isolations 
 
No. of patients 
  C. albicans             156  (52%)     121  (50%) 
  C. glabrata      68  (22.7%)  50  (20.7%) 
  C. parapsilosis      35  (11.7%)  28  (11.6%) 
  C. guilliermondii    10  (3.3%)  7  (2.9%) 
  C. dubliniensis  9  (3%)  7  (2.9%) 
  C. tropicalis  6  (2%)  6  (2.5%) 
  C. lusitaniae  6  (2%)  6  (2.5%) 
  C. krusei  3  (1%)  3  (1.2%) 
  Other species     7  (2.3%)  2  (0.8%) 
  Mixed species        12  (5%) 
                                                                                               Chapter 1: Introduction 
 
                                                                                           
   
  10 
1.3 Candida species associated with OPC 
The  genus  Candida  is  a  collection  of  some  150  yeast  species,  in  the  class 
Deuteromycetes (Lodder, 1970). Seven Candida species are of major medical 
importance,  with  C.  albicans,  C.  glabrata  and  C.  tropicalis  being  the  most 
frequently isolated, representing over 80% of isolates from medical specimens 
(Scully et al., 1994). The frequency of infections by Candida spp. is increasing 
worldwide,  with  the  risk  of  infection  being  particularly  high  in  immuno-
compromised  and  hospitalised  patients  (Sims  et  al.,  2005). These  susceptible 
populations  are  growing  due  to  increasing  life  span,  development  of  better 
treatments for cancer, and also conditions associated with AIDS. Yeasts (mainly 
C. albicans) are the third leading cause of catheter-related infections, with the 
second  highest  colonisation  to  infection  rate  and  the  overall  highest  crude 
mortality  (Crump  &  Collignon,  2000).  Candida  spp.  are  part  of  the  normal 
commensal microflora of the skin, mouth, intestinal tract and vagina (Epstein & 
Polsky, 1998). They are frequently isolated from the oral cavity, with between 40 
to 60% of the population being carriers (Epstein & Polsky, 1998), but few of these 
carriers  develop  clinical  symptoms  (Soysa  et  al.,  2008).  Modern  sequencing 
techniques have recently shown that a wide range of candidal species are found 
in healthy individuals (Ghannoum et al., 2010). Candida spp. are present in saliva 
as planktonic cells (free-floating), which act as a reservoir for subsequent biofilm 
formation on the soft tissues, hard tissues and dentures.  
 
C. albicans is the leading opportunistic pathogen associated with oral candidosis, 
and  is  known  to  be  one  of  the  most  successful  species  at  forming  biofilms 
(Hawser  &  Douglas,  1994).  Other  species  that  can  cause  disease  include          
C. glabrata, C. parapsilosis, C. tropicalis, C. guilliermondii, C. krusei, C. lusitaniae 
and C. dubliniensis (Kennedy et al., 2006; Odds et al., 1998). Mixed infections 
are  common,  both  multiple  yeast  species  and  yeast  /  bacteria  combinations                                                                                               Chapter 1: Introduction 
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(Bagg et al., 2003; Coco et al., 2008; Davies et al., 2002; Sweeney et al., 1998; 
Thein et al., 2009). A recent study in Glasgow isolated 7 yeast species from 37 
denture-wearers, as shown in Table 1.2 (Coco et al., 2008). Yeast was cultured 
from 92% of the denture-wearers. The main species isolated were C. albicans 
and C. glabrata, the same as observed for the Scottish candidaemia study (Table 
1.1). These two species were found in combination in 25% of patients. C krusei, 
C.  parapsilosis  and  C.  tropicalis  and  Saccharomyces  cerevisiae  were  also 
identified.  Note  that  percentage  figures  total  over  100%  due  to  isolation  of 
multiple species in some patients. 
 
Table 1.2: Yeast species isolated from 37 denture-wearers in Scotland  
Adapted from Coco and colleagues (Coco et al., 2008). 
 
         Species  No. of patients 
C. albicans  28  (75%) 
C. glabrata     11  (29.7%) 
S. cerevisiae       4  (10.8%) 
C. krusei     2  (5.4%) 
C. parapsilosis     1  (2.7%) 
C. tropicalis     1  (2.7%) 
C. famata     1  (2.7%) 
Mixed species  13  (35%) 
No yeast isolated  3  (8%) 
            
 
C.  albicans  is  the  predominant  pathogenic  yeast  species  and  is  therefore  the 
most well studied. It has an arsenal of virulence determinants including its cell 
wall,  adhesins  (agglutinins),  degradative  enzymes  (proteolytic,  haemolytic  and 
lipolytic  enzymes)  (Naglik  et  al.,  2008),  dimorphic  behaviour  (Whiteway  & 
Oberholzer, 2004), thigmotropism and phenotypic switching (Calderone & Fonzi, 
2001).  These  phenotypic  characteristics  give  C.  albicans  a  competitive                                                                                               Chapter 1: Introduction 
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advantage in the oral cavity, but it is the immune-competence of the host that is 
crucial in determining whether clearance, colonisation, or candidosis will occur 
(Cannon et al., 1995; Whiteway & Oberholzer, 2004). However, local factors such 
as the presence of a denture, salivary flow and compliance with oral hygiene also 
play a key role. The pathogenesis of C. albicans is beyond the scope of this 
thesis. However, a key phenotypic trait associated with pathogenicity which has 
received  an  increasing  amount  of  attention  by  the  research  field  has  been  in 
relation  to  biofilm  formation  and  the  resulting  recalcitrance  to  antimicrobial 
treatment (Ramage et al., 2009). C. albicans biofilms play a key role in the oral 
cavity with respect to OPC and inflammation of the oral mucosa (Ramage et al., 
2004). 
 
1.4 Candida biofilms 
OPC is caused predominantly by yeasts growing as biofilms on oral mucosa or 
denture  surfaces,  with  C.  albicans  being  the  most  frequently  isolated  species 
(Ramage et al., 2005). Denture stomatitis is the most common condition caused 
by  biofilm  growth  on  a  prosthetic  device  (Douglas  2003).  C.  albicans  biofilm 
growth  on  biomaterial  surfaces  is  increasingly  becoming  a  major  source  of 
infection (Douglas, 2002; Kojic & Darouiche, 2004). Central venous catheters, 
plastic  tubes  used  for  the  administration  of  intravenous  fluids,  are  the  most 
commonly  infected  surgically-implanted  medical  devices  (Donlan  et  al.,  2001; 
Donlan,  2008;  Ramage  et  al.,  2006b).  Infections  can  be  endogenous,  when       
C. albicans is transferred to the catheter tip due to the intestinal mucosa being 
punctured, or exogenous, from contamination by hospital staff (Douglas, 2003).  
 
Biofilms can be defined as a community of microorganisms attached to a surface, 
which  is  embedded  in  a  complex  extracellular  matrix  of  polymers  (Donlan  & 
Costerton, 2002; Ramage et al., 2009). Mature biofilms can more easily form on                                                                                               Chapter 1: Introduction 
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non-renewing surfaces, such as teeth, dentures and catheters, rather than on 
rapidly  shedding  oral  mucosa.  Dental  plaque  is  an  excellent  example  of  a 
bacterial  biofilm,  being  composed  of  streptococci,  particularly  Streptococcus 
mutans, and a diverse range of other bacteria. The matrix is generally slimy and 
‘glue-like’, aiding attachment to a surface, and is very important in protecting the 
microbes from environmental factors, such as antibiotics (natural, as well as man-
made)  or  disinfectants  (Ramage  et  al.,  2005;  Ramage  et  al.,  2009).  The 
synthesis of matrix products, or exopolymeric substance (EPS), increases when 
a  developing  biofilm  is  exposed  to  a  liquid  flow  (Baillie  &  Douglas,  2000),  as 
demonstrated in Figure 1.2 (Ramage et al., 2001b). This allows the microbe to 
attach more strongly to a surface to avoid being detached and washed away. It 
has  been  shown  that  the  biofilm  can  become  denser,  but  with  a  reduced 
thickness, when exposed to greater shear stress (Mukherjee et al., 2009). An 
interesting potential way to treat biofilms is to use enzymes which can digest the 
EPS, to allow better penetration of antimicrobials (Johansen et al., 1997). 
 
 
 
    
Figure 1.2: Candida albicans biofilm with EPS from static and continuous 
flow models. (A) biofilm grown under static conditions, (B) biofilm grown in a 
continuous media flow model (250x magnification). Arrow indicates increase of 
EPS resulting in a cloudy film over the biofilm (Ramage et al., 2001b). 
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Growth rate within a biofilm can be very slow, partially due to a lack of nutrients 
(Douglas, 2003). This results in reduced uptake of antimicrobials, making these 
agents much less effective. As Candida biofilms are difficult to treat, preventative 
chemotherapeutic measures which stop biofilm formation are desirable (Ramage 
et al., 2006a).  
 
As biofilms have high intrinsic resistance to antifungal therapies and immune cell 
assault  (Ramage  et  al.,  2001c),  their  characteristics  and  organisation  are  of 
increasing interest and concern. C. albicans biofilms normally contain a mixture 
of morphological forms, as this species is polymorphic. A mature biofilm will be 
composed  of  a  dense  network  of  oval,  budding  yeast  cells  (blastospores), 
pseudohyphae and elongated hyphae (Hawser & Douglas, 1994). The hyphae 
are formed  when  the  blastospores form germ tubes  and  begin  to  elongate,  a 
process  which  allows  the  yeast  to  form  a  mature  biofilm  to  cover  a  surface. 
Polymorphism is an important virulence factor, affecting adherence to epithelial 
cells (Villar et al., 2004). It has been shown that some other species, particularly 
C. glabrata and C. parapsilosis, do not produce true hyphae, and so produce an 
inferior biofilm (Kuhn et al., 2002a; Mukherjee et al., 2005). Numerous changes in 
gene  expression  occur  as  C.  albicans  develops  into  a  biofilm  (Yeater  et  al., 
2007), i.e. cells in the biofilm have a very different phenotype to their planktonic 
forms.  This  is  caused  by  changes  in  expression  of  genes  involved  in  hyphal 
morphogenesis such as EGF1, CPH1, TEC1 and BCR1 transcription factors (Lo 
et  al.,  1997;  Nobile  &  Mitchell,  2006;  Ramage  et  al.,  2002d),  upregulation  of 
methionine  and  cysteine  biosynthetic  genes  (Garcia-Sanchez  et  al.,  2004), 
upregulation  of  azole  efflux-pump  genes  CDR1  and  MDR1  (Mukherjee  et  al., 
2003;  Ramage  et  al.,  2002a)  and  upregulation  of  the  ALS  (agglutinin-like 
sequence) gene family of adhesins (Chandra et al., 2001a; Dranginis et al., 2007; 
Green et al., 2004; Nobile et al., 2008). Nobile and Mitchell have published an                                                                                               Chapter 1: Introduction 
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excellent review which tackles this burgeoning field (Nobile & Mitchell, 2006). A 
recent study used microarray analysis of RNA to compare gene expression levels 
within an in vivo catheter biofilm to expression in planktonic cells (Nett et al., 
2009). 124 transcripts were up-regulated in the biofilm and it was shown that 
cells at early stages of biofilm formation expressed particular adherence genes 
not seen in mature biofilms. 
 
C.  albicans  biofilm  formation  can  be  considered  as  three  separate  phases 
(Chandra et al., 2001a):  
 
    1) Attachment and colonisation of yeast cells to a surface  
    2) Proliferation of cells to form a basal layer of anchoring cells   
    3) Growth of pseudohyphae and hyphae, along with production of EPS, to   
        produce a complex, mature biofilm  
      (Nobile & Mitchell, 2006; Ramage et al., 2001b).  
 
Figure 1.3 illustrates the main stages of C. albicans biofilm formation. Microbial 
biofilm  model  systems  have  recently  been  reviewed  (Coenye,  T.,  2010).                                                                                              Chapter 1: Introduction 
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Figure  1.3:  Biofilm  maturation.  Overview  of  main  aspects  of  Candida  albicans  biofilm  development,  from  scanning  electron  
micrographs (SEM) of Thermanox™ coverslips. The three main phases of biofilm development are illustrated, as previously described 
(Chandra et al., 2001a). The SEM images demonstrate initial adhesion, filamentation, hyphal and yeast proliferation, with maturation and 
associated extracellular matrix (ECM) production. The key development phases are indicated, along with respective timelines. 
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1.5 Treatment of OPC 
Candida species commonly colonise the oral cavity at low levels, and given the 
opportunity  can  form  biofilms  resulting  in  various  forms  of  oral  candidosis. 
Biofilms  formed  by  Candida  spp.  can  resist  current  antifungal  treatments,  so 
development  of  novel,  more  effective  prophylactic  measures,  with  fewer  side-
effects, would be of great clinical benefit. This is particularly true for immuno-
compromised and elderly individuals, who are more likely to develop serious oral 
candidal infections. The following describes conventional and novel methods of 
chemotherapeutic intervention.  
 
1.5.1 Dentifrices, mouthrinses and gels  
Oral hygiene products such as dentifrices (toothpastes), mouthrinses and gels 
have  been  available  for  many  years  to  improve  oral  health.  They  have  been 
developed  to  augment  mechanical  removal  of  microbial  biofilms  by  tooth-
brushing and flossing, particularly to reduce dental plaque, and hence prevent 
excessive  dental  caries.  Most  conventional  toothpastes  have  few  active 
ingredients other than detergents (surfactant), such as sodium dodecyl sulphate 
(SDS), and fluorides which have strong anti-caries effects. Fluoride has several 
beneficial  properties,  including  reducing  acid  demineralization  of  enamel  and 
enhancing  enamel  remineralisation  which  together  help  to  reduce  caries  (ten 
Cate  &  Featherstone  1991).  Fluoride  also  has  multiple  effects  on  microbial 
metabolism, including inhibition of acid production by plaque bacteria, and can 
sensitize biofilm organisms to acid killing (Marquis et al., 2003; Bradshaw et al., 
2002).  Some  products  also  contain  other  antimicrobial  ingredients,  including 
chlorhexidine  (Lie  &  Enersen,  1986),  triclosan  (Russell,  2004),  cetylpyridinium 
chloride (Davies, 2007) and essential oils (Ciancio, 2003; Fine et al., 2007).  
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Antimicrobial mouthwashes are particularly useful as their active ingredients can 
access  hard-to-reach  areas  such  as  interproximal  plaque,  which  can  help  to 
reduce  gingivitis  (Charles  et  al.,  2000a).  It  should  be  noted  that  commercial 
mouthrinses also contain many other ingredients which are often not specified by 
the  manufacturers.  In  particular,  ethanol  is  often  present  at  high  levels  to  aid 
solubility of ingredients. The antiseptic chlorhexidine (CHX) has been used in oral 
products for 50 years, is considered by dentists as the ‘gold standard’ bactericidal 
agent and also has fungicidal properties (Ellepola & Samaranayake, 2001; Hiom 
et  al.,  1992).  A  0.2%  solution  can  prevent  development  of  the  dental  plaque 
biofilm  if  used  regularly  (Al-Tannir  &  Goodman,  1994)  and  chlorhexidine 
gluconate has been accepted by the American Dental Association for gingivitis 
treatment  (Fischman,  1994).  It  can  adsorb  to  tooth  surfaces,  remains  highly 
protein-bound,  and  disrupts  bacterial  cell  membranes  (Russell  &  Day,  1993). 
However, long-term use can cause yellow-brown staining, affects taste, promotes 
calculus formation and can cause mucosal desquamation, thus reducing patient 
acceptance (McCoy et al., 2008). 0.2% CHX has been shown to be cytotoxic in 
vitro, in keratinocyte and fibroblast skin cells (Boyce et al., 1995) and also in 
gingival  fibroblasts  (Flemingson  et  al.,  2008).  CHX  can  also  cause 
hypersensitivity reactions including contact dermatitis (Calnan, 1962; Ebo et al., 
1998),  and  there  have  been  safety  concerns  as  immediate  systemic 
hypersensitivity (anaphylaxis) has been reported; in 1984 the Japanese Ministry 
of  Health  recommended  avoiding  chlorhexidine  use  on  mucous  membranes 
(Krautheim et al., 2004). 
 
It has been suggested that Gram-negative bacteria (particularly Pseudomonas 
spp.) can develop CHX resistance (Thomas et al., 2000). In vitro studies have 
shown  that  there  are  less-susceptible  bacteria  within  mixed  biofilms  which 
become  more  common  with  CHX  use  (McBain  et  al.,  2003).  However,                                                                                               Chapter 1: Introduction 
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longitudinal clinical studies have not found significant changes in susceptibility of 
oral  flora  with  CHX  use  (Maynard  et  al.,  1993;  Schiott  et  al.,  1976a  and  b; 
Sreenivasan & Gaffar, 2002).   
 
The antiseptic mouthrinse Listerine
TM (Johnson & Johnson Healthcare Products) 
contains  the  phenolic  essential  oils  eucalyptol,  thymol,  menthol  and  methyl 
salicylate as active ingredients (Jackson, 1997). It disrupts microbial cell walls 
and  inhibits  bacterial  enzymes,  but  is  less  effective  than  chlorhexidine  at 
preventing plaque and gingivitis. It has similar adverse effects to chlorhexidine, 
including  burning  sensations,  a  bitter  medicinal  taste,  occasional  staining  and 
potential tissue irritation. Burning sensation is caused by high alcohol content, 
which  can  be  up  to  28%.  Listerine
TM  does  not  disrupt  the  normal  oral  flora 
(Fischman,  1994).  Essential  oil  dentifrices  (toothpastes)  are  also  available 
(Charles et al., 2000b).  
 
Triclosan is a chlorinated phenol with broad-spectrum antibacterial properties. It 
has been used as a dentifrice in toothpaste in combination with a copolymer, 
polyvinylmethyl  ether  maleic  acid  (Volpe  et  al.,  1996),  which  increases  the 
retention  of  the  triclosan  on  oral  surfaces,  and  also  with  zinc  (Davies,  2007; 
Gilbert et al., 2007; Saxton, 1986). It has also been shown that triclosan has an 
anti-inflammatory  effect  (Ramberg  et  al.,  1995),  which  may  be  useful  for 
controlling  some  of  the  symptoms  associated  with  candidosis. 
Triclosan/copolymer has also been used successfully in mouthwashes (Ayad et 
al., 1995).  
 
Cetylpyridinium chloride, used in mouthwashes since 1940 (Davies, 2007), is a 
quaternary ammonium compound which, like CHX, binds to oral tissues (Radford 
et  al.,  1997).  It  also  binds  to  negatively-charged  phosphates  in  bacterial  cell 
membranes, which can disrupt the cell wall and increase permeability.                                                                                                Chapter 1: Introduction 
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1.5.2 Denture cleansers  
The recommended method for cleaning dentures is regular mechanical brushing, 
which  removes  thicker  biofilms  from  the  denture  surface  (Jagger  &  Harrison, 
1995; Nikawa et al., 1999). This is an important first step, as biofilms can resist 
antiseptic treatments (Gilbert et al.,1997). Ultrasonic devices are also available 
as  cleaning  aids.  However,  mechanical  cleansing  often  does  not  remove  the 
biofilm completely, and can damage the denture surface.  Brushing can increase 
surface roughness on the dentures (Oliveira et al., 2007), which aids attachment 
and colonisation by Candida sp (Young et al., 2009). Biofilms can form in cracks 
or  imperfections  in  the  denture  bases,  and  these  are  difficult  to  remove  by 
brushing (Ramage et al., 2002d). Microwave irradiation is an excellent alternative 
which damages yeast cell membranes (Campanha et al., 2007; Polyzois et al., 
1995; Sanita et al., 2008). However, there can be problems with shrinkage of 
denture-lining (Dixon et al., 1999; Seo et al., 2007). Chemical denture cleansers 
are often preferred by elderly and handicapped patients (Buergers et al., 2008). 
There are a wide variety of cleansing agents and disinfection regimens available 
to  remove  biofilms  from  dentures,  ranging  from  chemicals  such  as  sodium 
hypochlorite, glutaraldehyde, hydrogen peroxide and enzymes (Budtz-Jorgensen 
&  Kelstrup,  1977),  to  commercial  mouth  rinses  (Schwartz  et  al.,  1988), 
effervescent cleansing tablets (e.g. Steradent), and even vinegar. The evidence 
for  the  effectiveness  of  these  chemicals  is  conflicting  (Basson  et  al.,  1992; 
Buergers et al., 2008; Schwartz et al., 1988). They can also cause weakening of 
the  dentures  and  undesirable  colour  changes.  Therefore,  the  search  for 
alternative prophylactic and therapeutic strategies to reduce denture stomatitis 
and other forms of OPC is ongoing.  
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1.6 Conventional antifungal therapy    
When candidosis is unresponsive to basic oral hygiene, pharmaceutical-based 
treatment  commences  with  a  small  number  of  antifungal  drugs,  including 
polyenes (nystatin and amphotericin B) or azoles (fluconazole, itraconazole, and 
more  recently  voriconazole  and  posaconazole)  (Laudenbach  &  Epstein,  2009; 
Scheinfeld, 2007; Spreghini et al., 2008; Webb et al., 1998b). The echinocandin 
caspofungin is used primarily for systemic infection, but is highly active against  
C. albicans biofilms (Bachmann et al., 2002; Denning, 2003; Kauffman & Carver, 
2008;  Keating  &  Figgitt,  2003).  Whilst  these  drugs  are  often  effective,  some 
strains show multi-drug resistance, particularly non-albicans Candida isolates (Li 
et  al.,  2007;  Niimi  et  al.,  2010).  An  earlier  study  in  Glasgow  looked  at  azole 
susceptibility in 300 yeast strains isolated from oral cancer patients and found 
13% of strains were resistant to both fluconazole and itraconazole (Bagg et al., 
2006).  Strains  that  seem  sensitive  to  drugs  in  vitro,  i.e.  planktonic  CLSI  MIC 
testing, can be resistant in vivo, as the biofilm gives them considerable protection 
(Chandra  et  al.,  2001b;  Hawser  &  Douglas,  1995;  Ramage  et  al.,  2002c). 
Resistant C. glabrata isolates are most common, and such resistance may well 
become more of a problem in the future, as patients with candidosis often have 
recurring infections which require repeated drug treatments (Bagg et al., 2005). 
These  repeat  exposures  may  encourage  changes  in  the  fungal  population, 
selecting  for  more  drug-resistant  species  like  C.  glabrata.  Guidelines  have 
recently  been  issued  for  use  of  these  drugs  in  both  systemic  and  mucosal 
infections (Pappas et al., 2009). Many of these drugs are systemic and there are 
issues with drug interactions, particularly in patients with cancer or AIDS. The 
interaction of azoles with agents such as antacids, insulin, oral anticoagulants 
and corticosteroids influences the level of these agents in blood, which can affect 
their efficacy or toxicity (van der Bijl & Arendorf, 1993). These antifungal drugs 
can  also  adversely  affect  the  immune  response  of  epithelial  cells  (Lilly  et  al.,                                                                                               Chapter 1: Introduction 
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2005). Finally, many antifungals have a very unpleasant taste which results in 
considerable  patient  non-compliance  with  recommended  treatments.  In 
summary, failure of OPC treatment is caused by biofilm resistance to antiseptics 
and antifungal drugs, in combination with poor patient compliance, often due to 
side-effects. Therefore, alternative methods for suppressing biofilm formation or 
treating severe candidosis are desirable. 
 
1.7 Alternative therapeutic strategies from nature 
Early civilisations used plants as their main source of medicines, and most of the 
world’s population still rely on them today. Plants have evolved a multitude of 
components  to  attract  pollinating  insects,  avoid  mechanical  damage  and  give 
protection from microbial and parasitic diseases. These have been exploited to 
prevent and treat human infections. In oral hygiene, chewing sticks from various 
plants have been traditionally used for thousands of years for brushing teeth, like 
a primitive toothbrush (Wu et al., 2001). In many Muslim countries, these are 
known as miswak (Arabic for tooth cleaning stick), and are made from the roots 
and stems of Salvadora persica (Al-Otaibi & Angmar-Mansson, 2004). Clinical 
studies have shown that miswak extract could inhibit C. albicans (al-Bagieh et al., 
1994)  and  also  the  periodontal  bacterial  pathogen  Actinobacillus 
actinomycetemcomitans (al-Otaibi, 2004) which resulted in reductions in plaque 
and gingival indices compared to tooth-brushing. Recent scientific research has 
shown extracts from plants used for African chewing sticks to have antibacterial 
properties (More et al., 2008), while the leaves and twigs of Azadirachta indica 
(Neem) are widely used in India for cleaning teeth (Patel & Venkatakrishna-Bhatt, 
1988).  Chewing sticks are still recommended as oral hygiene tools in developing 
countries as they are easily available, cheap and simple to use. 
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Aromatic plants contain essential oils which have been extracted and used for 
centuries  in  herbal  medicine,  perfumes  and  food  flavourings.  These  oils  are 
composed of a vast variety of components, particularly terpenes, which have a 
multitude  of  properties  including  anti-cancer  and  antimicrobial  effects  (Edris, 
2007). Fungi are common plant pathogens and essential oils can protect plants 
from  fungal  diseases  (Terzi  et  al.,  2007).  Plants  used  for  their  essential  oils 
include garlic, lavender, thyme, mint, eucalyptus and lemon balm. 
 
1.7.1 Tea tree oil  
Another  of  these  plants  is  Australian  tea  tree,  Melaleuca  alternifolia,  in  the 
Myrtaceae family, commonly called narrow-leaved paperbark tree (Figure 1.4), 
which provides tea tree oil (TTO), one of the most widely used essential oils. TTO 
is an aboriginal traditional medicine for bruises, insect bites and skin infections 
(Altman, 1988; Low, 1990). This aromatic essential oil is a complex mixture of 
over 100 terpene hydrocarbons extracted by steam distillation from the leaves 
and terminal branches of M. alternifolia and related species. The antimicrobial 
properties  of  TTO  and  its  components  were  first  investigated  in  the  1920s 
(Penfold & Grant, 1925), and mentioned in the British Medical Journal as early as 
1933 (Anonymous, 1933a; Anonymous, 1933b). It has been used as a topical 
antiseptic since these early publications and also as a veterinary antiseptic for 
many years (Mozelsio et al., 2003; Reichling et al., 2004). M. alternifolia Cheel 
(name  of  major  chemotype)  has  been  grown  in  commercial  plantations  since 
1970, mainly in New South Wales (Carson et al., 2006). Currently it is used in 
skin, nail, hair care and oral products, particularly mouthwashes (SCCP, 2008). 
TTO has antimicrobial activity against a broad spectrum of organisms including 
Escherichia coli, Staphylococcus aureus (Caelli et al., 2000; Carson et al., 1995; 
Carson et al., 2002), oral bacteria (Hammer et al., 2003b), fungi (Hammer et al., 
2004;  Nenoff  et  al.,  1996),  viruses  (Schnitzler  et  al.,  2001;  Timpanaro  et  al.,                                                                                               Chapter 1: Introduction 
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2007)  and  also  protozoa  (Mikus  et  al.,  2000).  The  antimicrobial  properties  of 
individual TTO components have also been investigated (Carson & Riley, 1995). 
Much more research is required to understand the mode of action and safety of 
TTO, before it is fully accepted as an alternative prophylactic or therapeutic agent 
(SCCP, 2004 and 2008). 
 
                                                 
Figure 1.4: Melaleuca alternifolia, the source of tea tree oil 
 
1.7.2 Composition of TTO 
TTO is a complex mixture of mono-terpenes, sesquiterpenes and other aromatic 
molecules, with around 100 components being identified (Brophy et al., 1989). 
The composition is influenced by genetic variation (chemotype of plant), growing 
conditions (habitat and climate), age of leaves and length of distillation. The best 
product is obtained from plants growing in native, swampy habitat of New South 
Wales. There is an International Standard ISO 4730:2004, which sets maxima 
and / or minima for several of the components (ISO, 2004). Terpinen-4-ol (T4-ol), 
the major component, has to be at a minimum of 30% and maximum of 48%. The 
main components of TTO and their proposed chemical structures are illustrated 
in Figure 1.5.                                                                                               Chapter 1: Introduction 
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Component    % 
terpinen-4-ol  40 
 g g g g-terpinene  23 
 α-terpinene  10 
 1, 8-cineole   5 
 terpinolene  3 
  p-cymene  3 
 α-terpineol  2.5 
     Others  13 
 
Figure 1.5: Typical tea tree oil composition and chemical structures 
of components  
 
 
1.7.3 Oral TTO products 
Essential oil mouthwashes, such as Listerine
TM (section 1.5.1), are in common 
use  (Ciancio,  2003),  and  TTO  is  now  also  widely  used  in  mouthwashes  at  a 
concentration of around 0.2% (Vazquez & Zawawi, 2002). Many in vitro studies 
have reported its inhibition of C. albicans (Bagg et al., 2006; Banes-Marshall et 
al.,  2001;  D'Auria  et  al.,  2001;  Hammer  et  al.,  1998;  Hammer  et  al.,  2000). 
Previous research in Glasgow Dental Hospital  has shown sensitivity of azole-
resistant yeasts to TTO at concentrations used in oral care products (Bagg et al., 
2006). Additionally, TTO has been used successfully in palliative care patients, to 
treat severe OPC infections that do not responded to conventional antifungals 
(Dr.  M.P.  Sweeney,  personal  communication).  TTO  has  also  recently  been 
successfully used to reduce inflammation in denture stomatitis (Catalan et al., 
2008).  
terpinen-4-ol      g-terpinene      α-terpinene     1,8-cineole 
terpinolene        p-cymene         α-terpineol                                                                                               Chapter 1: Introduction 
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A small clinical trial evaluated an alcohol-based TTO mouthwash as a treatment 
of OPC in 12 HIV-positive patients who had been treated unsuccessfully with oral 
fluconazole  (Jandourek  et  al.,  1998).  Six  patients  improved  after  2  weeks 
treatment, while 2 patients’ infections were resolved and 6 others had reduced 
symptoms after 4 weeks treatment. In a follow-up study, the alcohol-based TTO 
was  compared  with  an  alcohol-free  solution  in  an  attempt  to  reduce  the  oral 
burning side-effects commonly seen in the first study (Vazquez & Zawawi, 2002). 
Sixty percent of patients demonstrated a clinical response to the Melaleuca oral 
solutions (7 patient’s infections resolved and 8 patients improved clinically) at the 
4-week  evaluation.  The  alcohol-free  solution  produced  fewer  side-effects  and 
cured 5 patients, compared to 2 for the alcohol-containing solution. A TTO gel 
has been investigated in a clinical trial for chronic gingivitis (Soukoulis & Hirsch, 
2004).  A  2.5%  TTO  gel  was  compared  with  a  0.2%  chlorhexidine  gel  and  a 
placebo gel. The TTO gel reduced gingival inflammation more than chlorhexidine, 
but did not inhibit plaque formation. Chlorhexidine mouthwash has been shown to 
reduce plaque formation (Lennon & Davies, 1975). 
 
1.7.4 Mode of Action 
TTO is a broad-spectrum, membrane-active disinfectant similar to chlorhexidine. 
It  denatures  proteins  and  disrupts  normal  cellular  membrane  structure  and 
function,  which  causes  cytoplasmic  leakage,  cell  lysis  and  death  (Cox  et  al., 
1998; Cox et al., 2000; Giordani et al., 2006; Hammer et al., 2004; Soderberg et 
al., 1996). TTO components are lipophilic hydrocarbons, which accumulate in the 
membrane lipid bilayer and alter both the structural and functional properties of 
the  membranes.  This  causes  loss  of  chemiosmotic  control  which  results  in 
swelling  of  the  bilayer.  The  cell  membrane  loses  its  integrity,  increasing  its 
permeability to protons and ions, which disrupts the intracellular pH. Membrane 
proteins are also significantly affected by the terpenes (Sikkema et al., 1995).                                                                                               Chapter 1: Introduction 
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Stationary  phase  microbial  cells  are  more  tolerant  to  TTO  than  exponentially 
growing cells, as their membranes have different lipid composition (Cox et al., 
1998). Respiration of bacteria and Candida spp. is significantly inhibited by TTO 
(Cox et al., 2000), again due to membrane disruption. It has been shown that 
0.5% TTO damages membranes of Escherichia coli, Staphylococcus aureus and 
C. albicans, allowing entry of the fluorescent stain propidium iodide (PI) (Cox et 
al., 2001). However, C. albicans was less permeable to PI than both the bacterial 
species,  while  leakage  of  potassium  ions  (K
+  efflux)  was  substantial  in  E.coli, 
moderate in S.aureus and not detected from the yeast cells. This demonstrates 
differences in TTO effects, due to variation in cell membrane structure between 
Gram-negative and Gram-positive bacteria and between bacteria and yeasts. 
 
In  C.  albicans,  0.125%  TTO  has  been  shown  to  block  morphogenesis  to 
filamentous  growth  by  inhibiting  germ-tube  formation  (D'Auria  et  al.,  2001; 
Hammer et al., 2000). This can potentially block biofilm formation, but the effect is 
reversible with removal of TTO, resulting in filamentation. T4-ol is considered the 
principal  antimicrobial  component  (Carson  &  Riley,  1995)  and  it  has  recently 
been  shown  that  it  is  a  more  potent  antibacterial  agent  against  methicillin-
resistant S. aureus (MRSA) and coagulase-negative staphylococci isolates than 
TTO, with neither agent exhibiting toxicity to fibroblast cells at the concentrations 
tested (Loughlin et al., 2008). Therefore, based on the data from these studies 
there is the potential of using purified components in mouthwashes and denture-
cleansing  agents.  Unfortunately  the  action  of  TTO  is  not  specific  to  micro-
organisms, as it can also disrupt human cell membranes.  
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1.8 Effects of Tea tree oil on Human Cells 
In addition to antimicrobial activity, TTO has been applied to skin for many years 
for its proposed anti-inflammatory activity. However, TTO is documented to exert 
both cytotoxic and immuno-modulatory effects on mammalian cells (Carson et al., 
2006). Data on safety and toxicity of TTO is relatively limited (SCCP, 2008), but 
for  it  to  be  used  as  an  oral  hygiene  product  it  should  conform  to  the  EC 
Cosmetics Directive 76/768/EEC – application to toxicity testing of oral hygiene 
products and TTO (updated by EU Regulation 1223/2009).    
 
The  membrane-disrupting  properties  of  TTO  are  non-specific,  affecting 
mammalian cells as well as micro-organisms. Yeast cells are eukaryotic and so 
have  many  similarities  to  human  cells.  Cytotoxicity  is  therefore  a  potential 
problem in development of clinical treatments containing TTO.  
 
1.8.1 In vitro studies 
A number of studies have investigated the effects of TTO and its constituents on 
a variety of cell types. In vitro testing of cell lines is considered an economical 
and  ethical  adjunct,  or  potential  alternative  to  animal  testing  (Hammer  et  al., 
2006). 
 
i) Cytotoxic effects 
The simplest in vitro studies use various cell lines grown as a monolayer or in 
suspension.  A  Swedish  study  determined  cytotoxic  concentrations  of  TTO  to 
fibroblasts and epithelial cells isolated from human gingival tissue (Soderberg et 
al., 1996). They calculated the IC50, i.e. the concentration giving a 50% reduction 
in cell viability after a 1 h treatment. Both cell lines had similar IC50 values around 
0.03%,  with  epithelial  cells  being  slightly  more  sensitive.  They  simultaneously 
established  that  TTO  demonstrates  an  MIC50  around  0.014%  against 
Staphylococcus aureus, suggesting that the bacteria are more sensitive than the                                                                                               Chapter 1: Introduction 
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human cells to TTO. An Australian study investigated the effects of TTO and 
three water-soluble constituents (terpinen-4-ol, α-terpineol and 1,8 cineole) on a 
variety of cell lines (Hayes et al., 1997). HeLa cells (epithelial) had an IC50 of 
0.28%  TTO,  some  cell  lines  showed  similar  susceptibilities  (K562  chronic 
myelogenous leukaemia, HepG2 hepatocellular carcinoma), while others (CTVR-
1 and MOLT-4 leukaemia cells) were more susceptible (IC50 0.06%), similar to the 
Swedish study described above. It was also shown that TTO was extremely toxic 
to monocytes and neutrophils, with a 20 h exposure of TTO giving an IC50 of 
around 0.016% (Hart et al., 2000). This toxic effect could be reduced significantly 
by  using  the  water-soluble  fraction,  containing  terpinen-4-ol,  α-terpineol  and    
1,8-cineole.  Preparation  of  the  TTO  dilutions  in  plastic  tubes  in  RPMI  media 
without serum resulted in the most toxic components adsorbing to the plastic. 
This  method  made  a  0.125%  TTO  dilution  non-toxic.  Finally,  another  study 
demonstrated that exposure to 1% TTO for 60 min was toxic for total leukocytes, 
whereas 0.1% TTO for 30 min was toxic to peripheral blood mononuclear cells 
(Caldefie-Chezet et al., 2006).  
 
In summary, relatively low concentrations of TTO (0.1% or less) can be toxic to a 
wide variety of cells, but cytotoxic effects depend on cell type, and the length of 
exposure and concentration. There can be technical difficulties working with TTO 
due  to  adsorption  of  some  components  to  plastic,  particularly  the  more  toxic 
ones, and results are also influenced by the technique used to measure viability. 
There  can  also  be  significant  variation  in  the  composition  of  oil from  different 
sources,  which  can  make  comparing  studies  difficult.  In  comparison, 
chlorhexidine gluconate, a routine antimicrobial found in many mouthwashes, has 
been shown to inhibit growth of epithelial cells and fibroblasts at concentrations 
of 0.005%, below the antibacterial concentration of 0.05% (Boyce et al., 1995). 
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This  study  suggested  that  topical  use  of  chlorhexidine  in  wounds  was  not 
advisable, due to its cytotoxicity. A recent study confirmed in vitro cytotoxicity in 
human gingival fibroblasts (Flemingson et al., 2008). A summary of some key 
findings from the literature is shown in Table 1.3. 
 
 
 
Table 1.3: Summary of inhibitory concentrations of TTO in human cells 
   
            Cell type 
IC50 
%TTO 
Treatment 
   Time (h) 
 
   Comments 
    
     Primary gingival  
     epithelial / fibroblasts 
     (Soderberg et al., 1996) 
 
    
     0.03 
    
       
        1 
      
   MIC50  0.014% 
    S. aureus 
 
     HeLa (epithelial) 
     HepG2 (liver carcinoma) 
     K562 (leukaemia) 
     (Hayes et al., 1997) 
                                 
     0.28 
   
        4 
 
     CTVR-1 / MOLT-4 
     (leukaemia) 
     (Hayes et al., 1997) 
 
     0.06 
   
        4 
 
     Monocytes / Neutrophils 
     (Hart et al., 2000) 
                  
    0.016 
   
       20 
   0.125% water-  
 soluble fraction is  
     non-toxic 
      Total leukocytes 
   (Caldefie-Chezet et al., 2006) 
     
       1 
       
        1 
 
      Peripheral blood  
     mononuclear cells 
  (Caldefie-Chezet et al., 2006) 
   
     0.1 
   
       0.5 
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Monolayer cell cultures of individual populations of cells are simplified models of 
mucosal cell surfaces. Organotypic models provide a more sophisticated system, 
comprising a multilayered epithelial structure with similar organization to the cells 
in  native  mucosal  surfaces.  Three-dimensional  models  of  oral  mucosa  have 
recently  been  developed  using  immortalised  oral  keratinocytes (OKF6-TERT2) 
and 3T3 mouse fibroblasts (Dongari-Bagtzoglou & Kashleva, 2006; Klausner et 
al.,  2007).  Fibroblasts  are  important  components  of  these  models,  promoting 
keratinocyte growth and differentiation into stratified squamous epithelia. These 
3-D  models  resemble  the  commercially  available  system  from  SkinEthic  (de 
Brugerolle de et al., 1999), which is based on TR146, a buccal carcinoma cell 
line.  
 
A  study  in  Japan  used  a  skin  model  comprising  keratinocytes  and  dermal 
fibroblasts within a collagen gel to test the cytotoxicity of cyclic monoterpenes 
(Kitahara  et  al.,  1993).  Terpenes  were  shown  to  prevent  proliferation  of 
keratinocytes and also inhibited fibroblast growth, which blocked contraction of 
the  collagen  lattice.  There  are  limited  studies  investigating  terpene  toxicity  in 
organotypic models. 
 
ii) Immunomodulatory effects 
There  is  now  strong  evidence  from  in  vitro  studies,  mainly  using  human 
monocytes  and  polymorphonuclear  neutrophils,  to  support  the  hypothesis  that 
TTO  is  anti-inflammatory  (Carson  et  al.,  2006).  Hart  et  al found  0.125% TTO 
significantly  inhibited  production  of  TNF-α,  IL-1b  and  IL-10,  but  not  the 
chemokine IL-8 in LPS-induced monocytes (Hart et al., 2000). They also showed 
similar  inhibition  by  0.05%  terpinen-4-ol,  though  IL-8  was  also  suppressed 
slightly.  This  same  group  investigated  the  effects  of  TTO  on  superoxide 
production by human phagocytic cells (Brand et al., 2001). They found that T4-ol                                                                                               Chapter 1: Introduction 
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suppressed production of oxygen derived reactive species in monocytes, but not 
in neutrophils. These cells produce superoxide when stimulated in vivo, and this 
is involved in host defence. The authors somewhat speculatively surmised that 
inappropriate or excessive activation of monocytes and neutrophils, leading to 
release  of  reactive  oxygen  species,  can  cause  bystander  tissue  damage, 
therefore suppression by terpinen-4-ol can be advantageous. In addition, they 
hypothesise that neutrophils are still able to eliminate any foreign antigens, but 
the  monocyte  suppression  can  limit  tissue  damage.  Another  study  showed  a      
3-fold  induction  in  IL-4  from  phytohaemagglutinin  (PHA)  lectin-stimulated 
peripheral  blood  mononuclear  cells  (PBMC)  by  0.1%  TTO  and  a  2-fold  IL-10 
induction  with  0.01%  TTO.  This  therefore  indicates  a  possible  simultaneous 
allergic  response  through  IL-4  induction  with  an  anti-inflammatory  effect 
associated with IL-10, making the overall interpretation of the data problematic. 
Moreover,  a  reduction  in  IL-2  was  observed  in  cells  treated  with  0.01%  TTO 
(Caldefie-Chezet et al., 2006). This study also found that 30 min in 0.1% TTO 
was highly toxic to PBMC. Therefore, the IL-4 induction is significant as the cell 
viability  is  low.  This  study  adds  to  the  evidence  for  the  anti-inflammatory 
properties of TTO, but this comes with certain caveats, i.e. other immune-induced 
pathologies. 
 
To date there has been no in vitro research published on the immunomodulatory 
effects of TTO on epithelial cells, the first cells exposed on skin or oral mucosa. 
Epithelial cells act as an infection barrier but also produce cytokines which are 
crucial  in  regulating  inflammation  (Dongari-Bagtzoglou  &  Fidel,  2005).  Oral 
epithelial cells produce pro-inflammatory IL-6 and IL-8 in response to bacterial 
infections (Yumoto et al., 1999) and also a strong IL-8 response to C. albicans 
(Dongari-Bagtzoglou  &  Kashleva,  2003;  Schaller  et  al.,  2002).  C.  albicans 
infection  of  human  oral  epithelial  cells  induces  strong  expression  of  the                                                                                               Chapter 1: Introduction 
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chemokine  IL-8  and  the  cytokine  granulocyte-macrophages  colony-stimulating 
factor (GM-CSF), as well as moderate induction of IL-1α, IL1β, IL-6, IFN-γ and 
TNF-α  (Schaller  et  al.,  2004).  This  leads  to  the  chemo-attraction  of 
polymorphonuclear leukocytes (PMNLs) to the site of infection, which results in 
reduced growth of the pathogen and hence less tissue damage. This cytokine 
response is strongest when the yeast strain is highly invasive (Villar et al., 2005).  
 
1.8.2. In vivo studies  
i) Dermal effects  
The most common use for TTO is in skin and hair care products and for the 
treatment  of  acne  and  skin  infections.  Therefore  most  in  vivo  data  relates  to 
dermal exposure, either in human users or in animal studies. TTO can be a skin 
irritant at higher concentrations, and allergies have been reported (de Groot & 
Weyland, 1992; Rutherford et al., 2007). However, rates have been very low in 
the  80  years  of  its  commercial  use  (Carson  et  al.,  2006).  A  recent  study  in 
Australia screened 2320 individuals using TTO patch testing and found 41 (1.8%) 
gave positive reactions (Rutherford et al., 2007). Only 17 (0.7%) of these people 
had allergic contact dermatitis. However, this study deliberately used TTO which 
had been allowed to oxidise, as they found that freshly-opened TTO produced 
very  weak  or  no  reaction.  It  is  thought  that  degradation  products  of  mono-
terpenes are the main allergens in TTO (Hausen et al., 1999). Another study 
using higher quality TTO in patch-testing found only 1 positive reaction in 217 
patients (<0.5%) (Veien et al., 2004). The same group tested four different 5% 
TTO lotions in 160 patients, resulting in no allergies, but with irritation in 3% of 
patients. This suggests that a 5% solution of TTO produces skin irritation in a 
significant  number  of  individuals.  TTO  is  therefore  a  skin  sensitiser  and  can 
induce  contact  allergy  (SCCP,  2008).  Allergic  skin  reactions  have  also  been 
reported  after  oral  intake  of  TTO.  A  patient  who  was  using  undiluted  oil  for                                                                                               Chapter 1: Introduction 
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external treatment of dermatitis subsequently had more severe dermatitis after 
ingesting some of the oil (de Groot & Weyland, 1992).   
 
Other plant essential oil products are known to have irritant and allergic effects. 
Contact dermatitis was seen in 14% of patients given lavender oil in a Japanese 
study  (Sugiura  et  al.,  2000).  There  have  been  isolated  reports  of  immediate 
systemic  hypersensitivity  (anaphylaxis)  to  TTO  (Mozelsio  et  al.,  2003).  For 
comparison,  chlorhexidine  exposure  can  also  cause  contact  dermatitis  and 
anaphylaxis (Evans, 1992; Krautheim et al., 2004).  
 
Several murine studies have shown inhibitory effects on inflammatory processes, 
including  reduced  contact  hypersensitivity  to  a  chemical  hapten  (Brand  et  al., 
2002a), reduced histamine-induced oedema (Brand et al., 2002b) and blocking of 
zymosan-induced inflammation by inhaled TTO (Golab & Skwarlo-Sonta, 2007). 
In humans, nickel-induced contact hypersensitivity can be reduced by the topical 
application of 100% TTO (Pearce et al., 2005). Both TTO (Koh et al., 2002) and 
terpinen-4-ol (Khalil et al., 2004) have been shown to reduce histamine-induced 
weal and flare reaction in human skin. This contrasts with the studies mentioned 
above  which  found  immuno-stimulatory  effects,  such  as  allergies/contact 
dermatitis, from TTO used at higher concentrations (Rutherford et al., 2007). This 
highlights the very complex nature of the immune system and also the complexity 
of TTO.  Studies have also been performed with individual TTO components (T4-
ol,  α-terpineol  and  α-terpinene)  in  research  focusing  on  other  essential  oils.  
These in vivo studies showed that T4-ol, α-terpineol and α-terpinene had direct or 
indirect anti-inflammatory activity (Moretti et al., 1997; Pongprayoon et al., 1997). 
Table 1.4 summarises some of these in vivo findings.  
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Table 1.4:  In vivo immuno-modulatory effects of TTO and components 
 
        
 
Treatment 
 
                    Effects   
 
 
Human 
studies 
 
  100% TTO 
 
 
100% TTO/ T4-ol 
 
Reduction in nickel-induced contact hypersensitivity 
    (Pearce et al., 2005) 
 
Reduced histamine-induced wheal/flare reaction  
    (Khalil et al., 2004; Koh et al., 2002) 
 
 
 
 
Murine 
studies 
 
 
      TTO  
 
 
 
      T4-ol,  
  α-terpineol,  
  α-terpinene 
 
Reduction in contact hypersensitivity (Brand et al., 
2002a), histamine-induced oedema (Brand et al., 2002b) 
and zymosan-induced inflammation (Golab & Skwarlo-
Sonta, 2007)  
 
Anti-inflammatory effects (Pongprayoon et al., 1997) 
 
 
 
ii) Systemic effects of oral exposure 
A large number of cases of human intoxication with TTO have been reported, 
often accidentally in young children and usually with no long term problems. The 
American Association of Poison Control Center reported 787 incidents in 2003 
associated  with  TTO  ingestion  (Watson  et  al.,  2004).  66%  of  these  cases 
occurred  in  children  less  than  6  years  old,  while  in  a  minority  of  cases  (28) 
adverse reactions occurred after individuals followed the recommendations for 
the product. However, in the majority of cases outcomes were either no effect, or 
minor  effects  such  as  skin  irritation.  No  deaths  have  been  reported  in  the 
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Symptoms  following  TTO  ingestion  range  from  ataxia,  drowsiness,  nausea, 
stomach pain and skin rashes, to an extreme case of one individual who ingested 
half a cup of pure tea tree oil, resulting in a 12 h coma followed by hallucinations 
then abdominal pain and diarrhoea for 6 weeks (Hammer et al., 2006; SCCP, 
2008).  TTO  is  categorised  as  a  Schedule  6  poison  in  Australia.  Substances 
within this category have “ a moderate potential for causing harm, the extent of 
which  can  be  reduced  through  the  use  of  distinctive  packaging  with  strong 
warnings and safety directions on the label ” (Hammer et al., 2006). The LD50 oral 
dose of TTO in rats was found to be 2300 mg/kg body weight (Russell, 1999). 
LD50 is the lethal dose that kills 50% of individuals. 
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1.9 Hypothesis 
It  is  our  hypothesis  that  derivative  compounds  extracted  from  Melaleuca 
alternifolia (tea-tree) have powerful antimicrobial properties which could be used 
as  novel  mouthwashes  and  denture-cleansing  agents,  or  to  augment  current 
treatments.  
 
1.10 Aims 
C. albicans is the predominant yeast associated with oropharyngeal candidosis 
(OPC), which presents most often clinically as thrush or denture stomatitis. These 
infections  are  characterised  by  multispecies  biofilms  forming  on  the  oral 
epithelium  or  artificial  denture  surfaces.  Current  antifungal  treatments  have 
limited success due to resistance of biofilms, with recurring infections common. 
Therefore, alternative methods for suppressing or eradicating such biofilms are 
desirable. The main aims of this investigation are as follows:  
 
1. Examine the effects of M. alternifolia derivative compounds on inhibition and 
killing of planktonic and adherent populations of C. albicans. 
 
2.  Examine the toxicological effects of M. alternifolia derivative compounds using 
an oral epithelial cell model. 
 
3.  Examine the immuno-modulatory capacity of these compounds. 
                                                                        Chapter 2: Materials and Methods                                                                                             
   
                      
   
  38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2:  
Materials and Methods                                                                        Chapter 2: Materials and Methods                                                                                             
   
                      
   
  39 
2.1 Antifungal susceptibility testing 
2.1.1 Chemicals and antifungal compounds 
All  chemicals  were  obtained  from  Sigma-Aldrich  (Poole,  Dorset,  UK)  unless 
otherwise stated. Tea tree oil (TTO) and seven HPLC-grade derivatives of the oil 
were  used  in  the  study.  The  derivatives  used  were  terpinen-4-ol,  α-terpineol,      
1,8-cineole,  terpinolene,  α-terpinene,  g-terpinene  and  p-cymene.  Stock 
concentrations of each component were freshly prepared for each experiment in 
RPMI-1640  medium  AutoMod™  (RPMI,  R7755),  containing  0.5%  (vol/vol) 
Tween
®80  (ICI  Americas  Inc.).  Tween
®80,  or  polyoxyethylene  sorbitan 
monooleate, is a non-anionic surfactant and emulsifier that aids the dispersal of 
the  TTO  and  derivatives,  some  of  which  are  not  water  soluble.  The  final 
concentration  of  Tween
®80  in  all  susceptibility  tests  was  0.25%  v/v.  All  stock 
solutions  were  vortex  mixed  thoroughly  in  plastic  bijoux  prior  to  aliquoting  for 
dilutions. Care was taken to ensure consistency when preparing serial dilutions in 
96-well  plates.  For  MIC  assays,  serial  dilutions  of  TTO,  T4-ol  and  α-terpineol 
were  prepared  in  advance  in  96-well  plates  and  stored  at  -80ºC,  as  this 
minimised differences in preparing serial dilutions and was shown not to affect 
antifungal  activity  of  these  solutions.  Fresh  dilutions  were  used  for  all  other 
derivatives in MIC testing, while dilutions of TTO and derivatives were prepared 
freshly  each  time  for  sessile  experiments  (Section  2.1.3).  For  conventional 
antifungal  drug  testing,  voriconazole  (VRZ,  [VFend®]  Pfizer  Pharmaceuticals, 
New  York,  NY,  USA)  was  obtained  in  a  10  mg/ml  vial  of  clinical  formulation, 
amphotericin B (AMB, [AmBisome®] Gilead Sciences, Foster City, CA, USA) was 
obtained  in  a  50  mg  vial  of  clinical  formulation,  and  caspofungin  (CSP, 
[Cancidas®]  Merck  Sharp  Dohme  Ltd,  White  House  Station,  NJ,  USA)  was 
obtained in a 50 mg vial of clinical formulation. Each antifungal drug (VRZ, AMB 
and CSP) was prepared at stock concentrations of 10 mg/ml in molecular biology 
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24 h of reconstitution. Fresh ampoules of antifungal drug were used for each 
experimental procedure.  
 
2.1.2 Candida albicans isolates 
One hundred clinical C. albicans isolates were used in the course of this study, 
from a variety of clinical sources. These included isolates from denture stomatitis 
patients at the Glasgow Dental Hospital and School (n = 26) (Coco et al., 2008), 
elderly  palliative  care  patients  from  the  Accord  Hospice,  Paisley  (n  =  30), 
neonates from the Royal Hospital for Sick Children (Yorkhill Division) (n = 36), 
and  strains  from  a  Scottish  bloodstream  infection  study  (n  =  8)  (Odds  et  al., 
2007). All strains were maintained on Sabouraud dextrose (SAB) agar (Oxoid, 
Basingstoke,  UK)  at  4
oC  and  stored  indefinitely  on  Microbank  beads  (Prolab 
Diagnostics) at -80
oC. The type strain C. albicans ATCC 90028 was used as a 
control strain. 
 
2.1.3 CLSI broth microdilution susceptibility testing 
Antifungal  testing  to  determine  the  minimal  inhibitory  concentrations  (MIC)  of 
TTO and constituent components in planktonic C. albicans cells was performed 
using  the  Clinical  Laboratory  Standards  Institute  M27-A3  broth  microdilution 
method  for  yeasts  (CLSI,  2008).  All  preparations  of  microtitre  plates  were 
performed  in  a  Microflow  laminar  flow  biological  safety  cabinet  (Bioquell  UK 
Limited, Andover, UK). 100 ml aliquots of RPMI containing 0.5% v/v Tween
® 80 
were dispensed into columns 2 to 8 on 96-well microtitre plates (round-bottomed 
wells), using a multichannel pipette. 200 ml of each stock TTO component was 
dispensed  into  column  1  and  then  serially  double  diluted  to  give  a  final 
concentration range of 2% to 0.03% (columns 1 to 7) after the addition of yeast 
suspensions. Note that the final Tween
®80 concentration was 0.25%, as each 
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preparation. Column 8 served as a positive control with a final concentration of 
0.25%  Tween
®  80  (100  ml  of  RPMI  /  0.5%  Tween
®80  added  with  no  TTO 
components to an equal volume of yeast solution). The plates were sealed with 
an  adhesive  lid  (Mylar  plate  sealers,  Fisher  Scientific,  Loughborough,  UK)  to 
prevent evaporation of the volatile TTO chemicals, stored at 4
oC, and used within 
24  h.  After  initial  testing  of  the  first  16  strains,  it  was  clear  that  lower 
concentrations of terpinen-4-ol (T4-ol) and α-terpineol ought to be used, as their 
MIC values were lower than TTO. Also, the other derivatives were ineffective at 
the lower concentrations, so a more limited dilution range was selected (Table 
2.1). For TTO, T4-ol and α-terpineol, serial double dilution plates were prepared 
in advance and stored at -80
oC, then thawed as required. This was shown not to 
diminish  the  activity  of  each  component,  and  improved  consistency  of  test 
solutions. 
 
Each clinical strain was propagated on SAB agar overnight at 30
oC. A loopful of 
culture was taken and a yeast suspension prepared in sterile phosphate buffered 
saline  (PBS:  10  mM  phosphate  buffer,  2.7  mM  potassium  chloride,  137  mM 
sodium chloride, pH 7.4 [Oxoid, Cambridge, UK]). This suspension was further 
diluted  1:10  in  PBS  to  enable  enumeration  of  cells/ml  in  a  Neubauer 
haemocytometer (Fisher Scientific, UK). Each strain was subsequently adjusted 
to a density of 10
5 cells / ml in RPMI. 100 ml (10
4 cells) of suspension was added 
to microtitre wells
 containing 100 ml TTO components, including the antifungal-
free positive control. The microtitre plates were then sealed with adhesive lids 
and  incubated  at  37
oC  for  24  to  48  h.  The  MIC  was  determined  by  directly 
visualising  yeast  growth  within  the  microtitre  plate  and  selecting  the  lowest 
concentration  of  each  derivative  that  inhibited  growth  of  the  test  isolate, 
compared to the positive control.   
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Table 2.1: TTO and derivatives, with range of concentrations tested 
                 Component  Planktonic (%)  Biofilm (%) 
Pure Tea tree oil  0.03 - 2  0.5 – 4 
terpinen-4-ol, α-terpineol  0.05 - 1  0.25 - 2 
1,8-cineole, terpinolene  0.5 - 1  2 
α-terpinene, g g g g-terpinene, r r r r-cymene  2  4 
 
 
 
2.1.4 Repeat exposure MIC testing 
C. albicans strains from 8 palliative care patients were selected to investigate the 
potential influence of multiple exposures to TTO on the susceptibility to TTO and 
conventional antifungal agents. MIC testing was performed as described above in 
a  96-well  plate  using  a  more  sensitive  range  of  TTO  of  0  -  1.2%  v/v,  in 
incremental  steps  of  0.1%  (all  containing  RPMI  with  0.25%  Tween
®80). 
Subcultures  were  taken  from  wells  using  a  48-pin  replica  plating  tool  (Boekel 
Scientific, Feasterville, PA, USA) and grown on SAB agar overnight to determine 
the minimum fungicidal concentrations (MFCs). Colonies were then sub-cultured 
(from the highest TTO concentration giving growth) onto another SAB plate to be 
used in the subsequent MIC test. CLSI MIC testing was also performed on each 
strain at the initiation of the experiment and after the final challenge with TTO 
using amphotericin B, voriconazole and caspofungin at a clinically relevant range 
(0.0625 to 32 mg/L). This provided an indication of the potential for TTO-derived 
mouthwashes to alter susceptibility of C. albicans strains to these conventional 
antifungal drugs (Section 2.1.1). 
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2.1.5 Sessile susceptibility testing 
Antifungal  susceptibility  testing  of  sessile  cells  was  performed  as  described 
previously (Ramage et al., 2001a). Isolates were propagated overnight in yeast 
peptone dextrose broth (YPD: 1% w/v yeast extract, 2% w/v peptone, 2% w/v 
dextrose [Oxoid]). 10 ml YPD was dispensed into 50 ml centrifuge tubes, then 
inoculated with a loopful of cells from SAB agar plates containing freshly grown 
isolates.  These  were  incubated  at  30
oC  overnight  in  an  orbital  shaker  at  400 
revolutions  per  minute  (rpm)  [Vortemp1550,  Labnet  International  Inc., 
Woodbridge, NJ, USA]. All strains grew in the budding–yeast phase. Cells were 
centrifuged at 3000 rpm for 10 min, and the pellet resuspended in 5 ml PBS. This 
was  diluted  1:100  in  PBS  and  enumerated  as  described  in  section  2.1.3.  All 
isolates were adjusted to 1 × 10
6 cells/ml in RPMI 1640. Biofilms were formed on 
commercially  available  pre-sterilised,  polystyrene,  flat-bottomed,  96-well 
microtitre plates (CLS3628 Corning, Sigma-Aldrich) by pipetting standardised cell 
suspensions (200 ml of 1 ´ 10
6 cells/ml) into each well of the microtitre plate (final 
inoculum of 2 × 10
5 cells/well), with a multichannel pipette, and incubating for     
24  h  at  37
oC.  Following  biofilm  growth,  media  was  removed  and  TTO 
components  serially  double-diluted  in  RPMI  containing  0.25% Tween
®80  (final 
concentration of 0.25% Tween
®80, as all serial dilutions were added directly to 
biofilm  in  well  without  any  further  dilution),  to  give  final  concentration  ranges, 
within the microtitre plate, for TTO, T4-ol and α-terpineol as indicated in Table 
2.1.  Only  one  concentration  was  tested  for  the  other  components,  as  lower 
concentrations  were  shown  to  be  ineffective  against the  biofilms. These  were 
incubated at 37
oC for 24 h. Antifungal-free wells (with RPMI / 0.25% Tween
®80) 
and  biofilm-free  wells  were  included  to  act  as  positive  and  negative  controls, 
respectively.  Sessile  minimal  fungicidal  concentrations  (SMFC50  and  SMFC80) 
were determined as the lowest concentration of antifungal giving a 50% or 80% 
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control, using the XTT reduction assay, as described below (Pierce et al., 2008; 
Ramage et al., 2001a; Ramage & Lopez-Ribot, 2005). Testing of these isolates 
was performed in duplicate.  
 
2.1.6 XTT- reduction metabolic assay  
XTT  (2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-carboxanilide) 
was prepared in a saturated solution at 0.5 mg/ml in PBS. The solution was filter-
sterilised through a 0.2 mm filter and 11 ml aliquots stored at -80
oC. Prior to each 
assay, an aliquot of stock XTT was thawed, and menadione (10 mM in acetone) 
added to a final concentration of 1 mM. XTT/menadione solution (100 ml) was 
then added to each biofilm in a 96-well microtitre plate, and to the control wells to 
measure background XTT-reduction levels. The plates were then incubated in 
the dark for up to 3 h at 37
oC and the colour change quantified in an automated 
microtitre plate reader (Tecan Sunrise, Jencons, East Grinstead, West Sussex, 
UK)  at  490  nm.  The  colorimetric  change  (colourless  to  orange)  in  the  XTT-
reduction assay directly correlates with the metabolic activity of the biofilm, as 
previously  described  (Ramage  et  al.,  2001a).  The  assay  is  based  on  the 
reduction of XTT tetrazolium to tetrazolium formazan by active mitochondria in 
the presence of menadione, an electron-coupling agent. XTT was also used in a 
cytotoxicity assay to measure epithelial cell metabolism, using an optimised 0.25 
mg/ml solution in appropriate cell medium (Section 2.2.4.1) 
 
2.1.7 Quantification of biofilm formation  
Biofilm biomass was assessed using a crystal violet assay (Mowat et al., 2007). 
Following biofilm formation, media was removed and the biofilms were air dried at 
37
oC in an incubator. Crystal violet solution (100 ml 0.5% w/v) was added to each 
well for 5 min to stain the biofilm. The solution was then removed by carefully 
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all unbound stain was washed off. All liquid was carefully removed before the 
biofilms were destained by adding 100 ml of 95% ethanol into each well. The 
ethanol was then gently pipetted several times to extract the dye from the cells; 
each well being treated in an identical manner with a multichannel pipette. 80 ml 
of  stained  ethanol  was  transferred  to  a  clean  96-well  microtitre  plate  and  its 
absorbance  read  at  570  nm  in  an  automated  microtitre  plate  reader  (Tecan 
Sunrise).  The  absorbance  values  are  proportional  to  the  quantity  of  biofilm 
biomass. 
 
2.1.8 Inhibition of biofilm formation 
The effects of TTO and its most efficacious antifungal components on the early 
stages  of  biofilm  formation  were  investigated.  Four  C.  albicans  strains  were 
plated on 96-well plates at 2 × 10
5 cells/well, as described in section 2.1.5. Cells 
were treated at 0, 1, 2 or 4 h after plating with TTO (0.5, 0.25, 0.125%), T4-ol 
(0.25, 0.125, 0.0625%), and α-terpineol (0.25, 0.125, 0.0625%). The cells were 
then incubated for the remainder of the 24 h period at 37
oC. The levels of biofilm 
inhibition  were  compared  to  an  untreated  control  (treated  with  RPMI  /  0.25% 
Tween
®80) using the crystal violet assay, and morphological effects assessed 
microscopically,  i.e.  blocking  of  hyphae  formation  as  a  mechanism  of  biofilm 
inhibition.  
 
In addition, to model a short 1 h denture soak, cells were plated as above and 
allowed  to  attach for  an  hour.  Solutions  of TTO  and  derivatives,  at  the  same 
concentrations as above, were then added to cells for 1 h only. TTO solutions 
were then removed, biofilm cells washed in PBS and fresh RPMI added for 24 h 
at 37
oC. Biofilms were assessed using crystal violet to quantify biomass.   
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2.1.9 Effect of adsorbing (coating) substrate with TTO 
In order to assess the effect of coating a surface with TTO prior to cells attaching 
to a surface, 96-well plates were coated with various dilutions of TTO prior to 
inoculation  with  C.  albicans,  in  order  to  examine  the  ability  of  TTO  to  inhibit 
fungal growth and biofilm formation. TTO doubling dilutions were prepared from 
2% to 0.015%, in RPMI / 0.25% Tween
®80, and 40 ml added to individual wells. 
Wells with only 0.25% Tween
®80 in RPMI were used as controls. Plates were 
sealed with adhesive lids and stored overnight in the fridge to allow adsorption to 
the polystyrene plate, then solution was removed and excess liquid allowed to 
evaporate in a laminar flow cabinet. Four C.albicans strains (DS18, 20, 22, 23 - 
denture stomatitis isolates) were selected to be plated in replicates at 2 x 10
5 
cells/well.  Plates  were  sealed  with  parafilm  and  incubated  overnight  at  37
oC. 
Biofilms were examined microscopically to examine morphology, and biofilm was 
quantified using the crystal violet assay. 
 
2.1.10 Effect of short exposures to TTO and derivative components on pre-
formed C. albicans biofilm metabolism 
Two  denture  stomatitis  C.  albicans  strains  (DS19  and  DS23  –  isolated  from 
denture stomatitis cases) were grown as biofilms on 96-well plate for 24 h (see 
section  2.1.5).  The  strains  were  chosen  to  represent  a  weak  biofilm  former 
(DS19) and a strong biofilm former (DS23). These biofilms were then treated with 
2% TTO, 1% T4-ol or 1% α-terpineol for 2, 5, 15 or 60 min. Control biofilms were 
treated with RPMI / 0.25% Tween
®80 for appropriate times. Experiments were 
performed  in  quadruplicate  for  each  strain.  The  test  compound  was  removed 
after  exposure  and  RPMI  used  to  rinse  biofilm  briefly.  XTT  was  immediately 
added as described in Section 2.3.4, to determine relative inhibition of biofilm 
metabolism compared to untreated biofilm cells.                                                                        Chapter 2: Materials and Methods                                                                                             
   
                      
   
  47 
2.1.11 Scanning electron microscopy  
Scanning electron microscopy (SEM) was used to examine the morphology of a 
24 h C. albicans biofilm, comparing untreated cells with TTO or T4-ol exposed 
cells. Strain YH28 (neonate throat swab), which forms a strongly adherent in vitro 
biofilm  as  assessed  by  metabolic  and  biomass  assays,  was  prepared  as  in 
Section 2.1.5, and then inoculated in a 24-well flat bottom plate at 10
6 cells/ml, 
each  well  containing  a  Thermanox™  coverslip  (Nunc  Inc,  Thermo  Fisher 
Scientific). Cells were allowed to attach to coverslips for 2 h, washed briefly in 
PBS  and  then  TTO (0.25%),  T4-ol  (0.125%)  or  control  media  (RPMI  /  0.25% 
Tween
®80)  was  added  to  wells  for  overnight  incubation  at  37ºC.  Treatment 
solutions were then removed, coverslips washed carefully in PBS to detach any 
loosely adherent cells from the biofilm, and processed for SEM. 
 
An additional pilot experiment was designed to test if TTO or T4-ol could prevent 
formation of a yeast biofilm on denture material. Denture acrylic discs (a kind gift 
of  Dr.  Donald  Cameron,  Department  of  Restorative  Dentistry,  University  of 
Glasgow)  made  from  polymethylmethacrylate  (PMMA),  were  pre-treated  by 
soaking for 60 min in 0.5% TTO, 0.5% T4-ol or PBS (control), then inoculated 
with 1 × 10
5 C. albicans cells (BC071), as described previously, and incubated for 
24  h  at  37
oC.  Discs  were  briefly  rinsed  in  PBS  to remove  non-adherent  cells 
before processing. 
 
SEM Processing: Biofilms were fixed for 2 h on coverslips or denture acrylic 
using 2% para-formaldehyde, 2% gluteraldehyde, 0.15 M sodium cacodylate and 
0.15% Alcian Blue, pH  7.4 (Erlandsen et al., 2004). The fixative solution was 
removed and 0.15 M sodium cacodylate buffer added to the samples, which were 
then stored at 4
oC. Cacodylate has an arsenic component that prevents growth of 
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After fixation, the cacodylate buffer was removed and biofilms washed 3 × 5 min 
with 300 µl fresh buffer to remove any remaining gluteraldehyde. Following this, a 
solution  of  1%  Osmium  tetroxide  (OsO4)  prepared  1:1  with  0.15  M  sodium 
cacodylate  buffer  was  added  to  the  samples  and  incubated for  1  h.  Samples 
were  then  washed  with  distilled  water  3  ×  10  min  to  remove  osmium.  0.5% 
aqueous uranyl acetate was added to wells and incubated in the dark for 30 min 
at room temperature. This step improves the conductivity of the sample. Uranyl 
acetate  was  then  removed  and  samples  quickly  rinsed  with  distilled  water. 
Samples were then dehydrated 2 × 5 min each in an ascending ethanol series 
using 30%, 50%, 70%, 90% ethanol, then 4 × 5 min absolute alcohol (100%) 
followed by 2 × 5 min dried absolute alcohol. Coverslips and denture discs were 
then placed in a glass petri dish of hexamethyldisilazane (HMDS) for 5 min, then 
transferred to another dish of HMDS for 5 min before placing in a 24-well plate 
lined with filter paper (HMDS will corrode plastic) to dry overnight in a dessicator. 
Critical  point  drying  and  attachment  of  samples  to  stubs  with  double-sided 
conductive tape and sputter coating were performed by Margaret Mullin at the 
electron microscopy suite (Integrated Microscopy Facility, Joseph Black Building, 
University of Glasgow) and viewed under a JEOL JSM-6400 scanning electron 
microscope. It should be noted that SEM dehydrates samples which results in 
complexity of biofilm structure being lost. 
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2.2 Mammalian cell interactions with antifungal compounds 
Epithelial  and  fibroblast  cell  lines  were  grown  as  adherent  monolayers  in  5% 
CO2,  37
oC.  All  culture  media  and  supplements  were  obtained  from  Invitrogen 
(Paisley, UK), unless otherwise indicated. 
 
2.2.1  Primary periradicular fibroblasts (PRD) 
Primary  periradicular  disease  (PRD)  fibroblasts  (kind  gift  of  Professor  Colin 
Murray, University of Glasgow), were chosen initially to screen a selection of TTO 
components to discover potential cytotoxicity issues, as once they are isolated 
they  are  easy  and  inexpensive  to  culture  (Osorio  et  al.,  1998).  They  were 
cultured for approximately 12 passages in standard Dulbecco’s Modified Eagles 
Medium (DMEM) with 10% Foetal calf serum (FCS) [F9665, Sigma-Aldrich UK],  
2 mM L-glutamine, 100 IU penicillin and 100 mg/ml streptomycin in a 75 cm
2 flask 
(658170, Greiner). PRD fibroblasts were isolated from tissue specimens obtained 
from  patients  undergoing  periradicular  surgery  within  the  Department  of 
Restorative  Dentistry,  or  routine  dental  extractions  within  the  Oral  Surgery 
Department. Patients were in good health and not taking long-term medication for 
chronic conditions. Specimens were collected in DMEM on ice and processed 
within  three  hours.  Periradicular  tissues  obtained  upon  dental  extraction  were 
carefully dissected off the dental root apex with a sterile Swan-Morton
® scalpel 
(Swann Morton, Sheffield, UK), taking care to avoid contamination from adjacent 
periodontal  ligament  cells  or  attached  periodontal  tissue.  PRD  tissue  was 
subsequently  minced  and  placed  in  DMEM  supplemented  with  10%  FCS, 
penicillin/streptomycin/amphotericin B in T25 CellStar
® flasks (Greiner Bio-One 
GmbH,  Germany)  and  placed  in  a  humidified  5%  CO2  incubator  at  37
oC. 
Fibroblasts were allowed to outgrow from the PRD tissue fragments over a three-
week period and the culture medium changed every 3-4 days.  
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At sub-confluence, fibroblasts were washed twice with PBS then detached with 
0.025%  trypsin  and  0.05%  EDTA  (Sigma,  Poole,  UK)  at  37
oC  for  5  min  and 
seeded into a T75 CellStar
® flask (Greiner Bio-One GmbH, Germany). Once PRD 
fibroblasts had reached 80% confluence, this procedure was repeated to prepare 
larger quantities of cells for freezing and subsequent experiments. All fibroblasts 
cultures used in experiments were at passage 6 to 10.  
 
2.2.2 OKF6-TERT2 oral epithelial cell line  
OKF6-TERT2 cells (kind gift of the Rheinwald laboratory, Brigham and Woman’s 
Hospital, Boston) are an immortalized human oral keratinocyte cell line. These 
cells have been immortalized by forced expression of telomerase, and resemble 
primary oral keratinocytes in studies of cytotoxicity or inducible cytokine and beta-
defensin expression (Dongari-Bagtzoglou & Kashleva, 2003). These cells were 
initially  used  in  the  in  vitro  cytotoxicity  assay  described  below  and  then  for 
immunomodulation  studies.  OKF6-TERT2  cells  were  cultured  in  keratinocyte 
serum-free medium (KSFM) [37010-022 Invitrogen] supplemented with 100 IU 
penicillin, and 100 mg/ml streptomycin, 25 mg/ml bovine pituitary extract (BPE), 
0.2 ng/ml epidermal growth factor (EGF) and 0.3 mM CaCl2 (0.4 mM total Ca
2+). 
BPE and EGF were filter-sterilised (0.2 mm). Cells were seeded at 5 x 10
3 / ml in 
a 75 cm
2 flask (10
5 cells / flask). At approximately 30% confluence, media was 
changed to a mixture of 50% KSFM, 25% DMEM, 25% Ham’s F12 with 1.5 mM 
glutamine, supplemented as above with penicillin / streptomycin, BPE and EGF. 
Cells  were  passaged  at  approximately  90%  confluence,  using  0.05%  Trypsin 
EDTA.  For  cytokine  assays,  cells  were  cultured  in  defined-KSFM  (10744-019, 
Invitrogen) to remove batch variability found in BPE. In defined-KSFM, BPE is 
replaced  with  defined  growth-promoting  additives,  including  insulin,  EGF  and 
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BPE  only  has  around  one  month  stability  in  medium,  compared  to  3  months 
stability of defined-KSFM. 
 
2.2.3 TR146 human squamous cell carcinoma cell line  
TR146 (Cancer Research Technology, London, UK) is a human epithelial cell line 
derived from squamous cell carcinomas of the head and neck (Rupniak et al., 
1985).  These  were  cultured  in  DMEM  (D5671,  Sigma-Aldrich  UK)  containing     
4.5 g/L of glucose and supplemented with 10% foetal calf serum (F9665, Sigma-
Aldrich UK), 2 mM L-glutamine, 100 IU penicillin and 100 mg/ml streptomycin in a 
75  cm
2    flask  (658170,  Greiner).  These  were  used  in  cytotoxicity  assays  as 
another epithelial cell line to compare with OKF6-TERT2. 
 
2.2.4 Cytotoxicity assays 
The above human cells were used to determine cytotoxic concentrations of TTO 
and various components. TTO and component dilutions were prepared in KSFM 
with  0.25%  Tween
®80  (KSFMT).  0.12%  chlorhexidine  gluconate  [C9394,  20% 
aqueous  solution,  Sigma-Aldrich]  (CHX)  in  KSFMT  was  used  as  a  positive 
control, as this has been previously demonstrated to exhibit cytotoxic effects on 
epithelial cells (Eren et al., 2002; Shakespeare et al., 1988). KSFMT was also 
used for the negative (untreated) control cells, i.e. control cells were exposed to 
KSFMT  without  TTO  or  component,  which  had  no  adverse  effects  on cellular 
viability and morphology. 
 
2.2.4.1 Modified XTT-reduction assay 
Cells were added to a 96-well plate at 2 x 10
4 cells / well in KSFM (or DMEM / 
10% FCS for fibroblasts) and incubated for 18 h, or until cells were 70 to 80% 
confluent. Media was then removed and cells treated with 50 ml test compound 
for 2 min. Test compound was removed and cells washed gently 3 times in 150 ml 
Hanks’  balanced  salt  solution  (HBSS,  Sigma-Aldrich  UK).  A  modified  XTT                                                                        Chapter 2: Materials and Methods                                                                                             
   
                      
   
  52 
reduction assay was used to assess metabolism of treated cells (Section 2.1.6). 
100 ml of 0.25 mg/ml XTT in KSFM (or DMEM / 10% FCS for fibroblasts) was 
added to each well and plates incubated in 5% CO2 at 37
oC for 2 to 3 h. The 
colour  change  was  then  quantified  in  an  automated  microtitre  plate  reader  at   
490 nm (Tecan Sunrise, Jencons, UK).  
 
2.2.5 Assessing interleukin-8 production by zymosan-stimulated OKF6 cells  
OKF6-TERT2 cells were inoculated into 96-well plates, at 2 x 10
4 cells / well in 
defined-KSFM  and  incubated  for  18  h  in  5%  CO2  at  37
oC.  Yeast-derived 
zymosan A (S. cerevisiae cell wall component Z4250, Sigma-Aldrich) was used 
as a positive control which activates inflammatory mediators (Huber & Weiss, 
1989). A stock solution was prepared in dimethyl sulphoxide (DMSO >99.5%, 
60153, Sigma-Aldrich) at 30 mg/ml, which was then diluted in cell-culture medium 
(defined-KSFM)  to  final  concentrations  between  10  and  100  mg/ml  (maximum 
final concentration of 1:300 DMSO). This concentration of DMSO was compared 
with cell culture medium alone and found to have no impact on mRNA or protein 
expression  (data  not  shown).  Zymosan  A  (zym)  is  a  glucan  with  repeating 
glucose units connected by β-1,3-glycosidic linkages, which closely resembles 
glucans  found  in  candida  cell  wall.  Zym  binds  to  Toll-like  receptor  2  (TLR2), 
activating  transcription  of  inflammatory  cytokine  genes  (Netea  et  al.,  2002; 
Roeder et al., 2004). A dose response curve was initially performed with various 
concentrations (0, 10, 100 mg/ml, Figure 6.1). Supernatants were subsequently 
harvested  at  4  and  24  h,  stored  at  -80
oC,  then  processed  for  detection  and 
quantification  of  extracellular  interleukin  8  (IL-8)  protein  using  enzyme-linked 
immunosorbent assays (ELISA), as described in Section 2.4.2. Experiments were 
performed in triplicate on 2 independent cell preparations. 
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2.2.6  Assessing  IL-8  production  by  zymosan-stimulated  OKF6  cells  pre-
treated with TTO and derivative components 
OKF6-TERT2 cells were plated and grown in 1.6 ml defined-KSFM in a 12-well 
cell culture dish, at a density of 2 x 10
5 cells / well and incubated for 18 h in 5% 
CO2 at 37
oC to give cells at around 80% confluency. Media was then removed 
prior  to  a  2  min  treatment  with  400  µl  0.125%  TTO,  0.125%  T4-ol  or  control 
media,  all  in  defined-KSFMT.  Solutions  were  then  removed  and  cells  gently 
washed 3 times with 2 ml HBSS. Finally, 2 ml of 50 mg/ml zym (containing1/600 
DMSO, i.e. 0.167% DMSO) was added to half the wells, while defined-KSFM with 
the  equivalent  concentration  of  DMSO  (0.167%)  was  added  to  control  wells, 
followed by incubation for 4 or 24 h. Supernatants were harvested and frozen at -
80
oC for subsequent analysis by cytokine protein array (Section 2.4.1) and ELISA 
to quantify IL-8 protein (Section 2.4.2). In addition, cells were harvested from the 
12-well  plate  into  1  ml  TRIzol
®  (Invitrogen,  Paisley,  UK),  according  to  the 
manufacturer’s instructions. The TRIzol
® cellular suspension was then stored at -
80
oC.  RNA  was  subsequently  extracted  for  use  in  PCR  to  quantify  gene 
expression (Section 2.3).   
 
2.3 Gene expression studies 
2.3.1 RNA purification 
TRIzol
®  samples  were  removed  from  the  -80
oC  freezer,  thawed  to  room 
temperature and processed for RNA purification according to the manufacturer’s 
instructions (Invitrogen, Paisley, UK). Briefly, 100 ml bromochloropropane (Fisher 
Scientific)  was  added,  the  samples  mixed  by  vortexing  for  30  seconds  then 
centrifuged at ×13000 g (relative centrifugal force) for 15 min at 4
oC. The upper 
aqueous clear layer was then removed and placed into a clean microcentrifuge 
tube and an equal volume of isopropanol (100%) added. This was then stored 
overnight at -20
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15 min at 4
oC. The resulting pellet was washed with 1 ml of 70% ethanol, air 
dried and resuspended in 15 ml of RNase-free water at 60
oC for 10 min. RNA was 
then treated with 2 units RQ1 Dnase I (Promega, Southampton, UK) at 37°C for 
30 min to remove contaminating genomic DNA, with a further 40 units RNase 
OUT  Ribonuclease  inhibitor  (Invitrogen)  added  to  minimise  RNA  degradation. 
Dnase I was then inactivated by adding 2 ml stop solution and incubating at 65
oC 
for  10  min.  RNA  concentration  and  quality  was  then  assessed  using  a 
NanoDrop™  spectrophotometer  ND-1000  (Labtech  International  Ltd,  Ringmer, 
East Sussex, UK), prior to reverse transcription (RT) to make cDNA.  
 
2.3.2 RT-PCR (Reverse transcription polymerase chain reaction) 
cDNA  was  prepared  using  Superscript  II  Reverse  Transcriptase  (Invitrogen) 
according to the manufacturer’s instructions. Briefly, 500 ng RNA was incubated 
in  RNase-free  water  with  0.5  mg  Oligo(dT)12-18  (Invitrogen)  and  10  mM  dNTP 
mixture at 65
oC for 5 min, quick chilled, then reverse transcribed using 100 U 
Superscript  II  RT  (Invitrogen)  at  42
oC  for  50  min  in  the  presence  of  the 
manufacturer’s buffer (50 mM Tris HCL (pH 8.3), 75 mM KCL, 3 mM MgCl2) with 
0.01 M DTT and 1 µl (40 U) RNase OUT Ribonuclease inhibitor (Invitrogen) in a 
total volume of 25 ml. Finally, the Superscript was inactivated by heating to 70
oC 
for  15  min.  Oligo  (dT)  binds  to  the  poly-A  tail  of  messenger  RNA  (mRNA), 
producing cDNA from any RNA transcripts.  
 
The presence of genomic DNA contamination of the final synthesised cDNA was 
evaluated using PCR with primers known to amplify both genomic and cDNA, on 
no-RT control RNA, performed in the absence of Superscript. Any RNA sample 
associated with a visible band was deemed to be contaminated, re-treated with 
DNase  and  re-examined  for  residual  DNA  contamination.  cDNA  was  used 
immediately in PCR or stored at -20
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cDNA was added to 47 ml of 1.1× ReddyMix™ PCR Mastermix (ABgene, Epsom, 
UK,  containing  1.25U  Thermoprime  Taq  DNA  polymerase,  75  mM  tris-HCl,        
20 mM (NH4)2 SO4, 1.5 mM MgCl2, 0.01% Tween
®20, 0.2 mM each dNTP, plus 
precipitant and red dye for loading into gel) and 1 ml each of 10 mM forward and 
reverse primers for the interleukin genes IL-1b, IL-6, IL-8 and the housekeeping 
gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primer sequences 
are shown in Table 2.2.  
 
The PCR conditions were as follows: 
  94 ºC / 2 min 
          94 ºC / 30 sec   
          50 ºC / 30 sec            x 35 cycles 
          72 ºC / 30 sec   
          
  72 ºC / 10 min 
 
Standard  PCR  analysis  was  performed  to  determine  relative  end-product 
amounts, after all cycles were completed. PCR products were visualised on an 
agarose gel as described below. 
 
2.3.3 Horizontal gel electrophoresis  
The PCR products were run on a 1.8% (w/v) agarose gel (Invitrogen), prepared 
with 0.5 ´ Tris borate buffer (1 litre 0.5 × TBE contains: 5.4 g tris base [Fisher 
Scientific, UK]; 2.75 g boric acid [Fisher Scientific, UK], 2 ml 0.5 M EDTA pH 8.0 
in distilled H2O). 50 ml agarose solution (Sigma-Aldrich, UK) was heated in a 
microwave oven until it was molten, cooled to 50
oC and 5 ml of ethidium bromide 
(10  mg/ml)  added  and  mixed.  This  was  then  poured  into  a  casting  tray  and 
allowed to solidify at room temperature. 15 ml of PCR product was loaded into 
each well. 500 ng (1 ml) of 100 bp DNA ladder (New England Biolabs, UK) was 
mixed with loading dye and loaded into a separate well to allow estimation of                                                                        Chapter 2: Materials and Methods                                                                                             
   
                      
   
  56 
PCR product size. The tank was connected to the electric source and run at 65 V 
for  1  h.  The  gel  was  observed  under  the  UV  light  excitation  and  the  image 
digitally  photographed (Bio-Rad  Gel  Doc  2000,  Bio-Rad  Life  Sciences,  Hemel 
Hempstead, UK). 
 
2.3.4 Real-time quantitative PCR  
A better method for accurate measurement of gene expression (mRNA) is real-
time PCR. This measures the DNA product at each cycle, which in turn is relative 
to amount of mRNA in sample template, and allows calculation of changes in 
gene expression caused by various treatments. 
 
A series of preliminary experiments were performed to optimise the quantitative 
PCR reactions. This helped prevent both inhibition problems from using excess 
cDNA and also sensitivity / reproducibility issues from using too little cDNA (data 
not  shown).  Serial  dilution  of  cDNA  was  performed,  demonstrating  consistent 
linear  amplification  of  cDNA  using  an  MxPro  MX3000P  Quantitative  PCR 
machine  and  analysed  using  the  Mx3000P  software  (Stratagene,  Amsterdam, 
Netherlands).  Standard  curve  analysis  was  undertaken  for  all  primer  pairs 
detailed in Table 2.2. Standard curves were then analysed, with R Squared (R
2) 
and amplification efficiency values exceeding 0.9 and 90% deemed acceptable. 
Each  50  ml  real-time  PCR  reaction  contained  the  following:  0.5  ml  of  1  mg/µl 
cDNA, 0.5 ml forward and reverse primer (10 nmol) (Invitrogen), 0.25 ml ROX 
reference  dye  (Invitrogen),  12.5  ml  SYBR
®  Green  (Invitrogen)  and  10.5  ml  of 
molecular biology grade dH2O. 
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 PCR reaction conditions were as follows: 
  95 ºC / 10 min 
          94 ºC / 30 sec 
          58 ºC / 30 sec       x 40 cycles 
          72 ºC / 30 sec 
 
  72 ºC / 10 min 
 
For each condition 1 in 20 dilutions of cDNA samples were prepared, and 2 ml of 
this  was  PCR-amplified  using  200  nM  primers  (0.5  ml  forward  and  reverse 
primers at 10 mM) and SYBR green (Invitrogen), as described above. Reactions 
were performed in duplicate in 0.2 ml optical tube strips (Agilent Technologies, 
South  Queensferry,  West  Lothian,  UK)  using  the  Mx3000P  QPCR  machine 
(Agilent technologies). A standard dissociation curve protocol was included after 
the 40 amplification cycles to confirm that only one product was made and this 
was also confirmed in initial experiments by running products on a 2% agarose 
gel. The threshold cycle (Ct) was automatically determined and verified manually. 
Amplification plots were observed at the logarithmic scale and threshold selected 
to be above any baseline fluorescence, in the region where amplification was 
exponential (steep curve) and where the majority of replicates gave very similar 
Ct  values,  i.e.  where  duplicate  amplification  plots  were  parallel.  IL-6  and  IL-8 
values were normalised using GAPDH as a housekeeping gene. No-RT controls 
were included to check for DNA contamination and no template controls, with 
water, were run to rule out other contamination problems.  
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Table 2.2: PCR primer sequences, showing location and product size 
 
 
 Target 
 
Sequence of primer 
 
Binding 
site 
   Product  
size 
 (base pairs) 
 IL-1b b b b F   TCCCCAGCCCTTTTGTTGA  1103 -1121  90 
 IL-1b b b b R   TTAGAACCAAATGTGGCCGTG  1173 -1193   
 IL-6 F   CAATCTGGATTCAATGAGGAGAC  373 - 393 
 IL-6 R   CTCTGGCTTGTTCCTCACTACTC  466 - 488 
115 
 IL-8 F   CAGAGACAGCAGAGCACACAA  21 - 41  170 
 IL-8 R   TTAGCACTCCTTGGCAAAAC  171 - 190   
 
GAPDH F   CAAGGCTGAGAACGGGAAG  282 - 300  133 
GAPDH R   GGTGGTGAAGACGCCAGT  397 - 414   
 
 
2.4 Protein expression studies 
2.4.1 Cytokine array 
A human cytokine protein array kit, Proteome Profiler panel A (ARY005, R&D 
Systems, Abingdon, UK), was used to measure cytokine production from OKF6-
TERT epithelial cells in response to TTO and terpinen-4-ol, both in the presence 
and absence of zymosan A  (zym). The kit contains nitrocellulose membranes 
pre-blotted with duplicates of 36 capture antibodies to human cytokine proteins 
(Figure  2.1A).  Cell  supernatants  can  be  mixed  with  a  cocktail  of  biotinylated 
detection antibodies and incubated with the membrane. Any cytokine/detection 
antibody complex will bind to the membrane via the capture antibody. Proteins 
are  detected  using  Streptavidin-horseradish  peroxidase  and  chemiluminescent 
detection reagents. The level of light produced at each spot is proportional to the 
amount of bound cytokine. This is a very useful way to simultaneously look at the 
relative levels of different cytokines within a sample.                                                                        Chapter 2: Materials and Methods                                                                                             
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Figure 2.1: Cytokine array membrane. 
A) schematic of the membrane layout  
B) example of a processed membrane 
 
Kits were used following manufacturer’s instructions, with all incubations done at 
room  temperature  (20° C),  all  buffers  were  supplied  by  the  manufacturer 
(formulation undisclosed). Briefly, membranes were blocked in 2 ml array buffer 4 
for  1  h  on  rocking  platform.  Supernatants  were  briefly  centrifuged  to  remove 
particulates  then  1  ml  was  mixed  with  500  ml  array  buffer  4,  15  ml  detection 
antibody cocktail and this mixture incubated for 1 h. Buffer was then removed 
from membranes, sample mixture added and membranes incubated overnight on 
rocking platform at 4
oC. 
 
Membranes  were  washed  3  times  in  20 ml  wash  buffer,  then  2 ml  of 1/2000 
Streptavidin-HRP antibody was incubated with membrane for 30 min on rocker, 
followed by 5 x 15 min washes in 30 ml wash buffer. Extensive washing was 
used  to  minimise  background.  500  ml  immobilon  western  chemiluminescent 
detection  reagent  (Millipore)  was  put  onto  membrane,  carefully  covering  the 
whole  surface,  and  incubated  for  5  min.  Excess  solution  was  drained  off  the 
membrane, blots put in clingfilm and exposed to X-ray film. Digital images were 
taken  of  the  developed  films  using  a  Bio-Rad  Gel  Doc  2000  (Bio-Rad  Life 
A 
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Sciences, Hemel Hempstead, UK) and spot density analysed using Quantity One 
software (Biorad). 
 
2.4.2 ELISA Assays 
Enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Abingdon, UK) 
were used in accordance with the manufacturer’s instructions. All assays were 
optimised  and  validated  prior  to  use.  Immulon  4  HBX  flat-bottom  96-well 
microtitre  plate  (Fisher  Scientific,  UK)  were  coated  with  IL-8  capture  antibody     
(4  mg/ml  in  PBS),  sealed  and  incubated  overnight  at  4
oC.  All  subsequent 
incubations were at room temperature. 200 ml blocking buffer was added for 1 h. 
Standards and samples were added in duplicate or triplicate, incubated for 2 h, 
and then biotinylated IL-8 detection antibody (20 ng/ml in TBS + 0.1% BSA + 
0.05% Tween
®20)  was  added  and  incubated  for  2  h.  Streptavidin-horseradish 
peroxidase  (HRP)  was  added  for  20  min,  protected  from  light.  Plates  were 
developed with 100 ml 3,3¢,5,5’-tetra-methylbenzidine (TMB, R&D Systems, UK). 
Blue colour was allowed to develop in the dark, and plates were read at 630 nm 
with  an  automated  microtitre  plate  reader  (Tecan  Sunrise,  Jencons,  UK). 
Between  each  step  described  above,  the  plate  was  washed  three  times  with 
wash buffer. For each wash, wells were filled with wash buffer and allowed to 
stand for at least 2 min prior to removal of buffer. After the third wash, remaining 
wash buffer was removed by pounding the plate on paper towels. The detection 
range  for  the  assay  was  60-2000  pg/ml.  A  standard  curve  was  prepared  to 
calculate concentration of IL-8 in samples. 
 
 
 
 
                                                                        Chapter 2: Materials and Methods                                                                                             
   
                      
   
  61 
ELISA Reagents 
Blocking buffer: PBS +1% BSA 
Wash buffer: PBS pH 7.2 with 0.05% Tween
®20 
TBS: Tris-buffered saline 20 mM Trizma base, 150 mM NaCl pH 7.2 - 7.4  
Detection antibody buffer: TBS + 0.1% BSA / 0.05% Tween
®20, 0.2 mm filtered 
Substrate solution: 1:1 mix of colour reagent A (H2O2) + colour reagent B (tetra-
methylbenzidine DY999, R&D Systems, UK).  
 
2.5 Statistical analysis  
Graphpad Prism, version 4.0 for Windows (Graphpad Software, CA, USA) and 
SPSS
®  software  (Statistical  Package  for  the  Social  Sciences,  Chicago,  USA) 
were used for statistical analysis to determine significant changes, p values less 
than 0.05. p is the probability of seeing a difference, by chance, as large as the 
observed difference, where there really is no difference (Altman,1991). 
 
2.5.1 Independent data analysis 
 One-way analysis of variance (ANOVA) and Dunnett’s t-tests were performed to 
compare untreated controls with all treatments of C. albicans strains, human cells 
(toxicity  and  gene  expression  studies),  and  pre-treated  surfaces.  In  antifungal 
experiments, ANOVA Kruskal Wallis tests and Dunn’s multiple comparison tests 
were  performed  on  all  datasets,  to  test  for  significant  differences  in  patient 
groups,  regarding  sensitivity  of  strains  to  TTO  and  components.  Time-course 
inhibition  data  was  analysed  using  the  Jonckheere-Terpstra  non-parametric 
multiple  comparison  test  with  SPSS
®,  to  test  for  ordered  differences  among 
groups  treated  with  different  drug  doses  at  different  time-points.  This  was 
followed  by  a  one-way  ANOVA  with  Bonferroni’s  correction  for  multiple 
comparisons to identify significant changes due to exposure time or antifungal 
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2.5.2 Non-independent data analysis (replicate data) 
Using  the  General  Linear  model  in  SPSS
®  software,  replicate  data  in  single 
experiments  were  analysed  by  repeated  measures  ANOVA,  with  Bonferroni’s 
correction for multiple comparisons, comparing all time-points/drug doses to no-
exposure  controls,  to  determine  treatments  giving  statistical  significant  effects 
(Olsen, 2003).  
 
Further details are given in results sections. 
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3.1 Introduction  
Tea tree oil (TTO) has been shown to be an effective antibacterial and antifungal 
agent in a number of studies (Martin & Ernst, 2004; Willcox, 2005). It has activity 
against  many  bacteria,  including  Staphylococcus  aureus  and  Pseudomonas 
aeruginosa (Papadopoulos et al., 2006), and has been investigated in relation to 
both  microbial  planktonic  and  biofilm  growth.  An  earlier  study  from  within  our 
research group, investigating the effect of TTO on a wide variety of oral yeast 
species of varying antifungal sensitivity (Bagg et al., 2006), showed that TTO was 
an effective in vitro antifungal agent (with MIC50 of 0.5% TTO), and both azole-
resistant and azole-sensitive strains of planktonic Candida albicans and Candida 
glabrata  were  equally  susceptible  to  TTO.  88%  of  the  azole-resistant  strains 
exhibited an MIC of 0.5% TTO or less. This current study focuses on C. albicans, 
as it is the main OPC pathogen, partly because it forms biofilms more readily 
than  many  other  Candida  spp.;  this  is  also  seen  in  vitro,  where  C.  glabrata 
isolates generally do not form biofilms. Further studies have also reported that 
TTO  has  potent  inhibitory  effects  against  C.  albicans  using  a  variety  of 
methodologies (Hammer et al., 2004; Vazquez et al., 2000). Whilst these studies 
have supported the evidence for the broad antimicrobial activity associated with 
TTO, its complex constituent nature has hindered its development as a drug, due 
to variation in the composition of the oil. Therefore, understanding the nature of 
the active component(s) of TTO is pivotal to optimizing TTO as an antifungal 
agent.   
 
Mondello  and  colleagues  (2006)  previously  observed  that T4-ol  was  the  most 
effective  component,  and  that  it  exhibited  activity  against  both  azole-sensitive 
and azole-resistant C. albicans (Mondello et al., 2006). Similarly, previous studies 
have reported that this component demonstrates both superior antifungal activity 
(Hammer et al., 2003a; Terzi et al., 2007) and antibacterial activity (Hammer et                                                                                       Chapter 3: Antifungal effects 
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al., 2003b; Raman et al., 1995). Both T4-ol and a-terpineol have hydroxyl groups 
in their chemical structures, making them moderately water-soluble, which allows 
them  to  diffuse  through  water  and  enter  cell  membranes,  unlike  the  water-
insoluble  derivatives  tested  in  this  study  which  were  not  effective  at  inhibiting 
growth of C. albicans, presumably due to their inert structure, i.e. lacking hydroxyl 
groups on their terpene ring. 
 
Increasing  use  of  conventional  antifungals  in  parallel  with  larger  groups  of 
susceptible  individuals  (ageing  population  and  immunosuppressive  therapies 
more common), has resulted in the emergence of multidrug-resistant Candida 
strains (Akins, 2005; Cannon et al., 2007; Niimi et al., 2010; Sanglard & Odds, 
2002), which require novel approaches to control. This risk is amplified by the 
rates of non-compliance for recommended drug treatment, caused by side-effect 
issues and an unpleasant taste. Candida glabrata has emerged in recent years 
as an oral pathogen, and azole-resistance has been shown to be more common 
in this species and other non-albicans Candida spp. (Bagg et al., 2003; Li et al., 
2007). C. glabrata can be innately less susceptible to azoles than C. albicans, but 
can also develop resistance with repeated exposure to the drugs. One of the 
main mechanisms of azole resistance is over-expression of efflux-pump genes to 
allow increased removal of drug molecules from the cell (Cannon et al., 2009; 
Niimi et al., 2010). In addition to the drug-barrier effect of the biofilm lifestyle, 
there is the opportunity for transfer of these efflux-pump genes from C. glabrata 
to C. albicans, conferring drug resistance in these mixed populations. This can be 
seen  as  a  symbiotic  relationship,  with  the  strong  biofilm  forming  C.  albicans 
giving protection to the C. glabrata cells, while C. albicans can potentially benefit 
from acquisition of beneficial genes.  
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TTO  treatment  may  have  value  in  controlling  these  problem  infections,  but 
because  this  is  a  complex  mixture  of  derivative  components  it  is  difficult  to 
develop as a defined antifungal agent. These studies sought to elucidate which 
components of TTO demonstrate highest antifungal activity (both on sessile and 
planktonic growth) and investigate the effects of repeated exposure to TTO on 
susceptibility of C. albicans to TTO and conventional drugs.  
  
3.2 CLSI (M27-A) MIC susceptibility testing of C. albicans 
The planktonic minimal inhibitory concentrations (PMIC) of tea tree oil (TTO) and 
7 monoterpene derivatives were determined for one hundred clinical strains of    
C. albicans, as described in section 2.1.3. A summary of this data is shown in 
Table 3.1.  
 
Table 3.1: Planktonic MIC values (%) for C. albicans isolates (n = 100) 
   PMIC ATCC 90028   PMIC50 range   PMIC50   PMIC90  
 Tea tree oil  0.25  0.125 – 1.0  0.5  1.0 
 terpinen-4-ol  0.125  0.0625 – 0.5  0.25  0.5 
 a a a a-terpineol  0.125  0.125 – 0.5  0.25  0.5 
 
 1,8-cineole  >1.0  0.5 – >1  1.0  >1.0 
 terpinolene  >1.0  0.5 – >1.0  >1.0  >1.0 
 a a a a-terpinene  >2.0  2 – >2  >2.0  >2.0 
 g g g g-terpinene  >10  2 – >2  >2.0  >2.0 
 r r r r-cymene  20  2 – >2  >2.0  >2.0 
 
The  PMIC50  and  PMIC90  are  defined  as the  lowest  concentrations  required  to 
inhibit growth of 50% and 90% respectively of the C. albicans strains tested; i.e. 
50%  of  isolates  growing  in  the  planktonic  phase  of  growth  were  inhibited  by                                                                                         Chapter 3: Antifungal effects 
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0.5% TTO, and all strains tested were inhibited by 1% TTO. Terpinen-4-ol (T4-ol) 
and α-terpineol exhibited stronger inhibitory effects, with both showing activity at 
0.25%, i.e. effective at half the PMIC50 of TTO. 1,8-cineole and terpinolene were 
less active than TTO, both requiring at least 1% to inhibit at least 50% of strains. 
The other derivatives tested were ineffective at 2% v/v. 
 
PMIC50  concentrations  for  all  strains  in  a  specific  patient  group,  i.e.  denture 
(n=26), palliative (n=30), neonate (n=36) and candidaemia (n=8), were plotted 
together to compare the susceptibility of C. albicans strains isolated from different 
groups to the most active TTO components. The data indicated that the PMIC50 
for each group were within the same range for TTO, T4-ol and α-terpineol (Figure 
3.1).  Nevertheless,  statistically  significant  differences  between  groups  were 
observed, but only for TTO and α-terpineol with regards to their planktonic MICs 
when  using  a  Kruskal-Wallis  test  (p<0.0001  and  p=0.0122,  respectively).  In 
Dunn’s  multiple  comparison  tests,  no  statistical  differences  in  PMIC50  values 
between  clinical  groups  were  observed  for  T4-ol  and  α-terpineol  treatment 
(p>0.05),  whereas  for  TTO  treatment  the  PMIC50  for  denture  isolates  was 
significantly  higher  than  for  both  the  palliative  care  group  (p<0.01)  and 
candidaemia group (p<0.001) (Figure 3.1, Table 3.2). Mann Whitney t-tests were 
subsequently  performed  for  the  α-terpineol  MICs  groups,  based  on  earlier 
statistical analysis with the Kruskal-Wallis test that indicated significance, and it 
was shown that the PMIC50 values for palliative candida strains were significantly 
lower than for the denture (p=0.024) and neonate (p=0.026) groups.                                                                                       Chapter 3: Antifungal effects 
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Figure 3.1: PMIC50 of TTO and selected monoterpene components 
Planktonic MIC’s of Candida albicans isolates from different patient groups were 
determined for A) TTO, B) T4-ol and C) α-terpineol. Box and whisker plots show 
range of PMIC50 values, with boxes indicating inner quartile range and median 
(long vertical line). Isolates: denture (n=26), palliative (n=30), neonate (n=36) and 
candidaemia (n=8). Differences between patient groups were assessed by a one-
way Anova Kruskal-Wallis test, Dunn’s multiple comparison tests (Table 3.2) and 
Mann  Whitney  u-test  (where  appropriate).  Statistically  significant  p  values  are 
indicated in the figure. 
 
B 
A 
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Table 3.2: Dunn’s multiple comparison tests on TTO PMIC50 
 
 
 Dunn's Multiple Comparison Test 
Difference in    
rank sum 
 
 P value 
 
Summary 
       Neonate vs Denture  -19.03  P < 0.05         * 
       Neonate vs Palliative  4.516  P > 0.05        ns 
       Neonate vs Candidaemia  30.33  P < 0.05         * 
       Denture vs Palliative  23.55  P < 0.01        ** 
       Denture vs Candidaemia  49.36  P < 0.001       *** 
       Palliative vs Candidaemia  25.82  P > 0.05        ns 
 
Isolates:  denture  (n=26),  palliative  (n=30),  neonate  (n=36)  and  candidaemia 
(n=8) 
 
3.3 Effects of repeated TTO exposure on C. albicans susceptibility 
Given that TTO has potential as an oral hygiene product, it is likely that there 
would be repeated use of the product on a daily basis. To assess whether this 
may  have  an  impact  on  sensitivity  shifts  to  TTO  a  limited  repeated  exposure 
experiment  was  designed  and  performed,  as  described  in  section  2.3.2. 
Planktonic  MIC  testing  for  TTO  was  performed  on  8  selected  palliative  care       
C. albicans strains using CLSI methodology, using a specifically defined decimal 
range of TTO (0 to 1.2% in incremental steps of 0.1%). The initial PMIC for TTO 
ranged from 0.125 to 0.5%. Subcultures were taken from wells using a replica 
plating tool and grown on Sabourauds agar overnight to determine MFC values. 
Colonies were then sub-cultured onto another SAB plate to be used in the next 
MIC test. After ten repeated exposures MIC values fluctuated for the majority of 
strains from 0.2% to 1% TTO (Figure 3.2). Strain 8 maintained a stable TTO 
PMIC at 0.8%, until the last pass (decreased to 0.6%). Any decreased sensitivity 
found during the experiment was not maintained to the endpoint. 1% TTO always                                                                                       Chapter 3: Antifungal effects 
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inhibited growth of every strain tested. No strain had decreased TTO sensitivity 
after 10 cycles of growth in TTO. 
                              
                              
Figure 3.2: Changes in TTO PMIC after repeat TTO exposures of C. albicans 
isolates  (1  to  8)  from  palliative  care  patients.  PMIC  values  fluctuated  by 
around  0.4%  for  each  strain,  while  no  PMIC  above  1%  TTO  was  found. 
Decreased TTO sensitivities were not maintained by any strains. 
 
In  addition,  susceptibilities  of  these  8  strains  to  conventional  antifungal  drugs 
(amphotericin B, voriconazole and caspofungin) were determined after 1 and 10 
exposures to TTO (Table 3.3). Decreases in susceptibility to amphotericin B were 
observed  after  10  exposures  in  strain  7  (0.125  µg/ml  compared  to  original  of  
0.06 µg/ml) and also to caspofungin in strain 3 and 8 (0.5 µg/ml compared to 
original 0.25 µg/ml). All other susceptibilities remained stable. Strain 5 was tested 
at  intermediate  exposures  to  determine  if  susceptibility  to  conventional 
antifungals  changed  during  the  experiment.  There  was  no  change  in  the 
antifungal susceptibility profiles (data not shown).                                                                                       Chapter 3: Antifungal effects 
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Table 3.3: Conventional antifungal PMIC values (mg/L) for 8 C. albicans  
                 strains after 1 and 10 exposures to TTO 
              Strain 
  Exposures 
1  2  3  4  5  6  7  8 
1  0.03  0.06  0.06  0.06  0.06  0.06  0.06  0.06   
AMB 
10  0.03  0.06  0.06  0.06  0.06  0.06  0.125
*  0.06 
                   
1  < 16  16  512  62  512  256  256  512   
VRZ 
10  < 16  16  512  62  512  256  256  512 
                   
1  0.5  0.25  0.25  0.25  0.25  0.25  0.25  0.25   
CSP 
10  0.25  0.25  0.5
*  0.25  0.25  0.25  0.25  0.5
* 
 
(AMB: amphotericin B, VRZ: voriconazole, CSP: caspofungin) 
* bold denotes change in PMIC after 10 exposures to TTO 
 
3.4 Sessile susceptibility testing of C. albicans pre-formed biofilms 
Sessile susceptibility testing was performed as previously described (Ramage et 
al., 2001a). The clinical isolates were grown for 24 h to form biofilms and then 
incubated with TTO or its derivatives (in RPMI / 0.25% Tween
®80) for a further 24 
h. Inhibition was calculated by comparing with control biofilms incubated for 24 h 
in  RPMI  /  0.25%  Tween
®80.  The  50%  and  80%  sessile  minimal  fungicidal 
concentrations (SMFC) of TTO and 7 derivatives were determined using an XTT 
assay for all C. albicans strains, as shown in Table 3.4. Strains which formed 
poor biofilms were excluded from the analysis, leaving 69 isolates in this part of 
the study. An example of the XTT assay is shown in Figure 3.3.                                                                                        Chapter 3: Antifungal effects 
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Figure 3.3: Treated C. albicans biofilms in wells of 96-well plates, showing 
orange colour produced by cell metabolism of XTT.  Overnight treatment with 
0.25%  concentrations  of  TTO  or  T4-ol  effectively  kills  cells,  showing  as  pale 
orange wells. Lower concentrations have little effect. 
 
Table 3.4: Sessile MFC values (%) for C. albicans isolates (n = 69) 
 
*SMFC50 Range   *SMFC50   SMFC80  
TTO            1 –  4             1  2 
 
terpinen-4-ol        <0.25 – >1           0.25  0.5 
a a a a-terpineol         <0.25 – 1           0.25  0.5 
1,8-cineole          <2 – >2              2  >2 
terpinolene            2 – >2            >2  >2 
a a a a-terpinene            4 – >4              4  >4 
 
g g g g-terpinene            4 – >4            >4  >4 
 
     r r r r-cymene            4 – >4            >4  >4 
 
 
*SMFC50 and SMFC80 are defined as the concentrations required to inhibit biofilm 
metabolism  by  50%  and  80%  respectively,  compared  to  the  control  biofilm  in 
RPMI / 0.25% Tween
®80, as quantified by the XTT assay.  
0 
0.06% 
0.125% 
0.25% 
T4-ol 
 0  
 0.125% 
 0.25% 
 0.5% 
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1% TTO reduced biofilm metabolism by at least 50% in the majority of strains 
(SMFC50 = 1%). T4-ol and α-terpineol were more active than TTO (SMFC50 = 
0.25%),  effectively  inhibiting  biofilm  metabolism  at  the  planktonic  MIC50 
concentration.  1,8-cineole  gave  an  SMFC50  of  2%,  double  that  of  TTO.  The 
remaining derivatives exhibited poor inhibition of biofilm metabolism (SMFC50 > 
2%). In summary, TTO was shown to have strong antifungal properties against a 
wide  range  of  clinical  C.  albicans  isolates  and  the  two  derivatives,  T4-ol  and       
α-terpineol, were both more potent than the TTO mixture. 
 
SMFC50  concentrations  for  all  strains  in  a  specific  patient  group,  i.e.  denture 
(n=12), palliative (n=25), neonate (n=24) and candidaemia (n=8), were plotted 
together to compare the susceptibility of C. albicans strains from different groups 
to the most active TTO components. SMFC50 ranges for isolates from different 
clinical  groups  were  statistically  similar  (Figure  3.4).  No  statistical  differences 
were  observed  following  one-way  Anova  Kruskal-Wallis  analysis  and  Dunn’s 
multiple comparison tests (p>0.05).  
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Figure  3.4:  SMFC50  values  for  selected  treatments  with  TTO  and 
components,  plotted  in  different  patient  groups.  Sessile  MFC50  values  of      
C. albicans isolates were assessed for A) TTO, B) T4-ol and C) α-terpineol. The 
XTT reduction assay was used to measure metabolic activity after 24 h treatment 
of mature biofilms. Box and whisker plots show range of SMFC50 values, with 
boxes indicating inner quartile range and median (long vertical line). Differences 
between patient groups were assessed by a one-way Anova Kruskal-Wallis test 
and Dunn’s multiple comparison tests. No statistical differences between groups 
were  found  for  TTO,  T4-ol  or  α-terpineol  treatment  (p>0.05).  Strains  in  each 
group: Denture (n=12), palliative (n=25), neonate (n=24) and candidaemia (n=8). 
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3.5 Metabolic reduction of biofilms following PMIC90 exposure   
The previous data in Figure 3.4 illustrates inhibitory profiles at defined ranges for 
TTO, T4-ol and α-terpineol, but provides little quantitative data in relation to how 
these components perform in relation to killing the cells within the biofilm. This 
analysis examines the specific percentage of metabolic reduction of the biofilms 
when  exposed  to  defined  planktonic  MIC90  levels  of  TTO  or  individual 
monoterpene components (Figure 3.5). Note how T4-ol and α-terpineol at these 
low  concentrations  maintain  sustained  activity  within  the  biofilm,  and  are  both 
significantly more effective than TTO (* p<0.001). 
 
Figure 3.5: Reduction of biofilm metabolism on exposure to PMIC90 levels of 
TTO  components  (n=69  strains).  The  concentrations  of  the  various 
components, based on planktonic MIC90 levels, were TTO (1%), T4-ol (0.5%),     
g-terpinene (4%), α-terpinene (4%), 1,8-cineole (2%), terpinolene (2%), p-cymene 
(4%) and α-terpineol (0.5%).  Components are arranged in order of abundance in 
TTO, from left (most abundant) to right. Box and whisker plots show data range 
(outliers removed), with boxes indicating inner quartile range and median. T4-ol 
and α-terpineol at these low concentrations are significantly more effective than 
TTO (* p<0.001).  
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Figure  3.5  illustrates  the  difference  in  anti-biofilm  potencies  of  the  various 
components in relation to the effect of 1% TTO.  For each treatment there were a 
small number of strains  which  were poorly inhibited, but the box and whisker 
plots illustrate that the majority of strains were inhibited metabolically by a similar 
proportion,  within  an  approximate  20%  range.  Several  derivatives,  namely           
g-terpinene,  α-terpinene,  terpinolene  and  p-cymene  had  minimal  fungicidal 
activity on C. albicans biofilms. In contrast, T4-ol and α-terpineol (both in purple) 
were  very  effective;  0.5%  of  each  giving  higher  rates  of  metabolic  inhibition 
(mean 77%) than 1% TTO (mean 61%). Statistical analyses using a one-way 
Anova Kruskal-Wallis test and Dunn’s multiple comparison tests were performed. 
Statistically  significant  differences  were  found  in  effectiveness  of  the  different 
components at planktonic MIC90 levels. In particular, TTO was less inhibitory than 
T4-ol  and  α-terpineol  (p<0.001),  but  significantly  better  than  g-terpinene 
(p<0.001),  terpinolene  (p<0.001)  and  r-cymene  (p<0.001).  No  statistical 
difference  was  found  between  T4-ol  and  α-terpineol  treatment  at  the 
concentrations used (p>0.05).  
 
Subsequent analyses of the data were performed for TTO, T4-ol and α-terpineol 
by subdividing the strains into different patient groups (Figure 3.6). Susceptibility 
to each treatment was consistent between different groups. A comparison of the 
activity of compounds against planktonic and sessile cells is summarised in Table 
3.5. 
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Figure  3.6:  Reduction  in  biofilm  metabolism  for  different  clinical 
populations  of  C.  albicans  on  exposure  to  PMIC90  levels  of  the  most 
efficacious  TTO  components  (TTO  [1%  v/v],  T4-ol  and  α-terpineol  [0.5% 
v/v]). Box and whisker plots show data range, with boxes indicating inner quartile 
range and median. This illustrates the similar ranges of metabolic inhibition for 
each  patient group  of C.  albicans  clinical  isolates. The two  components gave 
similar results, each effective at 0.5%. Mean levels of inhibition were 61% for 
TTO,  and  77%  for  T4-ol  and  α-terpineol.  Statistically  significant  differences  in 
treatment effects were found when comparing TTO with each component within 
groups  of  strains.  No  statistical  difference  was  found  between  T4-ol  and  α-
terpineol treatment (p >0.05). 
 
Table 3.5: Summary of the most effective anti-candidal TTO components 
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3.6 C. albicans biofilm survival after short TTO exposure  
Previous  sections  investigated  overnight  exposure  of  biofilms  to  various 
treatments, to determine which of the TTO components exhibited the strongest 
antifungal properties, i.e. the components that inhibited biofilm metabolism at the 
lowest concentrations (lowest SMFC50) However, a major aim of this study is to 
ascertain  the  antifungal  potential  of  TTO  components  in  a  mouthwash,  which 
therapeutically requires shorter exposure times. Therefore, this section aimed to 
examine the activity of short exposures of TTO and the two strongest antifungal 
components  (T4-ol  and  α-terpineol)  against  two  clinical  isolates  from  denture 
stomatitis  patients  that  represented  effective  and  ineffective  biofilm  formers 
(Figure  3.7). These  isolates  were  DS19  –  an  ineffective  biofilm former  (OD490         
< 0.9) and DS23 – an effective biofilm former (OD490 >1). Pre-formed biofilms of 
both strains were exposed to TTO (2%), T4-ol (1%) or α-terpineol (1%) for 2, 5, 
15 and 60 min (quadruplicate treatments and controls were used). Metabolism 
was measured immediately after treatment by XTT assay.  
 
A 2 min exposure with 2% TTO reduced metabolism of DS19 by 48%, and DS23 
by  31%.  Longer  exposures  (5  and  15  min)  produced  greater  inhibition. 
Nevertheless,  60  min  exposure  did  not  completely  stop  metabolism  of  either 
strain,  with  DS23  showing  moderate  metabolism  (OD490  ~0.5)  after  exposure. 
Inhibition levels after short exposures to 1% T4-ol were equivalent to 2% TTO for 
DS19,  but  lower  for  DS23  (18%  inhibition),  whereas  1%  α-terpineol  produced 
stronger levels of inhibition than 2% TTO (DS19 69%, DS23 40%). When strains 
were exposed for 60 min to either component, their metabolism was reduced to 
near background levels. The DS19 controls showed considerable variation, as 
the weak biofilm had loose cells which could be dislodged in the washing step. 
Data  were  analysed  by  repeated  measures  ANOVA,  with  Bonferonni  multiple 
comparison  correction,  using  the  General  linear  model  in  SPSS
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comparing all time-points to no-exposure controls, to determine exposure times 
giving  statistical  significant  effects  (*  p<0.05,  **  p<0.01).  Statistical  analysis 
indicated that significant inhibition of the strong biofilm former (DS23) required 60 
min exposure with 2% TTO, while the poor biofilm (DS19) was inhibited by a 15 
min exposure (p<0.05). 1% T4-ol gave significant inhibition (70%) of DS23 after 
15 min, while DS19 was inhibited after 2 min exposure, i.e. 1% T4-ol inhibited the 
C. albicans biofilms faster than 2% TTO. The 1% α-terpineol solution reduced 
biofilm metabolism of both strains after 2 min. It should be noted that these data 
are preliminary, as experiments were not repeated due to time constraints. 
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Figure 3.7: Time-kill studies of C. albicans with TTO components 
Quadruplicate wells with pre-formed biofilms were exposed to A) TTO (2%), B) 
T4-ol (1%) or C) α-terpineol (1%) for 2, 5, 15 and 60 min (n=4 for each). Note the 
effectiveness of 60 min exposures of T4-ol and α-terpineol in comparison to TTO, 
particularly for strain DS23. Repeated measures ANOVA was performed using 
the General linear model in SPSS
®, to determine statistical significance (* p<0.05, 
**  p<0.01).  Inhibition  of  the  strong  biofilm  former  (DS23)  required  60  min 
exposure with 2% TTO, 15 min 1% T4-ol or only 2 min in 1% α-terpineol. The 
poor biofilm (DS19) was inhibited by a 15 min exposure to 2% TTO while the 
components were effective after 2 min.                                                                                        Chapter 3: Antifungal effects 
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3.7 Summary and Discussion  
 
The data presented in this component of the study clearly demonstrates that TTO 
is  an  effective  inhibitor  of  Candida  albicans,  with  a  1%  TTO  concentration 
(dissolved in RPMI / 0.25% Tween
®80) consistently inhibiting growth of all the 
clinical  strains  tested  and  the  PMIC50  for  all  100  strains  being  0.5%  (range 
0.125%  to  1%  TTO).  This  is  consistent  with  an  earlier  study  from  within  our 
research group investigating the effect of TTO on a wide variety of oral yeast 
species  (Bagg  et  al.,  2006).  The  aforementioned  study  did  not  examine  the 
antifungal  effects  of  individual  TTO  components,  and  a  major  aim  was  to 
determine  which  of  these  components  had  antifungal  properties  and  also  to 
discover if any component was more effective than the complete oil. The data 
indicated  that  T4-ol  and  α-terpineol  exhibited  the  most  effective  antifungal 
activity,  with  PMIC50  concentrations  of  0.25%.  Many  of  the  other  individual 
components  tested  were  ineffective  at  inhibiting  planktonic  cells  at  the 
concentrations used.  
 
The earlier study by our group (Bagg et al., 2006) suggested a potential role for 
TTO  in  candidosis  management,  but  the  anti-biofilm  effect  remained  to  be 
examined  in  the  present  study,  as  biofilm  resistance  is  a  crucial  obstacle  to 
successful control of these infections as described in Section 1.4 (Seneviratne et 
al., 2008). In the current study, inhibition of mature biofilm metabolism with 1% 
TTO  was  excellent;  inhibition  rates  were  generally  >50%  (SMFC50  =  1%).  In 
comparison, T4-ol and a-terpineol both inhibited biofilm metabolism by >50% at 
only 0.25% (SMFC50 = 0.25%), i.e. the planktonic MIC50 concentration of these 
two components had powerful fungicidal effects on the in vitro biofilms. Statistical 
analysis indicated that there was no difference in biofilm resistance to treatment 
between strains isolated from different patient groups. 1,8-cineole, which has an 
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(SMFC50  =  2%).  As  predicted  from  the  planktonic  studies,  other  components 
tested  were  ineffective  at  inhibiting  pre-formed  biofilm  metabolism  (SMFC50         
>  2%).  These  results  confirm  that  biofilm  resistance  is  a  factor  in  protecting           
C.  albicans,  i.e.  inhibition  of  strains  growing  as  biofilms  required  higher 
concentrations  of  TTO  and  many  of  the  derivative  compounds,  compared  to 
planktonic inhibition. In the case of TTO, biofilms were inhibited at two times the 
planktonic  MIC  values.  The  only  derivatives  giving  significant  biofilm  inhibition 
were  T4-ol  and  α-terpineol.  Both  gave  excellent  inhibition  of  biofilms  at  one 
quarter the SMFC value of TTO. These experiments used 24 h treatments as an 
initial  screen  to  determine  the  most  potent  antifungal  components.  This  long 
exposure could be used in a denture cleanser (overnight soak) to potentially kill 
biofilm  cells  on  dentures,  or  in  an  oral  gel  to  treat  candidosis  on  mucosal 
surfaces. 
 
The  MIC  values  for  TTO  agree  well  with  published  data.  An  earlier  study  in 
Glasgow Dental School (Bagg et al., 2006) gave PMIC50 values of 0.5% for 301 
yeast isolates, with specific PMIC50 values of 0.5% for C. albicans strains and 
0.25% for C. glabrata strains. The PMIC90 was 1% for C. albicans, C. glabrata 
and C. dubliniensis and 0.5% or less for other species. C. albicans values are the 
same as were found in the current study. Many other studies have found broadly 
similar  susceptibilities  (Banes-Marshall  et  al.,  2001;  Hammer  et  al.,  1998; 
Vazquez  et  al.,  2000).  Variation  in  PMIC  values  can  be  partly  explained  by 
differences in methods used and also the source and quality of the tea tree oil. 
Mondella et al found PMIC90 values of 0.25% for TTO, 0.06% for T4-ol and 4% 
for 1,8-cineole (Mondello et al., 2006), confirming the potency of T4-ol and weak 
activity  of  1,8-cineole.  Previous  reports  stated  T4-ol  to  be  responsible  for 
antimicrobial activity of the oil (Carson et al., 2006; Mondello et al., 2006). The 
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with PMIC90 of 0.5% for both C. albicans and C. glabrata. This study validates 
these findings. Therefore, further investigations focussed on these derivatives.  
 
The  in  vitro  effects  of  these  treatments  may  not  be  reproduced  in  vivo,  as            
C.  albicans  biofilms  in  plastic  wells  differ  from  natural  biofilms.  Oral  candida 
biofilms  form  in  a  stressed  environment  to  give  protection  from  salivary  flow, 
chewing and the host immune response. This allows the yeast to attach more 
strongly to the oral surfaces and hence avoid being detached and washed away 
(Section  1.4)  (Mukherjee  et  al.,  2009).  The  biofilm  produces  a  matrix  of 
exopolymeric substances (EPS) to protect it in vivo, and this EPS increases in 
vitro when a developing biofilm is exposed to a continuous media flow (Figure 
1.2).  All  the  antifungal  experiments  in  this  study  were  performed  on  biofilms 
grown in static conditions (no flow-stress). Therefore, it would be interesting to 
use a continuous flow model to produce biofilms of a selection of clinical strains, 
which  could  then  be  treated  to  determine  antifungal  effects  of  TTO  and 
components  on  more  natural  biofilms,  i.e.  a  more  complex  structure  than  the 
simple artificial biofilms used in this project. In addition, the oral environment is 
also  far  more  complex  than  any  in  vitro  model;  the  activity  of  a  TTO-based 
mouthwash  can  be  influenced  by  many  variables  in  the  mouth,  including  the 
influence of salivary components (interactions with proteins) which are not tested 
in these in vitro experiments. Future studies could include saliva (sterile artificial 
saliva can be prepared) within both the planktonic and sessile sensitivity assays 
to investigate the influence of saliva on the mouthwash ingredients. 
 
The use of 0.2% TTO mouthwashes may not be sufficient to control candidosis; 
the  data  in  this  study  suggest  that  a  minimum  concentration  of  0.5%  TTO  is 
necessary to inhibit planktonic C. albicans cells (PMIC50 = 0.5%), and possibly 
higher  concentrations  would  be  required  to  treat  biofilm  infections.  However,                                                                                       Chapter 3: Antifungal effects 
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mouthwashes also contain other active ingredients (such as SDS, fluorides and 
ethanol) which can augment antimicrobial activity or reduce the effective TTO 
concentration  (synergistic  effect).  The  test  solutions  used  in  this  study  were 
standard laboratory yeast culture broth with only TTO or components added, plus 
the  detergent  Tween
®80  (0.25%)  to  improve  dispersal  of  poorly-soluble  TTO 
components. In retrospect, it would have been useful to have a commercial TTO 
mouthwash, with fully disclosed ingredients, to determine if the other ingredients 
in the formulation altered the activity of the TTO compared to the laboratory TTO 
solution  used  in  these  experiments.  However,  the  main  point  of  these 
experiments was to find an individual molecule that could be used independently, 
making it more attractive for pharmaceutical companies. The TTO proportion on 
commercially  available  formulations  is  not  clear  and  they  only  stipulate  a 
maximum concentration of T4-ol, rather than a defined concentration. The TTO 
and components used in this study were HPLC grade, which were high purity. 
Therefore, comparison with a lower grade product would not have provided a fair 
comparison.  Clinical  studies  into  TTO-based  mouthwashes  have  been 
performed, but often the proportion of TTO used is not clearly stated (Vazquez & 
Zawawi, 2002) [Section 1.7.3]. Therefore, determination of a ‘safe’ concentration 
for use in oral products is crucial. Another limiting factor is the strong taste of 
TTO, with 1% being the maximum tolerated concentration.  
 
It is inadvisable to have widespread use of any drug at ineffective levels, as there 
is  the  potential  for  selection  of  less-sensitive  strains.  In  this  investigation,  the 
multiple exposure TTO study did not result in any change in TTO sensitivity after 
ten exposures to sub-inhibitory concentrations (Section 3.1.2). However, slightly 
reduced sensitivity to conventional antifungal drugs was seen in 3 out of 8 strains 
after ten TTO exposures (Table 3.3). This multiple exposure study was too small 
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antifungal drugs, if the TTO mouthwash is ineffective (McMahon et al., 2007). 
Experimental increases in resistance to antibiotics in E. coli, Salmonella spp. and 
Staphylococcus  spp.  have  been  induced  by  exposure  to  sub-lethal 
concentrations of TTO (McMahon et al., 2007; McMahon et al., 2008; Nelson, 
2000).  However,  another  small  study  could  not  induce  TTO  resistance  in             
C. albicans (Mondello et al., 2003) and evidence for this type of effect on yeast 
by TTO is lacking. Moreover, no studies to date have demonstrated whether TTO 
exposure might upregulate candida efflux pump expression. In addition, there is a 
potential  for  repeated  exposure  to  TTO  to  induce  ‘stress  hardening’  of  the 
bacteria, where one antimicrobial treatment can increase general resistance to 
other agents. Any cells that survive exposure to TTO may become more resistant 
to  future  antimicrobial  challenge,  for  example  by  activating  efflux  pump 
mechanisms to excrete drugs more quickly.  Also, TTO treatment may alter the 
overall  microbial  population,  by  killing  sensitive  organisms  and  allowing 
expansion of resistant strains/species. This can significantly change the ratio of 
species,  which  alters  the  competition  between  organisms  and  thus  results  in 
selection of a resistant population. 
 
The final experiment in this chapter focussed on short exposures (2 min to 1 h) of 
biofilms to TTO and the two best antifungal components, T4-ol and α-terpineol 
(Figure  3.7),  to  determine  effective  concentrations  and  times  for  use  in 
mouthwash or denture cleansers.  Two minute exposures to 2% TTO or 1% T4-ol 
were not very effective (inhibition of 31% for TTO, 18% for T4-ol) against a strong 
biofilm former, while inhibition after 2 min in 1% α-terpineol was more significant 
(40%). T4-ol (1%) gave strong biofilm inhibition (70%) with 15 min exposure; i.e. 
at  least  four  times  the  MIC50  was  required  in  a  short  exposure.  TTO 
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the in vitro planktonic C. albicans inhibitory concentration (PMIC50 = 0.5%) found 
in this study. 
 
Several  studies  have  shown  efficacy  of  TTO  against  azole-resistant  Candida 
spp.,  and  this  study  confirmed  this  as  itraconazole-resistant  Candida  isolates 
demonstrated no cross-resistance to the 4 effective TTO components (Bagg et 
al.,  2006;  Jandourek  et  al.,  1998;  Mondello  et  al.,  2003;  Vazquez  &  Zawawi, 
2002). With activity against all tested Candida spp., and effective use against      
C. albicans biofilms, TTO has been promoted as an alternative treatment for oral 
care (Jandourek et al., 1998; Vazquez & Zawawi, 2002). 
 
Another  advantage  to  using  a  broad-spectrum  antimicrobial,  such  as  TTO, 
instead of conventional antifungals is that OPC often involves mixed microbial 
biofilms  containing  multiple  yeast  species,  or  yeast  with  bacterial  species, 
particularly C. albicans with oral streptococci (Silverman et al., 2010). Specific 
antifungal  drugs  such  as  azoles  are  inactive  against  bacteria,  whereas  TTO 
targets most microbial species. Therefore, in future studies it would be important 
to investigate the effectiveness of TTO and its components on mixed Candida 
biofilms and also on biofilms containing both yeast and bacteria. 
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4.1 Introduction 
Biofilm experiments up to this point in the study have focussed on treatment of 
pre-formed biofilms with tea tree oil (TTO) and constituent components, followed 
by measuring their effects on cellular metabolism. This relates to the potential of 
treating  established  biofilms  on  mucosal  surfaces  or  dentures,  i.e.  oral 
candidosis. The current section investigates the inhibitory (prophylactic) role, i.e. 
early treatments to prevent both C. albicans colonisation and the early stages of 
biofilm formation. 
 
Studies have shown that morphogenesis plays a pivotal role in C. albicans biofilm 
development,  in  which  hyphae  are  essential  elements  for  providing  structural 
integrity and for multi-layered architecture (Baillie & Douglas, 1999; Ramage et 
al., 2002d). A gene encoding a major regulator of hyphal development is EFG1, 
which has been shown to be involved in regulation of the morphological transition 
and is associated with ability to form coherent biofilm structures (Ramage et al., 
2002d).  Murillo  and  colleagues  (2005)  investigated  the  early  stages  of biofilm 
formation and found that after only 30 min there were substantial differences in 
gene expression between adherent and non-adherent C. albicans cells, which 
impacts antifungal resistance genes, including efflux pumps which are a defined 
factor in azole resistance (Murillo et al., 2005).  
 
Small  molecules  such  as  farnesol  and  EDTA  have  been  shown  to  inhibit  the 
yeast to hyphal transitional stage of C. albicans, and are able to reduce biofilm 
development  in  a  concentration-dependent  manner  (Ramage  et  al.,  2002b; 
Ramage  et  al.,  2007).  Another  class  of  molecules  that  affect  C.  albicans 
morphology  includes  3-oxo-C12-homoserine  lactone  (3OC12HSL),  a  signalling 
molecule produced by Pseudomonas aeruginosa, and dodecanol (Hogan et al., 
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C.  dubliniensis  planktonic  and  biofilm  cells  produce  a  series  of  chemical 
signalling  molecules  (including  isoamyl  alcohol,  2-phenylethanol,  1-dodecanol,   
E-nerolidol, and E,E-farnesol) which all affect morphogenetic transitions, and also 
that  secretion  of  these  alcohols  was  species,  culture  mode  and  growth-time 
specific (Martins et al., 2007).  
 
Together these studies demonstrate that small molecules can be used to inhibit 
biofilms through modulation of hyphal formation, which is critical for the basis of 
its structural stability. This chapter will examine the effects of TTO and the two 
most effective derivative molecules in the previous chapter on early adherent and 
immature  biofilms  to  determine  their  usefulness  at  preventing  C.  albicans 
biofilms. It is the hypothesis that lower concentrations of these molecules may 
inhibit adhesion and C. albicans hyphal formation, therefore preventing biofilm 
formation. This would reduce the need for active biofilm treatment at potentially 
toxic concentrations.   
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4.2  Prolonged  treatment  during  early  adhesion  inhibits  biofilm 
formation 
To investigate inhibitory effects of TTO and its two main antifungal components 
on  early  stages  of  adhesion,  four  C.  albicans  strains  (YH3,  YH28,  YH31  and 
YH32 from neonates, all forming coherent biofilms in vitro) were inoculated into a 
96-well plate. At 0, 1, 2 or 4 h after inoculation of the yeast cells into wells, cells 
were  treated  with  TTO  (0.5,  0.25,  0.125%),  T4-ol  (0.25,  0.125,  0.0625%)  or        
α-terpineol (0.25, 0.125, 0.0625%), all in RPMI / 0.25% Tween
®80, (quadruplicate 
treatments for each strain and time-point), then incubated for a 24 h period (with 
TTO or component still present) at 37
oC (Section 2.1.8). Control wells for each 
strain were treated with RPMI / 0.25% Tween
®80 at each time-point. The biofilm 
was then quantified at 24 h using the crystal violet biomass assay (Section 2.1.7). 
Biofilm inhibition for each treatment was calculated by comparing to untreated 
control  biofilms  without  TTO  or  component  (in  RPMI  /  0.25%  Tween
®80),  as 
illustrated in Figure 4.1. Figure 4.2 shows all the replicate TTO inhibition data for 
strain  YH3  as  an  example  (part  of  Figure  4.1  data),  showing  a  statistically 
significant  inhibitory  effect  of  0.125%  TTO  when  cells  treated  within  2  h  of 
attachment. Repeat measures ANOVA tests were performed, with Bonferroni’s 
correction,  using  the  General  linear  model  in  SPSS  to  identify  significant 
changes. In addition, morphological effects were assessed microscopically, i.e. 
blocking of hyphae formation as a mechanism of biofilm inhibition (Figure 4.3 and 
4.4).  
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Figure 4.1: Mean inhibition of C. albicans biofilm development by A) TTO, 
B) T4-ol and C) α-terpineol. At 0, 1, 2 or 4 h after inoculation of the yeast cells 
into a 96-well plate (2 × 10
5 cells/ well), cells were treated with TTO (0.5, 0.25, 
0.125%), T4-ol (0.25, 0.125, 0.0625%) or α-terpineol (0.25, 0.125, 0.0625) then 
incubated for a 24 h period at 37
oC (mean of 4 wells for each strain, n = 4 strains 
[YH3, YH28, YH31 and YH32]) The biofilm was then quantified at 24 h using the 
crystal  violet  biomass  assay,  and  %  inhibition  calculated  by  comparing  to 
untreated controls for each strain at each time point. Each column represents the 
mean  inhibition  of  4  strains  (4  replicates  for  each  strain),  with  bars  showing 
standard error of mean. The highest concentration of each is equivalent to the 
planktonic MIC50, which effectively inhibited biofilm formation at all time points. It 
was  shown  that  each  treatment  was  most  effective  if  given  within  2  h  of 
inoculation,  with  most  significant  differences  in  inhibition  observed,  relative  to 
time  treated,  at  lower  concentrations.  Jonckheere-Terpstra  non-parametric 
multiple comparison tests were performed using SPSS software, followed by a 
one-way  ANOVA  with  Bonferroni’s  correction,  to  identify  significant  changes. 
Statistical analysis on timing of treatment (hours after inoculation) gave adjusted 
p  values:  0.125%  TTO  0  h  versus  4  h  p<0.001,  2  h  versus  4  h  p<0.05,  no 
significance for 0.5% and 0.25% TTO 0 h versus 4 h (p>0.05), 0.125% T4-ol 0 h 
versus  4  h  p<0.005,  no  significant  difference  due  to  timing  with  higher 
concentration (p>0.05), and no significant difference for 0.125% α-terpineol due 
to timing (i.e. delay of treatment was not significant - treating cells at 0, 1, 2 or 4 h 
after inoculation all gave similar results).                                                                 Chapter 4: Inhibition of Biofilm formation 
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TTO effectively inhibited the ability of C. albicans to filament and form mature 
biofilms at a concentration equivalent to the planktonic MIC50 (0.5%), at all pre-
treatment times tested (Figure 4.1A). Treatment within 2 h of inoculation gave 
90% inhibition, while treatment at 4 h resulted in a 70% mean biomass reduction. 
At  a  lower  TTO  concentration  of  0.25%,  similar  levels  of  inhibition  were 
demonstrated up to 2 h (80%). Scanning electron microscopy analysis (SEM) 
demonstrated reduced hyphal growth and filamentous extensions, with a scant 
covering  of  the  substrate,  compared  to  the  no-TTO  control  in  RPMI  /  0.25% 
Tween
®80 (Figure 4.4A and B). However, after 4 h adhesion and colonisation, 
the inhibition was reduced overall to a mean of 56%. 0.125% TTO also produced 
around 60% inhibition of biofilm formation if present within 2 h of adhesion, i.e. at 
early stages of hyphae elongation. However, at 4 h adhesion this resulted in only 
a  30%  mean  inhibition.  Figure  4.2  shows  replicate  data for TTO  treatment  of 
strain YH3, while Figure 4.3 shows cells treated with 0.125% TTO at different 
stages of biofilm formation. 
 
T4-ol effectively inhibited the ability of C. albicans to filament and form mature 
biofilms at a concentration equivalent to the planktonic MIC50 (0.25%), at all pre-
treatment times tested (Figure 4.1B), giving very similar results to TTO treatment. 
Treatment within 2 h of inoculation gave around 90% inhibition, while treatment at 
4 h resulted in a 74% mean biomass reduction. SEM analysis demonstrated poor 
overall hyphal growth with limited filamentous extensions, with a scant covering 
of the substrate (Figure 4.4C). At a lower concentration of 0.125%, the inhibition 
was time-dependant with respect to adhesion, with inhibitory levels decreasing 
with increasing adhesion/elongation time, ranging from 80 to 50% mean inhibition 
from  0  to  4  h  adhesion.  At  0.0625% the  pattern  was  similar,  but  exhibiting  a 
range of 75 to 25% mean inhibition for treatment 0 to 4 h after adhesion. 
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α-terpineol similarly inhibited the ability of C. albicans to filament and form mature 
biofilms at a concentration equivalent to the planktonic MIC50 (0.25%), at all pre-
treatment times tested (Figure 4.1C). Treatment within 2 h of inoculation gave 
90%  inhibition,  while  treatment  at  4  h  resulted  in  an  82%  mean  biomass 
reduction.  SEM  analysis  demonstrated  stunted hyphal  extension,  with  minimal 
substrate coverage (results not shown). At a lower concentration of 0.125%, the 
inhibition was consistent up to 2 h adhesion (80%), dropping to 58% after 4h 
adhesion. At the lowest concentration tested (0.0625%), inhibition was high at 0 h 
adhesion (72%), dropping to only 39% after 4 h adhesion.  
 
SEM  was  used  to  examine  the  morphology  of  a  24  h  C.  albicans  biofilm, 
comparing  untreated  (in  RPMI  /  0.25%  Tween
®80)  cells  with  TTO  or  T4-ol 
exposed cells. Strain YH28 (neonate throat swab), which forms a coherent in 
vitro  biofilm,  was  inoculated  onto  Thermanox™  coverslips  (Nunc  Inc,  Thermo 
Fisher Scientific) at 10
6 cells/ml. Biofilms were allowed to attach to coverslip for 2 
h,  washed  briefly  in  PBS,  then  treated  with  TTO  (0.25%)  or  T4-ol  (0.125%). 
Untreated cells were included as a control. Coverslips were incubated overnight 
at  37ºC,  before  treatment  solutions  were  removed  and  coverslips  washed 
carefully in PBS to detach any loosely adherent cells. Coverslips were processed 
for SEM and images taken of representative cells (Figure 4.4). Both treatments 
effectively blocked biofilm formation, with only short hyphae present after 24 h.  
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Figure 4.2: Inhibition of biofilm development in C. albicans strain YH3 by 
addition of TTO at A) 0 h, B) 1 h, C) 2 h and D) 4 h. At 0, 1, 2 or 4 h after 
inoculation of the yeast cells into a 96-well plate (2 × 10
5 cells / well), cells were 
treated in quadruplicate with TTO (0.5, 0.25, 0.125%), then incubated for a 24 h 
period at 37
oC. The biofilm was then quantified at 24 h using the crystal violet 
biomass assay. Mean absorbance after each treatment is shown by horizontal 
line,  and  %  inhibition  calculated  by  comparing  treated  values  to  untreated 
controls  for  this  strain.  Repeat  measure  ANOVA  tests  were  performed,  with 
Bonferroni’s  correction,  using  the  General  linear  model  in  SPSS
®  to  identify 
significant changes. The highest concentration is equivalent to the PMIC50, which 
effectively inhibited biofilm formation at all time points. It was shown that 0.125% 
TTO treatment was most effective if given within 2 h of inoculation (** p<0.01), 
while inhibition at 4 h was not statistically significant (p>0.05). 
 
 
 
 
                                                                 Chapter 4: Inhibition of Biofilm formation 
   
                                                                                                        
   
  96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: C. albicans biofilm formation can be blocked by 0.125% 
TTO. Light microscopy images (x 40) of C. albicans biofilm (strain YH3) 24 h 
after  treatment  with  0.125%  TTO  at    A)  0  h  post-inoculation,  B)  2  h  post-
inoculation, C) 4 h post-inoculation and D) untreated control (in RPMI / 0.25% 
Tween
®80). 0.125% TTO completely blocked biofilm formation if present when 
cells  were  attaching  to  surface  (A),  stopping  both  cell  division  and 
morphogenesis  of  blastospores  into  hyphae.  In  (B),  hyphae  were  very  short, 
showing early filamentation in first two hours, followed by inhibition when TTO 
was added. Cells in (C) had more elongated hyphae, due to the longer time they 
had  to  develop  prior  to  treatment,  while  the  untreated  control  biofilm  showed 
extensive filamentation (D).  
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Figure 4.4: Scanning electron micrographs of 24 h C. albicans biofilm 
after various treatments (SEM x1000). C. albicans (YH28, neonate throat 
swab)  was  plated  onto  coverslips  in  a  24-well  plate,  and  treated  2  h  after 
inoculation  with  B)  TTO  (0.25%)  or  C)  T4-ol  (0.125%).  Untreated  cells  (A,  in 
RPMI / 0.25% Tween
®80) were included as a positive control. Cells were fixed on 
coverslips at 24 h and processed for scanning electron microscopy. Untreated 
adherent  cells  developed  into  mature  biofilms  consisting  of  both  yeast  and 
hyphae within a complex 3-D architecture (A). Adherent cells treated with TTO 
were only able to form stunted hyphae which were unable to develop into full 
hyphae and mature biofilms (B). Cells treated with T4-ol were also inhibited from 
hyphal extension, and the cells could only form a scant monolayer (C). Due to the 
inability to form a coherent framework of hyphae, both TTO and T4-ol treated 
cells were less adherent than untreated cells, and many were removed during the 
SEM processing procedure. 
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4.3  Short  treatment  (1  h)  during  early  adhesion  inhibits  biofilm 
formation at high concentrations 
 
These experiments were designed to assess the potential of TTO and constituent 
components in terms of a short treatment denture cleanser, by assessing how a 
one hour treatment of adherent cells, impacted on growth and biofilm formation 
when cells were removed from the active agent. C. albicans (YH28 – neonate 
throat swab) was plated as above, allowed to adhere for only 1 h, then treated in 
duplicate wells for 1 h with varying concentrations of TTO, T4-ol and α-terpineol 
(control cells were treated with RPMI / 0.25% Tween
®80 for 1 h), washed in PBS 
and then incubated in fresh RPMI for 24 h (Section 2.1.8). Inhibition of treated 
biofilms  were  calculated  by  comparing  to  the  control  cells  (n=4).  Resultant 
cellular growth was quantified using the crystal violet biomass assay (Figure 4.5).  
 
Treating the 1 h adherent population with TTO at concentrations of 0.125 and 
0.25% did not affect subsequent biofilm growth, whereas 0.5% TTO was shown 
to reduce biofilm formation by 53%. For T4-ol, both 0.625% and 0.125% did not 
reduce  the  biomass  compared  to  the  untreated  control.  However,  0.25%  was 
able to reduce biofilm growth by 90%. α-terpineol was less effective than T4-ol, 
with 0.25% giving a mean 53% reduction in biofilm development, T4-ol was more 
effective than TTO and α-terpineol for this strain, but data needs confirmation 
with a variety of clinical strains. Figure 4.6 shows biofilms in wells treated for 1 h 
with a range of TTO concentrations, illustrating the inhibitory effect of 0.5% TTO. 
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Figure 4.5: Inhibition of C. albicans biofilm development by 1 h treatment 
with A) TTO, B) T4-ol and C) α-terpineol. C. albicans YH28 was inoculated into 
a 96-well plate (2 × 10
5 cells / well), allowed to adhere for 1 h, and then treated in 
duplicate for 1 h with varying concentrations of TTO, T4-ol and α-terpineol or a 
positive control of RPMI / 0.25% Tween
®80. Treatment solutions were removed, 
cells  washed  in  PBS  and  then  incubated  for  24  h  in  RPMI.  T4-ol  was  more 
effective than TTO and α-terpineol -reductions in mean biomass of the biofilms 
(represented by horizontal bar) were as follows: 90% for 0.25% T4-ol, and 53% 
for 0.5% TTO and 0.25% α-terpineol. 
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            0.5% TTO         0.25% TTO       0.125% TTO         Control  
 
Figure 4.6: Crystal violet stained biofilms at 24 h. Cells were treated with 
TTO for 1 h, washed in PBS, incubated for 24 h in RPMI then stained with crystal 
violet. A positive control of RPMI / 0.25% Tween
®80 was included. Inhibition of 
biofilm formation by 0.5% TTO is apparent in the left hand well, and marginally at 
0.25%. 
 
 
 
4.4 Pre-coating of substrate with TTO inhibits biofilm formation  
This experiment was designed to assess the effect of coating a substrate with 
TTO prior to attachment of yeast cells. 96-well plates were coated with serial 
doubling  dilutions  of  TTO  from  2%  to  0.015%,  in  RPMI  containing  0.25% 
Tween
®80, and 40 ml added to individual wells, including a media control (RPMI / 
0.25% Tween
®80). Plates were sealed with adhesive lids, stored overnight at 4ºC 
to allow adsorption to the plate, then solution removed. Four C.albicans strains 
(DS18,  20,  22,  23  -  denture  stomatitis  isolates)  were  selected,  and  plated  in 
replicates  at  2  x  10
5  cells  /  well  (duplicates  of  each  strain  for  each  TTO 
concentration). Plates were sealed with parafilm and incubated overnight at 37
oC. 
Biofilms were examined microscopically to observe morphology, and quantified 
using the crystal violet assay (Figure 4.7). TTO (1%) consistently inhibited biofilm 
formation for all 4 strains (** p<0.01), while concentrations below 0.5% had little 
effect.  
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Figure  4.7:  Effect  of  adsorbing  (coating)  substrate  with  TTO.  Four                 
C. albicans strains DS18, DS20, DS22 and DS23 were inoculated in duplicate 
after overnight treatment of wells with TTO at concentrations from 2 to 0.015%, 
including a media control. Biofilm formation was measured at 24 h using crystal 
violet assay. Data were normalised using mean of all control data. Data-points 
represent  mean  of  each  strain,  while  horizontal  bars  represent  mean  biofilm 
absorbance of all four strains. Statistical analyses were performed using a one-
way  ANOVA  and  Dunnett’s  t-test  to  compare  all  treatments  with  untreated 
controls. 0.5% TTO was required to reduce biofilm formation significantly, while 
1% TTO gave stronger inhibition of all 4 strains tested (** p<0.01).  
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4.4.1 Scanning electron microscopy of pre-treated denture acrylic 
An additional experiment was performed to test the potential inhibitory effect of 
treating denture material with TTO or T4-ol, prior to yeast inoculation. This was 
also a way to illustrate morphological effects of such pre-treated denture material 
on C. albicans cells with scanning electron microscopy (SEM). Denture acrylic 
discs  (polymethylmethacrylate  (PMMA),  made  in  Glasgow  Dental  Hospital  by    
Dr.  Donald  Cameron)  were  soaked  in  0.5%  TTO  or  0.5%  T4-ol  for  60  min, 
inoculated  with  10
5  C.albicans  cells  (BCO71-  denture  stomatitis  isolate),  as 
described previously, and incubated for 24 h at 37
oC. Discs were removed at 24 
h, fixed and processed for SEM analysis (Section 2.1.11). Images are shown in 
Figure 4.8.  
 
0.5% T4-ol inhibited biofilm formation in this strain by reducing the visible number 
of cells able to attach to surface, or by blocking morphogenesis. Any reduction in 
hyphae with TTO pre-treatment is marginal. This data is only observational, but 
demonstrated the physical impact of treatment. Parallel quantitative analysis with 
defined software would be appropriate with a number of different strains.  
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Figure 4.8: Denture acrylic discs pre-treated for 1 h with A) PBS, B) 0.5% 
TTO  or  C)  0.5%  T4-ol,  prior  to  inoculation  with  C.  albicans  (BC071)  and 
harvested at 24 h (SEM x1000). Untreated disc at 24 h (A) had both extensive 
hyphae and yeast cells at quite low density. Pre-treatment with 0.5% TTO (B) 
had no obvious effect on hyphal length or number of cells attached to surface, 
whereas 0.5% T4-ol (C) appeared to reduce length of hyphae and attached cell 
numbers.  
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4.5 Summary and Discussion 
This  chapter  investigated  the  potential  inhibitory  role  of  TTO  and  two  key 
derivatives, shown in Chapter 3 to have effective antifungal properties. Intrinsic 
biofilm  resistance  results  in  higher  concentrations  of  TTO  being  necessary  to 
effectively inhibit planktonic cells to the same extent. Therefore, a treatment used 
to  kill  planktonic  cells  before  they  attach  to  oral  surfaces  and  form  a  biofilm 
should require lower antifungal concentrations than candidosis treatment.  
 
For 24 h exposures (Figure 4.1), biofilms were successfully inhibited by addition 
of  TTO,  T4-ol  or  α-terpineol  (all  at  0.125%)  within  2  h  of  cell  attachment  to 
surface, i.e. before morphogenesis has started. SEM images in Figure 4.4 clearly 
show  blocking  of  hyphal  extension  with  0.25% TTO  and  0.125% T4-ol,  which 
results in biofilm inhibition (illustrated for TTO in Figure 4.2C and 4.3B). 
 
In the shorter 1 h treatment experiments (Figure 4.5), 0.5% TTO or 0.25% T4-ol 
was  required  to  block  biofilm  formation.  At  these  concentrations,  T4-ol  gave 
stronger  inhibition  than  TTO  (90%  versus  53%)  and  0.25%  α-terpineol  (53% 
inhibition).  When  concentrations  were  below  PMIC50  levels,  removal  of  the 
antifungal after 1 h allowed regrowth of the biofilm, i.e. sub PMIC levels did not 
kill  cells  in  1  h.  This  observation  requires  a  larger  study  with  more  strains  to 
confirm that T4-ol is more effective than TTO, and also to determine a minimum 
effective prophylactic T4-ol concentration. These concentrations were shown to 
be cytotoxic to in vitro human oral cells (Chapter 5). These results contrast with 
the  initial  experiment  (Figure  4.1),  where  longer  exposures  were  effective  at 
lower doses, and illustrate the time-dependent effect of these antifungals. The 
nature of the oral cavity demands that an effective antimicrobial agent has to 
work using a short exposure, or that the compound has to remain on mucosal 
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known as substantivity, where an antiseptic such as chlorhexidine can adsorb to 
a surface and be released gradually, resulting in longer term protection. The final 
part of this section investigated the potential substantivity of TTO in small pilot 
studies. 
 
Coating the plastic well surface with 1% TTO prior to C. albicans inoculation was 
very effective in blocking biofilm formation, while 0.5% TTO had some inhibitory 
effect (Figure 4.7). Clearly some of the TTO adsorbs to the plastic, resulting in a 
reduction  in  the  ability  of  Candida  cells  to  attach  and  effectively  colonise  the 
surface. This was investigated further by pre-soaking denture material to test the 
ability of TTO and T4-ol to adsorb to a more clinically relevant material. Coating 
with  0.5%  T4-ol,  prior  to  C.  albicans  inoculation,  resulted  in  reduced  biofilm 
formation as visualised by SEM, whereas 0.5% TTO had no effect (Figure 4.8). 
This data is not quantitative and requires further work with more than one strain. 
Quantification would be possible using appropriate software to sample random 
sections of treated and untreated materials. This could be applied to a denture 
soak, to reduce biofilm formation on dentures, or a longer-term inhibitory strategy 
could be the impregnation of denture materials with TTO / T4-ol. The use of TTO 
to pre-soak polydimethyl siloxane discs has recently been investigated (De Prijck 
et al., 2010). A 24 h pre-soak with 20% TTO solution produced a 2 log10 reduction 
in C. albicans biofilm biomass, which was comparable with a 0.02% miconazole 
pre-treatment,  while  a  2.5%  TTO  solution  gave  a  log10  reduction.  The 
effectiveness of this strategy in vivo is uncertain as the effects of saliva on this 
anti-biofilm effect are unknown, and also the long-term safety and stability upon 
denture  materials  remains  to  be  determined.  A  recent  study  has  shown  that 
denture cleansers with the active ingredients EDTA, sodium bicarbonate, sodium 
perborate,  hydrogen  peroxide  and  sodium  hypochlorite  were  largely  effective 
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entirely  effective  (Jose et  al.,  2010). The  preliminary  studies  described  in  this 
chapter and Chapter 3 indicate that TTO could potentially be more effective than 
these denture cleansers, and may have the same applications as chlorhexidine. 
 
Chlorhexidine  is  considered  by  dentists  as  the  gold  standard  of  antimicrobial 
mouthwashes.  It  has  broad-spectrum  antimicrobial  activity  through  membrane 
disruption, is highly active against the planktonic cells present in saliva, which 
contribute to colonisation and subsequent biofilm formation (Giuliana et al., 1997; 
Shapiro  et  al.,  2002)  and  demonstrates  substantivity  by  adsorbing  to  protein, 
extracellular  material  and  surfaces,  resulting  in  extended  protection  from 
infections. It has been shown to give excellent inhibition of C. albicans biofilms 
when impregnated into polymer materials (Redding et al., 2009), or when used in 
mouthwashes  (0.12%)  against  fungal  biofilms  (Meiller  et  al.,  2001).  It  was 
recently reported that substantivity could be improved by duration of exposure, so 
it is likely that an increased duration of exposure to greater than 60 sec would 
improve overall C. albicans killing, which is similar to what has been shown within 
this  chapter for  the molecules  studied  (Tomas et  al.,  2010).  It  has  also  been 
shown that chlorhexidine is significantly more effective than the azoles against   
C.  albicans  biofilms  grown  in  a  constant  depth  film  fermenter  (Lamfon  et  al., 
2004).  
 
Biofilm  formation  in  C.  albicans  is  associated  with  increases  in  expression  of 
genes associated with surface adhesion of cells and maturation of the biofilm 
(Murillo  et  al.,  2005).  Azole  drug  therapy  can  increase  expression  of  genes 
associated  with  drug  /  toxin  efflux  (Mateus  et  al.,  2004),  and  this  can  be 
accompanied by a corresponding decrease in expression of biofilm-associated 
genes, which can prevent biofilm formation (Bruzual et al., 2007). Bruzual et al. 
showed  that  presence  of  fluconazole  can  inhibit  biofilm  formation,  even  in                                                                 Chapter 4: Inhibition of Biofilm formation 
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fluconazole-resistant strains. This is similar to the effect of TTO and derivatives 
described in Section 4.2. This inhibitory effect can also be produced by factors 
released by bacteria such as Pseudomonas aeruginosa (Holcombe et al., 2010). 
The  formation  of  a  biofilm  can  therefore  be  influenced  by  various  antifungal 
factors, and the inhibition seen in this chapter from treating cells with TTO and 
derivatives during adhesion and early biofilm formation could be explained by 
such effects on genes involved in this process, which have also been reported 
elsewhere (Ramage et al., 2002, Hogan et al., 2004, Murillo et al., 2005, Martins 
et al., 2007).  
 
Another  strategy  for  reducing  biofilm  formation  on  artificial  surfaces  such  as 
denture  materials  is  impregnating  them  with  antimicrobials  that  are  released 
gradually over time (Bach et al., 1994; Solomon & Sherertz, 1987). There have 
been many studies into inhibiting bacterial colonisation through the incorporation 
of  various  antiseptics  (chlorhexidine,  silver  sulphadiazine)  and  antibiotics  into 
catheters, indwelling medical devices and dentures (Price et al., 1996; Schierholz 
et  al.,  1998;  Wilson  &  Wilson,  1993;  Wu  &  Grainger,  2006).  Impregnation  or 
coating of polymer materials with antifungals has been less well studied (Pigno et 
al., 1994), but several recent publications show the potential of such strategies 
for controlling fungal attachment and hence reducing the problems associated 
with  C.  albicans  biofilm  infections  (Arai  et  al.,  2009;  De  Prijck  et  al.,  2010; 
Redding et al., 2009). 
 
Overall, the data from this chapter indicates that tea tree oil based compounds 
are inhibitory and this effect has the capacity to be utilised within mouthwash 
formulations.  Further  comparative  studies,  with  chlorhexidine  for  example,  are 
required to fully establish their potential.   
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5.1 Introduction  
 
The data from previous chapters demonstrate that TTO and its components are 
effective  antifungal  compounds.  TTO  and  its  components  offer  a  potentially 
effective  prophylactic  or  therapeutic  mouthwash.  In  this  context,  human  oral 
epithelial cells would be regularly exposed to these antifungal agents; therefore 
the  possible  cytotoxic  effects  of  TTO  and  its  components  needed  to  be 
determined.  In  addition,  cytotoxicity  would  influence  the  reported 
‘immunomodulatory’ effects of TTO. Previous studies have documented cytotoxic 
effects of TTO on various cell lines after one or more hours exposure (Table 1.3). 
As an example, a 1 h exposure to 0.03% TTO was toxic to primary fibroblasts 
and  primary  epithelial  cells  (Soderberg  et  al.,  1996),  although  another  study 
found a 4 h exposure to 0.28% TTO was required to inhibit the HeLa epithelial 
cell line by 50% (Hayes et al., 1997). It seems that the laboratory-adapted HeLa 
cell  line  is  less  susceptible  to  damage  from  TTO  than  primary  cells.  In  vivo, 
fibroblasts support keratinocyte growth and differentiation. Substances that may 
impact on epithelial cells may therefore also exert effects on fibroblasts, which 
are located in close proximity to oral keratinocytes. The aims of these studies 
include  assessment  of  immunomodulatory  effects  of TTO  and  its  components 
therefore it was essential to determine cytotoxic effects so that these could be 
delineated from immunomodulatory effects. Therefore, in vitro toxicity of TTO and 
its components was investigated, using a 2 min exposure to model a mouthwash, 
in both oral epithelial and oral fibroblast cells. Chlorhexidine gluconate (CHX), 
arguably the current ‘gold standard’ antifungal mouthwash agent, has previously 
demonstrated marked in vitro cytotoxicity, at concentrations below those found in 
oral products (0.2%), in keratinocyte and fibroblast skin cells (Boyce et al., 1995) 
and also in gingival fibroblasts (Flemingson et al., 2008; Wilken et al., 2001). 
Therefore, 0.12% CHX was used throughout these experiments as a relevant 
positive control, known to have cytotoxic effects.                                                                        Chapter 5: Cytotoxic effects of TTO 
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5.2 Toxicity of TTO and components to periradicular fibroblast cells 
Toxicity  of  TTO  and  its  constituents  was  initially  investigated  using  primary 
human periradicular (PRD) fibroblasts (Section 2.2.1), which are readily available 
and  easily  cultured.  Fibroblasts  from  one  donor  were  exposed  to  planktonic   
MIC50 concentrations of TTO and its constituent components (in KSFM / 0.25% 
Tween
®80 (KSFMT) for 2 min, in order to reflect the time of exposure during a 
mouthwash treatment. All cells were then washed with PBS to remove residual 
TTO / component. The metabolism of treated cells was measured using the XTT 
assay and compared to controls (2 min in KSFMT). The reduction in metabolism 
for each exposure is presented as proportional data in Table 5.1. In addition, 
several  dilutions  of  TTO  and  the  two  most  effective  antifungal  components 
(terpinen-4-ol  [T4-ol]  and  α-terpineol)  were  used  to  confirm  non-cytotoxic 
concentrations (Figure 5.1). The data indicates that antifungal PMIC50 levels of 
TTO (0.5%) and T4-ol (0.25%) were largely cytotoxic to the PRD fibroblasts. α-
terpineol  demonstrated  no  apparent  cytotoxicity  at  its  PMIC50  (0.25%) 
concentration. T4-ol was not toxic at 0.125%, half the PMIC50. In contrast, TTO 
remained moderately cytotoxic (approximately 37% inhibition) at half the PMIC50
 
concentration  (0.25%).  Other  components  tested  were  cytotoxic  at 
concentrations below the PMIC50 for C. albicans. 
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Table 5.1: Cytotoxicity of TTO and components to PRD fibroblast cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Concentrations represent the planktonic MIC50 for C. albicans of individual components 
# Planktonic
 MIC50 values of these compounds were all greater than that tested 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Concentration 
tested (%) 
* 
Mean % 
Inhibition 
TTO  0.5  86 
terpinen-4-ol  0.25  87 
α-terpineol  0.25  0 
1,8-cineole  1  91 
terpinolene  1 
#  77 
α-terpinene  2 
#  88 
g g g g-terpinene  2 
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Figure 5.1: Effects of TTO and constituent components on PRD fibroblast 
metabolism. Fibroblasts were treated in quadruplicate for 2 min then washed 
gently in PBS. Dilutions were prepared in KSFMT, which was also used to treat 
controls (0). The metabolic activity of fibroblast cells was then assessed by XTT 
assay. Horizontal bars represent mean absorbance values. The results indicate 
that 0.5% of each component inhibited metabolic activity of PRD cells. 0.25% T4-
ol  was  cytotoxic,  while  0.125%  T4-ol  was  non-toxic.  In  contrast,  0.25%  α-
terpineol was not inhibitory and 0.25% TTO demonstrated variable inhibition. The 
two constituent components of TTO shown here were not inhibitory at 0.125%.  
 
 
5.3 Toxicity of TTO and terpinen-4-ol to oral epithelial cells  
The human oral epithelial cell line OKF6-TERT2 was used to further evaluate 
toxicological  properties  of  TTO  and  T4-ol.  This  cell  line  was  immortalised  by 
forced expression of telomerase, and has been shown to exhibit ‘normal’ cellular 
characteristics (Dickson et al., 2000). Cells were grown in a 96-well plate until 
around 70% confluent and then treated for 2 min with defined concentrations of 
TTO or T4-ol in KSFMT. Control cells (0) were treated for 2 min with KSFMT. All                                                                       Chapter 5: Cytotoxic effects of TTO 
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cells were washed in Hanks’ balanced salt solution (HBSS). It was decided to 
focus on T4-ol because of its potent antifungal effect (low SMFC50), and because 
of  its  abundance  in  TTO.  Although  α-terpineol  also  has  strong  antifungal 
properties, its epithelial cell toxicity was not tested as it is not toxic to fibroblasts 
at MIC50 levels, and is a minor TTO component (around 2.5% content).  
 
These  short  exposures  of  TTO  and  T4-ol  were  highly  toxic  at  0.25%,  while 
0.125%  of  each  had  no  significant  effect  (Figure  5.2).  0.12%  chlorhexidine 
digluconate  (CHX)  in  KSFMT  was  used  as  a  known  toxic  control  to  give  a 
comparison with toxicity of TTO and T4-ol. The figure shows that both 0.5% TTO 
and 0.25% T4-ol have comparable in vitro cytotoxic effect to 0.12% CHX. It is not 
surprising  that  0.5%  TTO  and  0.25%  T4-ol  give  equivalent  effects,  as  T4-ol 
makes up 40% of the TTO, i.e. 0.5% TTO contains approximately 0.2% T4-ol. 
While Figure 5.2 illustrates data obtained from the range of concentrations tested 
in  one  experiment,  it  should  be  noted  that  multiple  immuno-modulatory 
experiments using 0.125% TTO and 0.125% T4-ol exposures in OKF6-TERT2 
cells  confirmed  this  concentration  to  be  non-toxic.  In  addition,  alternative  cell 
viability assays were also performed to confirm the XTT results (data not shown). 
 
To ensure the results were representative of oral epithelial cells, and not a result 
of  any  atypical  properties  of  a  particular  cell  line,  a  further  epithelial  cell,  the 
squamous cell carcinoma cell line TR146, was tested to confirm toxicity levels. In 
these  studies,  similar  results  were  observed  (data  not  shown).  0.25%  TTO 
appeared  to  be  more  toxic  to  OKF6-TERT2  epithelial  cells  than  to  PRD 
fibroblasts. 
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Figure  5.2:  Effects  of  TTO  and  T4-ol  on  OKF6-TERT2  cell  metabolism. 
Epithelial cells were treated in triplicate with TTO / T4-ol solutions in KSFMT for  
2 min then washed gently in HBSS (controls (0): 2 min in KSFMT, then washed in 
HBSS). The metabolic activity of these cells was then assessed by XTT assay. 
Horizontal bars represent mean absorbance values. 0.25% TTO and 0.25% T4-ol 
both  exhibited  an  inhibitory  effect  on  OKF6-TERT2  cell  metabolism.  Lower 
concentrations had no inhibitory effect. The toxic control, 0.12% CHX, was as 
toxic as 0.25% T4-ol and 0.5% TTO. 
 
 
Figure 5.3A illustrates confluent untreated OKF6-TERT2 cells, appearing orange 
from XTT reduction, compared with sparse and damaged cells after 2 min 0.25% 
TTO treatment (Figure 5.3B). Lack of orange colour indicates inhibition of cell 
metabolism.  Figure  5.4  illustrates  a  96-well  plate  with  OKF6-TERT2  cells 
exposed  for  2  min  to  various  concentrations  of  TTO  and  T4-ol,  prior  to  4  h 
zymosan A incubation. Note that 10 mg/ml zym does not alter XTT colour, further 
discussed in Chapter 6.                                                                       Chapter 5: Cytotoxic effects of TTO 
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   A                     B  
 
Figure  5.3:  Morphology  of  OKF6-TERT2  cells  after  2  min  in  TTO. 
Monolayer cells were exposed for 2 min to (A) KSFMT (control), or (B) 0.25% 
TTO in KSFMT, followed by 3 washes in HBSS and 2 h incubation in 100 ml of 
0.25  mg/ml  XTT  in  KSFM  (400x  magnification).  TTO  clearly  destroys  the 
monolayer. 
 
  
Figure 5.4: OKF6-TERT2 cells exposed to various concentrations of 
TTO and T4-ol. Monolayer cells were treated in a 96-well plate for 2 min, then 
washed  3x  in  HBSS.  Cells  were  then  incubated  for  4  h  in  zym  (10  mg/ml  in    
KSFM) or KSFM. Cell metabolism was measured using the XTT assay. Lack of 
orange colour indicates inhibition of cell metabolism by 0.25% TTO and 0.25% 
T4-ol. 0.125% TTO / T4-ol (2 min exposures) had no effect on overall metabolism 
of these cells. Central wells show no toxic effect from 10 mg/ml zymosan A. 
 zym  No zym 
ym 
No zym   zym    % T4-ol 
  
           0 
      0.06 
    0.125 
      0.25 
% TTO  
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5.4 Summary and Discussion 
The  cytotoxic  concentrations  of  TTO  and  components  to  oral  cells  were 
determined  to  estimate  potential  toxicity  of  TTO.  Cells  were  exposed  for              
2 minutes to model a typical mouthwash exposure time. Exposure to residual 
concentrations remaining on mucosa for longer periods may still be significant; 
however, the current experiments did not address the possibility of TTO binding 
to,  or  being  taken  up  by  epithelial  cells.  Initial  experiments  with  fibroblasts 
indicated  that  2  min  exposure  to  antifungal  PMIC50  levels  of  TTO  or  all 
components  used  in  this  study,  except  α-terpineol  (toxic  at  double  PMIC50), 
demonstrated cytotoxic effects (Table 5.1). Subsequent experiments using TTO 
and terpinen-4-ol showed cytotoxicity in OKF6-TERT2 epithelial cells at 0.25%, 
with  0.125%  being  non-toxic  (Figure  5.2).  Variations  in  experiment  design 
prevent meaningful comparison with data from previous studies (Hayes et al., 
1997; Soderberg et al., 1996) using longer exposure times. It is clear that 0.25% 
TTO / T4-ol rapidly kills OKF6-TERT2 cells, while lower concentrations tested do 
not.  Future  work  could  determine  a  non-toxic  concentration  for  TTO  or 
components between the two levels tested here (0.25% and 0.125%), i.e. 0.2% 
TTO or component may not be cytotoxic. The variation between studies may be 
accounted for by several factors including a genuine variation in cytotoxic effect, 
variations  in  dose  or  composition  of TTO,  and variation  in  TTO  adherence  to 
plastic, which can all result in variable effective concentrations.  
 
It would be interesting to test a much lower concentration of TTO / T4-ol with a 
longer exposure time (1 h or longer), to determine the susceptibility of oral cells 
to extended residual exposures. Exposure from mouthrinses is only ever going to 
be for  short  periods  (minutes),  with  any  residual  TTO  likely  to  be  diluted  and 
washed away by salivary flow. However, use of a TTO-based gel on oral surfaces 
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Other mouthwash constituents can influence the toxic properties of TTO and the 
overall  safety  of  the  mouthwash,  and  the  cell  monolayer  model  is  different 
structurally  from  in  vivo  epithelial  cells,  which  are  in  a  complex  multilayered 
structure, with the outer layer being composed of dead or dying cells. Toxicity of 
mouthwash  components  also  depends  on  penetration  into  the  inner  epithelial 
cells. Individual components in TTO have different tissue-penetration potential, 
i.e. how well they can be absorbed, which results in changes in proportion of 
these constituents reaching inner mucosal layers (Nielsen, 2008). 
 
Tissue-barrier effects, where a drug or topical lotion does not reach certain cells 
in vivo, can be investigated using in vitro three-dimensional organotypic models. 
Three-dimensional models of oral mucosa have been developed using epithelial 
cells  in  combination  with  fibroblasts  (Dongari-Bagtzoglou  &  Kashleva,  2006; 
Klausner  et  al.,  2007).  The  stratification  and  differentiation  found  in  epithelial 
tissues or organotypic models can act as an antimicrobial barrier which gives 
protection  from  bacterial  and  fungal  challenge  (Kimball  et  al.,  2006).  These 
models  are  therefore  also  potentially  useful  for  studying  infections  and  the 
subsequent  immune  response.  This  study  planned  to  include  the  use  of  an 
organotypic model containing the two monolayer cell types described above, but 
time did not permit this part of the investigation. Future work with such a cell 
model would be valuable in understanding the potential effects of any TTO-based 
oral product. 
 
Extrapolating from in vitro toxicity of a mixture such as TTO, with differing bio-
availability of components, to in vivo toxicity and hence human hazard and risk 
assessment is not straightforward. Legislative standards, such as ISO 10993-5: 
2009 (ISO, 2009), provide a platform for defined in vitro assays which may be 
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However, the relevance of in vitro cytotoxicity testing is challenged by clear in 
vitro  cytotoxic  effects  of  CHX,  which  is  widely  used  clinically.  Clinical  studies 
would  be  required  to  determine  if  the  reduced  cytotoxicity  of  TTO  or  its 
derivatives improved patient acceptance and comfort. These results suggest that 
TTO  and  its  components  demonstrate  concentration-dependent  cytotoxicity  to 
oral epithelial cells and these observations provide the necessary information to 
allow investigation of the reported immunomodulatory effects.  
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6.1 Introduction 
TTO has been used over many years for treatment of skin infections and insect 
bites,  as  it  is  thought  to  have  anti-inflammatory  properties  in  addition  to  its 
antimicrobial effects. However, evidence for immuno-modulation by TTO in the 
oral cavity is very limited, and previous studies have not always controlled for 
cytotoxicity.  
 
Inflammation  accompanies  candidosis,  and  in  some  cases  is  associated  with 
discomfort and / or a burning sensation. Inflammation is a necessary part of the 
immune  defence  to  control  yeast  infections  and  prevent  invasion.  Reducing 
inflammation  with  a  bioactive  anti-inflammatory  agent  could  be  beneficial  for 
short-term control of symptoms, but there are also potential problems with this 
approach. Several studies have provided a potential link between lower levels of 
pro-inflammatory  cytokines  (including  IL-1α,  IL-6,  IL-8  and  TNF-α)  and 
susceptibility to oral C. albicans infection, suggesting that such cytokines may be 
involved in immune protection (Dongari-Bagtzoglou & Fidel, 2005). Inflammatory 
cytokines released from oral epithelial cells have a major role in innate mucosal 
immunity, via recruitment of neutrophils and macrophages to infected mucosal 
sites,  hence  promoting  phagocytosis  of  microbial  cells  (Schaller  et  al.,  2002). 
Failure  of  polymorphonuclear  leukocyte  (PMNL)  activation,  due  to  defects  in 
PMNL or cytokines, can lead to candidosis. Patients with defects in neutrophil 
function or neutropenic patients are more susceptible to oral candidosis (Epstein 
et  al.,  2003).  Neutrophils  have  also  been  shown  to reduce  C.  albicans  tissue 
penetration  and  damage  in  a  3-D  in  vitro  model  (Schaller  et  al.,  2004).  Anti-
inflammatory  effects  of  therapy  could  hypothetically  exacerbate  infection 
problems  by  decreasing  phagocytosis  of  candida  cells  and  hence  reducing 
control of tissue penetration. Immuno-compromised patients, such as those with 
HIV infection, are also more susceptible to candidosis (Ellis et al., 1988); it is                                                           Chapter 6: Immunomodulatory effects of TTO 
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clear  that  many  OPC  patients  have  an  abnormal  immune  system.  Therefore, 
there is uncertainty concerning the benefits of attempting to control inflammation 
in these patients 
 
The role of tea tree oil (TTO) in immuno-modulation was discussed in detail in the 
introduction  (Section  1.8).  Previous  studies  into  the  effects  of TTO  on  human 
cells have demonstrated modulation of cytokine and chemokine production, but 
have not excluded the possibility of toxicity mediating such effects (Brand et al., 
2001; Caldefie-Chezet et al., 2006; Hart et al., 2000). Cytotoxic studies in Section 
5.3 showed that 2 min exposures to 0.125% TTO and terpinen-4-ol (T4-ol), which 
can also inhibit biofilm formation, were non-toxic to the OKF6-TERT2 cell line. 
Therefore, this concentration was chosen to investigate immuno-modulation at 
the transcriptional and translational level. Zymosan A (zym), a purified fungal cell 
wall component, was used throughout as a positive control, as an inflammatory 
agonist to the cells. The experiments in this chapter aimed to test the hypothesis 
that a TTO-based oral product could be immuno-modulatory, using both zym-
stimulated and unstimulated oral epithelial cells. 
 
6.2 Optimising OKF6-TERT2 cell stimulation  
To establish an in vitro model of an oral epithelial inflammatory response, OKF6-
TERT2  cells  were  challenged  with  zym,  which  provided  a  more  efficient  and 
reproducible cell stimulant than live or dead intact candida species. Zym was re-
suspended in DMSO, with a maximum final concentration of 1:300 DMSO in cell 
culture  medium.  This  concentration  of  DMSO  was  compared  with  cell  culture 
medium alone and found to have no impact on mRNA or protein expression (data 
not  shown).  Initial  experiments  were  carried  out  to  demonstrate  a  dose  and 
kinetic  response  of  OKF6-TERT2  cells  to  zym  (Figure  6.1),  assessing  IL-8 
release by ELISA. Briefly, OKF6-TERT2 cells at approximately 70% confluency                                                           Chapter 6: Immunomodulatory effects of TTO 
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were incubated in defined-keratinocyte serum-free medium (KSFM) with zym at 
0,10 and 100 mg/ml  for 2, 4 and 24 h. Supernatants were harvested at end of 
incubation and extracellular IL-8 levels determined by ELISA. At 4 h, supernatant 
from untreated control cells had a mean IL-8 concentration of 553 pg/ml. This 
increased to 892 pg/ml with 10 mg/ml zym, and 2200 pg/ml with 100 mg /ml zym. 
These experiments demonstrated that 10 -100 mg/ml zym reproducibly activated 
IL-8 production in OKF6-TERT2 cells. Therefore, this concentration range was 
used in further experiments to assess the effect of TTO / T4-ol on this model of 
an inflammatory response.  
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                                          2 h         4 h                       24 h 
Figure 6.1: IL-8 production by OKF6-TERT2 cells in response to zymosan 
exposure. Cell supernatants were harvested after 2, 4, and 24 h in zym (or from 
unstimulated  control  cells  in  defined-KSFM)  and  IL-8  concentration  was 
measured  using  ELISA.  Each  column  represents  4  replicate  treatments  in  a 
single experiment, with standard error bars. Zymosan within the range 10 – 100 
mg/ml induced IL-8, with longer exposures giving stronger induction. 4 h and 24 h 
time-points were chosen for all other experiments. 
 
 
6.3 PCR analysis of cytokine gene expression 
6.3.1 Changes in gene expression cannot be detected using standard PCR 
OKF6-TERT2 epithelial cells were treated for 2 min with 0.125% T4-ol in defined 
KSFM with 0.25% Tween
®80 (KSFMT), or KSFMT alone, and then incubated in 
zym (100 mg/ml) or defined-KSFM for 4 h. RNA was harvested using the Trizol
® 
extraction methodology, as described in Section 2.3.1. cDNA was prepared and 
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IL-1b, IL-6, IL-8, and the housekeeping gene GAPDH. Similar product levels were 
seen in each sample visualised on an agarose gel (Figure 6.2), i.e. no difference 
seen in expression, even in the presence of zym.  
 
Figure 6.2: Qualitative analysis of cytokine gene expression from treated 
OKF6-TERT cells. Cells were treated for 2 min with either defined-KSFMT (1, 2) 
or 0.125% T4-ol (3, 4), washed and then incubated for 4 h in defined-KSFMT (1, 
3) or 100 mg/ml zym (2, 4). The final column is the negative (-ve) water control. 
Products were run on a 1.8% agarose gel and stained with ethidium bromide. 
Based on visual analysis, the cells from each treatment have equivalent levels of 
each cytokine after 35 cycles. Similar GAPDH product intensity shows that DNA 
is  at  similar  levels  for  each  sample,  i.e.  RNA  harvested  from  an  equivalent 
number of cells for each sample. 
 
6.3.2 Quantitative PCR analysis of cytokines from OKF6-TERT2 cells after a   
short exposure to TTO or T4-ol revealed no differential expression 
OKF6-TERT2  cells  were  treated  with  TTO,  T4-ol  (both  0.125%  solutions  in 
defined-KSFMT) or defined-KSFMT (control) for 2 min, and then incubated for      
4  or  24  h  in  50  mg/ml  zym  or  media  control  (defined-KSFM)  [Section  2.4.3]. 
Treatments  were  repeated  in  2  independent  experiments.  RNA  was  then 
harvested using the Trizol
® extraction methodology, as described in section 2.3.1. 
cDNA  was  prepared  and  real-time  PCR  was  performed  using  primers  for 
cytokines IL-6, IL-8, and the housekeeping gene GAPDH. Real-time PCR is the 
best method for accurate measurement of gene expression as it measures the                                                           Chapter 6: Immunomodulatory effects of TTO 
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DNA  product  at  each  cycle,  which  in  turn  is  relative  to  amount  of  mRNA  in 
sample template and allows calculation of changes in gene expression caused by 
various treatments. Each sample was run in duplicate to provide a mean Ct value 
(the  threshold  cycle  when  fluorescent  product  is  present  at  a  level  above 
background). Ct values were normalised with the housekeeping gene GAPDH 
(Section 2.3.4). Untreated samples were given a relative expression value of 1, 
and relative expression of genes in treated cells was calculated from mean Ct 
values. Data were analysed using a one-way Anova followed by a Dunnett’s t-
test,  comparing  each  treatment  to  the  appropriate  control  cells  without  pre-
treatment. 
 
After 4 h treatment with 50 mg/ml zym, there was a substantial induction of IL-6 
and IL-8 mRNA, with around a 40-fold increase in both (Fig. 6.3A). TTO and T4-
ol pre-treatment of the cells did not induce IL-8 compared to the control, while the 
elevated mean levels of IL-6 were not statistically significant (p>0.05). Following 
TTO  and  T4-ol  treatment,  zym-stimulated  cells  showed  a  similar  level  of  IL-8 
induction  to  that  of  the  untreated  control.  At  24  h,  zym-stimulated  mRNA 
induction  was  less  reproducible  (Figure  6.3B),  but  pre-treatment  made  no 
significant difference to gene expression of either cytokine at 24 h, compared to 
both zym-induced and untreated cells (p>0.05).                                                            Chapter 6: Immunomodulatory effects of TTO 
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Figure 6.3: TTO and T4-ol pre-treatment produced no significant alteration 
in  IL-6  and  IL-8  transcript  induction  from  OKF6-TERT2  cells  following 
stimulation  by  zym.  OKF6-TERT2 cells  were  treated for  2 min  with  defined-
KSFMT, 0.125% TTO or 0.125% T4-ol, washed and incubated for 4 h (A) or 24 h 
(B), in defined KSFMT or 50 mg/ml zym. IL-8 and IL-6 mRNA expression was 
then  assessed  by  real-time  RT-PCR,  using  GAPDH  to  assess  relative 
expression. A) TTO and T4-ol treatment of the cells did not induce IL-8, while   
IL-6 expression was increased moderately (p>0.05). 50 mg/ml zym produced a 
40-fold induction of both IL-6 and IL-8. Following TTO and T4-ol treatment, zym-
stimulated cells showed a similar level of IL-8 induction to that of the untreated 
zym control. IL-6 induction was slightly raised from that of the untreated controls 
for both TTO and T-4-ol, but not significantly (p>0.05). B) Pre-treatment with TTO 
or T4-ol had no significant effect on gene expression of either cytokine at 24 h 
(p>0.05),  although  induction  levels  were  less  reproducible  at  this  time-point, 
particularly  for  zym-treated  cells.  Data  shown  represent  two  independent 
experiments (or three for 4 h zym), the mean of which is indicated by a horizontal 
bar. Each point represents the mean from PCR duplicates.  
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6.4 Quantitative protein analysis of cytokines from OKF6-TERT2 cells 
after a short exposure to TTO or T4-ol revealed no significant effect  
 
The previous experiments suggest that exposure to non-cytotoxic concentrations 
of TTO or T4-ol does not significantly influence cytokine mRNA expression. To 
further  investigate  potential  effects  of TTO  or  T4-ol  on  epithelial  cell  function, 
analysis  of  supernatants  was  performed  to  measure  changes  in  extracellular 
protein  concentrations following  exposure  to  various  treatments. The following 
sections present results from the two types of protein assay used in this study. 
 
6.4.1 Cytokine Array  
 
The quantitative PCR focussed on IL-6 / IL-8 gene expression. Levels of proteins 
released by cells are more biologically relevant than levels of gene expression. In 
addition, the inflammatory response is a very complex process involving many 
interacting molecules. It is therefore critically important to have an indication of 
changes in this immuno-modulatory mixture. Frozen supernatants from epithelial 
cell experiments described in section 6.3 were analysed using the cytokine array 
procedure (Section 2.4.1). This is a very useful way to simultaneously look at the 
relative levels of different cytokines within a sample, avoiding multiple PCR or 
ELISA assays.   
 
6.4.2 Effects of zymosan A on extracellular cytokine levels 
 
OKF6-TERT2  cells  were  grown  in  defined-KSFM  overnight  in  12-well  dishes 
(Section 2.2.6), then treated for 4 or 24 h with 0 or 50 µg/ml zym in defined-
KSFM.  Supernatants  were  harvested  and  frozen  at  -80
0C.  1  ml  of  each 
supernatant  was  incubated  with  a  cytokine  array  membrane  as  described  in 
Section  2.4.1.  Processed  membranes  were  exposed  to  X-ray  film  and  the 
resultant images analysed using Quantity One software (Biorad). This allowed 
comparison of 36 cytokines in zym-treated versus untreated cells (Figure 6.4),                                                           Chapter 6: Immunomodulatory effects of TTO 
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showing  results  from  two  independent  experiments.  Few  cytokines  were 
detectable in untreated cells, with only serpin peptidase inhibitor clade E (serpin 
E1) giving a signal in both experiments, while 2 additional proteins were detected 
in experiment 2: macrophage migration inhibitory factor (MIF) and the growth-
regulated oncogene CXCL1 (GRO-α). Four-hour zymosan treatment resulted in 
increases  in  several  cytokines,  most  notably  the  pro-inflammatory  interleukins   
IL-6 and IL-8. Interestingly, after 4 h zym-stimulation only four of the 36 proteins 
were  detected  in  experiment  1,  while  seven  were  detected  in  the  second 
experiment, i.e. most proteins being assayed for were below detectable levels. 
The array kit manufacturer claims that sensitivity of this assay is equivalent to 
Western blotting and similar to ELISA assays, although sensitivity may vary for 
the different array proteins. ELISA experiments indicated that 4 h untreated cell 
supernatants had mean IL-8 concentration of approximately 400 pg/ml (Figure 
6.8). The weak IL-8 array signal from this supernatant indicates the sensitivity of 
the array is close to 400 pg/ml, as signal was not always present in untreated cell 
supernatant. 
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Figure  6.4:  Cytokine  profiles  of  OKF6-TERT2  cell  supernatants  after  4  h 
treatment  with  A)  control  -  no  zym,  and  B)  50  µg/ml  zym  (1  and  2  are 
independent experiments). In A1 only serpin E1 gave a signal, while in A2 MIF, 
GRO  α  and  serpin  E1  were  present.  4  h  zym  treatment  (B1/B2)  produced 
increases  in  several  cytokines,  most  notably  the  pro-inflammatory  interleukins   
IL-6 and IL-8. IL-1 receptor antagonist (IL-1 ra) and colony stimulating factor 3 
(G-CSF) were also detected in B2. 
 
 
6.4.3 Effects of TTO and T4-ol on extracellular cytokine levels 
 
OKF6-TERT2 cells were plated in a 12-well cell culture dish, grown overnight, 
then treated for 2 min with 400 ml TTO, T4-ol  (both 0.125% solutions in defined-
KSFMT) or control media (defined-KSFMT), before incubation in defined-KSFM 
with or without zym for 4 and 24 h, as described in Section 2.2.6. Supernatants 
were harvested and frozen at -80
oC for later analysis using a proteome profiler 
array (R & D Systems) to detect a range of cytokines (Section 2.4.1). Images of 
array membranes are shown in Figures 6.5 (4 h) and 6.6 (24 h). Density was 
analysed for each pair of spots using Quantity One software (Biorad), and mean 
induction from control cells calculated for IL-6 and IL-8, as shown in Figure 6.7.         
  A1  A2 
B2    B1 
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In the first  4  h  array  experiment  (Figure  6.5A), five  proteins  were  detected  in 
control cell supernatant (i), namely serpin E1, MIF, GRO-α, with weak signals for 
IL-6  and  IL-8.  ELISA  data  from  these  experiments  indicated  that  IL-8 
concentration  in  untreated  control  cells  was  approximately  400  pg/ml  (Figure 
6.8), so the weak IL-8 signal described above suggests that this concentration is 
close to the limit of sensitivity for the array. TTO pre-treatment produced slight 
increases in IL-6, IL-8 and MIF, with little difference in GRO-α at 4 h (Figure 6.5A 
ii). Zym-induced cell supernatant (Figure 6.5A iv) had much higher levels of IL-6 
and  IL-8,  increased  MIF  and  GRO-α,  and  also  signals  for  G-CSF  (colony 
stimulating  factor-3),  IL-1ra,  IL-1α  and  IL-13.  TTO  pre-treated  cells  with  zym 
induction (Figure 6.5A iii) gave very similar array profile to zym treated panel. In 
experiment  2  (Figure  6.5B),  only  serpin  E1  was  detected  in  control  cell 
supernatant  (Figure  6.5B  i).  T4-ol  pre-treatment  produced  a  slight  increase  in 
serpin E1, with GRO-α also detected, but no IL-6 or IL-8 was detected at 4 h 
(Figure 6.5B ii), in contrast to TTO result above. Zym-induced cell supernatant 
(Figure 6.5B iv) had high levels of IL-6 and IL-8, increased serpin E1 and GRO-α, 
but  no  other  proteins  were  detected  at  4  h.  T4-ol  pre-treated  cells  with  zym 
induction (Figure 6.5B iii) gave similar array profile to zym-treated panel (Figure 
6.5B iv), but with increased IL-8, GRO-α, and detectable levels of MIF and G-
CSF.  
 
At 24 h (Figure 6.6), only serpin E1 and GRO-α gave a signal in untreated control 
cells (6.6A i). T4-ol pre-treatment had little effect (Figure 6.5A ii), while TTO pre-
treatment (Figure 6.6A iii) increased IL-6, IL-8 (Figures 6.7C, 6.7D) and MIF to 
detectable levels. Zym treatment (Figure 6.6B i) resulted in high levels of pro-
inflammatory IL-6 and IL-8 (Figures 6.7C, 6.7D) increases in serpin E1 and GRO-
α, and also detectable levels of MIF and G-CSF. T4-ol treatment prior to 24 h 
zym  incubation  (Figures  6.6B  ii,  6.7C)  produced  reductions  in  all  proteins 
detected in zym panel (Figure 6.6B i), with MIF and G-CSF no longer detectable.                                                           Chapter 6: Immunomodulatory effects of TTO 
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In contrast, TTO pre-treated cells (Figures 6.6B iii, 6.7C, 6.7D) showed possible 
increases in all the zym-induced proteins seen in Figure 6.6B i, particularly IL-6, 
IL-8,  MIF  and  G-CSF.  The  changes  described  here  are  clearly  seen  in  the 
original X-ray films, although some weak signals are not clear in the scanned 
images shown in the figures.     
 
                
    A                  B           
Figure  6.5:  Digitised  images  from  X-ray  exposure  of  Proteome  profiler™ 
arrays  (4  h).  OKF6-TERT2  cells  were  treated  as  described  below  and 
supernatants harvested for membrane array analysis:  
6.5A i) Control cells, ii) 2 min TTO,  iii) 2 min TTO + 4 h zym,  iv) 4 h zym 
6.5B i) Control cells, ii) 2 min T4-ol, iii) 2 min T4-ol + 4 h zym,  iv) 4 h zym 
Control cells: no pre-treatment or zym. 0.125% TTO/T4-ol used in pre-treatment. 
Zym  used  at  50  mg/ml  in  defined-KSFM.  Experiments  on  2  panels  used 
independent cell preparations, as reflected in different control array profiles (i). 
TTO  induced  IL-6  and  IL-8  (A  ii),  but  much  less  than  zym  (A  iv)  which  also 
produced detectable levels of several other proteins. TTO had no visible effect on 
zymosan induction profile. T4-ol pre-treatment increased serpin E1 and GRO-α 
(B ii), and also increased zym induction of IL-8, GRO-α, MIF and G-CSF (B iii). 
The strong signals at 3 corners are positive controls. 
 
i 
ii 
   iii 
 iv                                                           Chapter 6: Immunomodulatory effects of TTO 
   
                                                                                                        
   
  132 
 
 
                         
                
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
                                            
 
                                        A                                          B 
 
 
Figure  6.6:  Digitised  images  from  X-ray  exposure  of  Proteome 
profiler™ arrays (24 h).  
Cytokine profiles of OKF6-TERT2 cell supernatants after 24 h treatment with :  
A) no zym and B) 50 µg/ml zym (both in defined-KSFM), following 2 min pre-
treatment  with  (i)  control,  only  KSFMT,  (ii)  T4-ol,  (iii)  TTO  (both  0.125%  in 
defined-KSFMT).  
Serpin E1 and GRO-α gave a signal in untreated control cells (A i), T4-ol pre-
treatment  had  little  effect  (A  ii)  in  contrast  to  TTO  treatment  (A  iii),  which 
increased  IL-6,  IL-8  and  MIF  to  detectable  levels.  24  h  zym  treatment  (B  i) 
produced increases in both proteins seen in A i, but also resulted in high levels of 
IL-6 and IL-8, as well as smaller amounts of MIF and G-CSF. T4-ol treatment 
prior  to  24  h  zym  incubation  (B  ii)  produced  some  reduction  in  all  proteins 
detected in B i, with MIF and G-CSF no longer detectable. In contrast, TTO pre-
treated  cells  (B  iii)  had  possible  increases  in  all  the  proteins  seen  in  B  i, 
particularly IL-6, IL-8, MIF and G-CSF. 
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Figure 6.7: Change in spot density of A) IL-6,  B) IL-8 (both 4 h), C) IL-6 and  
D)  IL-8  (both  24  h),  after  2  min  pre-treatment  with  0.125  %  TTO  /  T4-ol, 
followed by 0 or 50 µg/ml zym.  
At 4 h (A and B), zym produced a marked increase in both cytokines (IL-6: 26 
fold, IL-8: 90 fold), while TTO alone produced small increases (IL-6: 2 fold, IL-8: 
3.3 fold). TTO pre-treatment had little effect on zym induction. IL-6 and IL-8 in T4-
ol pre-treated zym-treated cell supernatant was similar to zym control, but neither 
cytokine was detected in ‘no zym’ control, so induction could not be quantified.  
At 24 h (C and D), zym produced a strong increase in both cytokines (IL-6: 16 
fold, IL-8: 11 fold), TTO also produced an increase in both (IL-6: 4 fold, IL-8: 3.2 
fold), while T4-ol had little effect. TTO pre-treatment seemed to slightly increase 
zym induction of IL-6 and IL-8, while the effect of zym on both cytokines was 
slightly reduced by T4-ol pre-treatment. 
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6.4.4 ELISA: IL-8 level in supernatant not significantly affected by TTO 
An  ELISA  assay  was  performed  to  more  accurately  quantify  changes  in 
extracellular IL-8 protein seen in array experiments on treated cells. To establish 
a dose response, OKF6-TERT2 cells were grown overnight, treated for 2 min with 
TTO,  T4-ol  (both  0.125%  solutions  in  defined-KSFMT)  or  defined-KSFMT  for 
controls, then incubated in 0, 10 or 50 mg/ml zym in defined-KSFM for 4 h before 
harvesting supernatants (Sections 2.2.6 and 2.4.2), which were frozen at -80ºC 
then analysed by IL-8 ELISA (Section 2.4.2). The sensitivity of the IL-8 ELISA 
assay  was  found  to  be  approximately  60  pg/ml.  The  supernatants  from  cells 
treated with 0 and 50 mg/ml zym were the same as those used in the cytokine 
arrays  described  in  the  previous  section.  These  experiments  measured  IL-8 
produced by cells and released into supernatant within 4 hours of treatments. 
Figure 6.8 shows combined data from 3 independent experiments.  
 
Mean concentrations of IL-8 in supernatants from both TTO and T4-ol pre-treated 
cells were 400 pg/ml, not significantly different from untreated cells. TTO pre-
treatment had no effect on IL-8 production by cells exposed to 10 µg/ml zym, 
while T4-ol pre-treatment resulted in a reduction from 877 to 662 pg/ml. TTO pre-
treatment had a small inhibitory effect on IL-8 production from cells exposed to 
50  mg/ml  zym,  while  T4-ol  pre-treatment  resulted  in  a  reduction from  1621  to 
1095  pg/ml.  This  suppression  of  zym-induced  IL-8  protein  levels  by  T4-ol 
pretreatment  was  not  significant,  due  to  excessive  experimental  variation,  i.e.  
T4-ol had strong inhibitory effect on IL-8 production in one experiment, but this 
effect  was  much  reduced  in  the  other  experiments  (Unpaired  t-tests  were 
performed on individual experiments at each zym dose, comparing control with 
TTO or T4-ol. One experiment gave significant p values for control versus T4-ol 
[no zym: p=0.0122, 10 zym: p=0.0037, 50 zym: p<0.0001], but no difference was 
seen in other experiments, or for TTO treatment). However, the trend indicates a                                                           Chapter 6: Immunomodulatory effects of TTO 
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possible T4-ol inhibition of IL-8, an important inflammatory cytokine, which merits 
further investigation.  
 
 
       No zymosan     zym (10µg/ml)    zym (50µg/ml) 
 
 
Figure 6.8: Mean zymosan dose response of OKF6-TERT2 cells pre-treated 
for 2 min with defined-KSFMT, 0.125% TTO or 0.125% T4-ol. Each experiment 
was performed on quadruplicate wells, on 3 independent cell preparations (n=3). 
Columns represent mean IL-8 concentration from 3 experiments, with error bars 
showing  standard  error  of  mean.  4  h  zym  treatment  increased  IL-8  in  the 
supernatant  in  a  dose-dependent  manner  at  the  concentrations  tested.  Pre-
treatment of cells with TTO or T4-ol at 0.125% had no significant effect on IL-8 
levels in the supernatant at all zym doses shown (p>0.05). Statistical analysis 
using  one-way  ANOVA  was  performed  to  compare  all  treatments  to  controls, 
followed  by  Bonferroni's  correction  for  multiple  comparisons,  to  compare  all 
columns, to identify significantly different treatments. 
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6.5 Summary and Discussion  
The data presented in this chapter suggest minimal, if any, immuno-modulatory 
effects  of  TTO  or  T4-ol  on  oral  epithelial  cells  stimulated  with  zymosan,  and 
highlight the importance of controlling for cytotoxicity when investigating immuno-
modulatory effects. As with any in vitro study there are a number of caveats with 
this conclusion. There were some variability problems between experiments for 
TTO-treated  cells,  with  one  experiment  showing  no  change  while  the  repeat 
experiment gave a 4-fold induction in IL-6 expression at 4 h. Reproducibility was 
good for T4-ol treated cells, but less reliable for TTO treatments at both 4 and   
24 h. Any cell lines may show variation in response, therefore experiments were 
repeated independently. Experimental variability in zymosan induction could be 
due to differences in the health of the cells at the time of exposure. In addition, 
the TTO and T4-ol are poorly soluble and the complex mixture of molecules in 
TTO could lead to unequal final concentrations arising in different experiments, 
although this was minimised by thoroughly vortex mixing all dilutions immediately 
before  use.  Small  inaccuracies  in  treatment  solutions  combined  with  slight 
changes  in  cell  health  may  therefore  result  in  significant  changes  in  cell 
responses  to  treatment.  Adequate  repeats  of  independent  experiments  were 
carried out to provide a good estimation of the effects of TTO and T4-ol.  
 
Zymosan stimulation of an epithelial cell line provides an in vitro model system of 
candidal infection. However, it is possible that this model is too crude to detect 
subtle changes in cell function, thereby masking any immuno-modulatory effects 
of  TTO  or  T4-ol.  More  complex,  3-dimensional  tissue  culture  models  are 
commercially  available,  which  combine  fibroblasts  and  epithelial  cells  in  a 
collagen matrix (Dongari-Bagtzoglou & Kashleva, 2006; Klausner et al., 2007). 
Although  these  are  histologically  reminiscent  of  oral  mucosa,  there  is  limited 
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cell mono-layers. However, it is possible that such a system may reveal more 
subtle effects of TTO / T4-ol. In addition, zymosan stimulation mimics only part of 
the challenge of a candidal biofilm, and an ideal in vitro model would arguably 
combine  a  more  complex  host  cell  structure  with  a  more  realistic  pathogen 
challenge. These experiments were, however, outwith the scope of the current 
studies.  
 
Although there were no statistically significant differences following TTO or T4-ol 
exposure,  there  was  a  small  reduction  in  cytokine  production  following  T4-ol 
exposure. It could be speculated that this may be due to membrane / lipid raft 
disruption, which has previously been described as an antimicrobial mechanism 
of TTO (Hammer et al., 2004). However, further investigation would be required 
to validate this suggestion.  
 
Finally,  the  in  vivo  immune  response  of  oral  cells  to  TTO  exposure  is  also 
influenced by the immuno-competence of the OPC patient. Many OPC infections 
are in immuno-compromised individuals, including newborns with an immature 
immune system, AIDS / cancer patients with damaged immune responses, and 
the elderly population. All these individuals will respond to Candida infection in 
different ways, including variable inflammatory responses. Therefore, it is unwise 
to predict a possible TTO / T4-ol treatment effect from experiments performed on 
‘normal’ cells. Any in vitro anti-inflammatory effect would require a careful clinical 
study to be undertaken to confirm if this had potential benefits for symptom relief 
in particular patient groups.  
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The three major aims of this study were to examine the beneficial properties of 
tea  tree  oil  (TTO)  and  its  derivatives,  particularly  their  antifungal  effects  and 
potential anti-biofilm properties, to investigate any detrimental effects on human 
cells  (cytotoxicity),  and  finally  to  improve  understanding  of  possible  immuno-
modulatory effects of TTO components (which may or may not be beneficial). In 
this study it  was shown that terpinen-4-ol (T4-ol) was the most effective TTO 
component  against  C.  albicans,  both  for  free-floating  planktonic  and  sessile 
biofilm cells.  Concentrations  of  0.25% T4-ol  /  1% TTO  were  toxic  to  Candida 
albicans biofilms, but were also cytotoxic to epithelial cells. A lower concentration 
of 0.125% T4-ol was able to inhibit biofilm growth (although was not toxic to pre-
formed biofilms). These lower concentrations were found to be non-cytotoxic to 
epithelial cells and demonstrated a slight, although statistically insignificant trend 
to  down-regulate  the  pro-inflammatory  chemokine,  IL-8.  Cytotoxicity  can  be 
assessed  using  standard  methods,  such  as  ISO  10993-5:  2009  (ISO,  2009), 
which  recommends  particular  cell  lines  and  quantitative  assays,  including  the 
XTT assay used in this study. Human oral cells were used in this study to make 
the results relevant to oral candidosis. One purpose of the cytotoxic studies was 
to allow selection of TTO and component concentrations that would not kill cells 
in the immunomodulation studies, using 2 min exposures. The cytotoxicity results 
are  also  useful  for  assessing  the  antifungal  inhibition  in  relation  to  potential 
patient  side-effects.  Biocompatibility  indexes  can  be  calculated  for  potential 
antiseptics, using antimicrobial potency and cytotoxic activity, in an attempt to 
evaluate agents for clinical usefulness (Muller & Kramer, 2008). The relatively 
long  exposure  times  used  in  most  of  the  antifungal  tests  compared  with  two 
minute exposures of human cells also has to be considered. Biofilm formation 
was inhibited using overnight 0.125% TTO / T4-ol exposures; shorter exposures 
required higher concentrations. A useful additional experiment would be to test 
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0.125%  TTO  /  T4-ol  for  longer  (1  or  more  hours  instead  of  2  min).  The  ISO 
method would be important when legal authorisation for clinical use was required. 
Mouthwashes and toothpastes are classed as cosmetics (EC1223/2009, updated 
version of EC Cosmetics Directive 76/768/EEC), not medicines, and so do not 
require  as  strict  safety  regulations,  or  strong  evidence  of  effectiveness  as 
antifungal  drugs.  This  is  partly  why  there  are  numerous  oral  products  on  the 
market  with  essential  oils,  such  as  TTO,  which  have  inconclusive  efficacy. 
Studies such as this aim to provide scientific evidence to aid better selection of 
appropriate products with proven active ingredients. 
 
The widespread use of azole anti-mycotics has been a driving force behind the 
development of resistance, including point mutations in the ERG genes and up-
regulation  of  efflux  pumps  (Niimi  et  al.,  2010;  Sanglard  &  Odds,  2002). 
Furthermore,  azoles  have  been  reported  to  have  little  effect  against  intact 
biofilms, both phenotypically and genotypically (Kuhn et al., 2002b; Vediyappan 
et al., 2010). Management of oropharyngeal candidosis (OPC) with commercially 
available  mouthwashes  offers  an  alternative,  reducing  both  the  frequency  of 
clinical resistance to azoles and the antimycotic cost burden to health providers. 
These mouthwashes are highly active against planktonic cells (Balbuena et al., 
1998; Jenkins et al., 1994a) that are likely to be present in saliva and contribute 
to colonisation and subsequent biofilm formation. These active components in 
the  commercially  available  mouthwashes  have  broad-spectrum  antimicrobial 
activity through membrane disruption (Hugo & Longworth, 1966; Russell, 1986) 
which, unlike the azoles and polyenes, is not related to cell membrane ergosterol, 
resistance  and  toxicity  (White,  1997).  Defined,  purified  components  of  these 
mouthwashes  were  not  available  to  the  current  study;  therefore  direct 
comparisons with TTO and T4-ol could not be made. Moreover, compounds such 
as  chlorhexidine  demonstrate  substantivity  by  adsorbing  to  protein  and                                                                                 Chapter 7: General Discussion 
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extracellular material, which can be improved by duration of exposure (Bonesvoll,  
et al., 1974; Jenkins et al., 1994b; Tomas et al., 2009; Tomas et al., 2010). This 
increases the antimicrobial effect of CHX, but potentially can also increase the 
risk  of  cytotoxic  /  irritant  effects.  It  is  therefore  difficult  to  compare  in  vitro 
antifungal activity of TTO with CHX and link this to a clinical effect in the oral 
environment. 
 
There are however detrimental aspects to over-the-counter (OTC) mouthwashes, 
such as bad taste, enamel staining, burning sensation and, more controversially, 
the high alcohol content which has been implicated in oral cancer (McCullough & 
Farah, 2008; Weaver et al., 1979). As a result, alternatives such as TTO have 
attracted  some  attention,  as  these  compounds  may  be  a  more  desirable 
alternative to prescription anti-mycotics for the management of OPC. 
 
With regard to alcohol mouthrinses, a recent review found that 8 epidemiological 
studies had been done in the past 25 years and no link between oral cancer and 
use of alcohol-containing mouthrinses was found (Lewis & Murray, 2006). Certain 
mouthrinses have high ethanol content (McCullough & Farah, 2008), particularly 
some  Listerine™  brand  products  (>20%  alcohol),  and  it  could  be  argued  that 
these should not be used long-term, particularly in smokers and heavy drinkers 
who have been shown to be at a 50-fold increased risk of developing oral cancer 
(Castellsague  et  al.,  2004).  The  data  from  the  McCullough  study  and  other 
studies over a number of years are open to debate (Conway, 2009; La Vecchia, 
2009).  The  combination  of  short  exposure  times  with  mouthrinse,  and  the 
influence of saliva in flushing away any residual alcohol would indicate that the 
risks  involved  are  probably  low  (Ciancio,  2009;  Smigel,  1991).  However,  the 
British  Dental  Journal  advised  that  dentists  should  inform  patients  of  the               
‘  hypothetical  risk  for  the  development  of  oral  cancer  from  repeated  use  of 
alcohol  containing  mouthwashes  ’  (Werner  &  Seymour,  2009).  To  counteract                                                                                 Chapter 7: General Discussion 
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these  potential  problems,  essential  oils  such  as  thymol  and  TTO  have  been 
proposed to have anti-cancerous properties. For example, TTO and T4-ol have 
been shown to induce cell cycle arrest in aggressive tumour cells, by increasing 
apoptosis and inducing necrotic cell death (Calcabrini et al., 2004; Greay et al.,  
2010; Medina-Holguin et al., 2008).   
 
OPC  results  from  overgrowth  of  Candida  spp.  as  biofilms  on  hard  and  soft 
tissues, such as oral epithelial surfaces, or artificial denture surfaces. Protection 
within the biofilm is a major factor in failure of conventional antiseptics found in 
mouthwashes  and  denture  cleansers  (Ramage  et  al.,  2009).  It  was  recently 
reported by our group that whilst denture cleansers exhibit effective anti-biofilm 
activity, both in terms of removal and disinfection, residual biofilm retention could 
lead  to  regrowth  and  denture  colonization  (Jose  et  al.,  2010).  The  paper 
concluded that alternative mechanical disruptive methods may be an appropriate 
mechanism to enhance biofilm removal. However, are other chemotherapeutic 
approaches available? In vitro studies have demonstrated that TTO has broad 
antimicrobial effects and because of this it may have the potential for controlling 
overgrowth of detrimental oral bacteria and fungi (Bagg et al., 2006; Hammer et 
al., 2003b). Mouthwashes and denture-cleansers containing TTO are currently 
available, with TTO concentration of approximately 0.2%  As the purpose of this 
study  was  to  compare  TTO  with  its  derivatives,  defined  compounds  were 
required. The OTC mouthwashes and denture cleaners contain TTO of undefined 
composition and a wide variation in other ingredients therefore excluding their 
use in the current study. Moreover, evidence to support the use of TTO or its 
derivatives  is  lacking  and  an  initially  reductionist  approach  was  required  to 
elucidate  their  effects.  The  complexity  of  the  oils  chemical  composition  and 
requirement for oil extraction from plants grown in native conditions has limited its 
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and  limitations  with  growth  conditions  has  restricted  its  widespread  use  to  its 
native Australia.  
 
As man-made antiseptics and drugs are often toxic, expensive, and can create 
resistance problems, there is much interest in natural alternatives (Edris, 2007). 
Plant essential oils are complex mixtures of aromatic chemicals which have been 
used for centuries in medicine and cooking. However, further research is required 
to understand the mode of action and safety profiles of TTO before it is fully 
accepted as drug (SCCP, 2004; SCCP, 2008).  
 
Cell toxicity of TTO and T4-ol was dose-dependent. This has the potential to be 
minimised,  as  bioactive  molecules  derived  from  natural  sources  can  be 
synthesised  as  exogenous  molecules  or  adapted  from  their  current  form  to 
improve  activity,  availability,  reduce  costs,  and  reduce  side-effects.  TTO  is  a 
complex  mixture  of  molecules,  which  limits  the  potential  for  modification. 
However, the data from this study demonstrated that T4-ol was the most potent 
and abundant molecule of those tested, which would make modification and/or 
derivatisation an attractive option. Given that T4-ol possesses a hydroxyl group, 
which is one likely source of its antimicrobial action, then this would provide a 
starting  point  for  the  engineering  of  a  new  antimicrobial.  In  nature  it  is  a 
ubiquitous  molecule  found  in  a  wide  variety  of  plants,  including  oranges, 
origanum, the New Zealand lemonwood tree, Japanese cedar and black pepper 
(Camp,  2004).  Therefore,  presumably  T4-ol  functions  as  an  ancient  innate 
antimicrobial  molecule  within  the  plants  defences  to  protect  against  microbial 
infection, thus supporting rationale for its further study and development. T4-ol 
has been shown to control C. albicans vaginal infections in rats (Mondello et al., 
2006). 
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Another natural plant product currently being investigated for denture stomatitis 
treatment is propolis gel, which is extracted from bee honey (Santos et al., 2008). 
Propolis is a complex mixture of chemicals including terpenes, and like TTO it 
has reported antifungal and anti-inflammatory properties (Borrelli et al., 2002; Ota 
et al., 2001), giving it the potential as an agent against candidosis. Similarly, plant 
extracts  from  chewing  sticks  used  in  African  (More  et  al.,  2008),  Muslim  (al-
Otaibi,  2004),  and  Indian  traditional  medicine  (Prashant  et  al.,  2007)  have 
recently been investigated for antimicrobial activity against oral micro-organisms. 
For the African plants, several extracts were shown to be anti-bacterial, but these 
did not inhibit C. albicans. In contrast, clinical studies found that miswak extract 
could inhibit C. albicans (al-Bagieh et al., 1994) and also the periodontal bacterial 
pathogen  Actinobacillus  actinomycetemcomitans  (al-Otaibi,  2004),  resulting  in 
plaque and gingival index reduction compared to tooth-brushing. Prashant et al. 
found that extracts from neem tree twigs could inhibit growth of oral streptococci. 
A recent review of the herbal medicine literature concluded that evidence from 
controlled clinical studies for the antifungal efficacy of plant extracts is generally 
weak, although ‘the most thoroughly clinically tested is tea tree oil, which holds 
some promise’ (Martin & Ernst, 2004). In fact, the earlier work by our group also 
suggested a potential role for TTO in candidosis management, but the lack of any 
clear  anti-biofilm  work  remained  a  concern  (Bagg  et  al.,  2006),  as  biofilm 
resistance has been reported to be a crucial obstacle to the successful control of 
these infections (Seneviratne et al., 2008). 
The treatment of biofilms always remains problematic, and this was no different in 
this study. This study focussed on C. albicans isolates, as it is the main OPC 
pathogen and it forms biofilms more readily than many other Candida spp. This is 
also  seen  in  vitro,  where  C.  glabrata  isolates  generally  do  not  form  biofilms. 
Therefore, C. albicans was the most appropriate species to use for investigating 
effects  of  TTO  and  components  on  yeast  biofilms.  Although  effective  biofilm                                                                                 Chapter 7: General Discussion 
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activity was demonstrated by T4-ol and TTO, toxicity was associated with these 
concentrations,  as  has  been  reported  elsewhere  (Hammer  et  al.,  2006; 
Soderberg et al., 1996). Therefore, an arm of this study was devised to evaluate 
what the impact of T4-ol and TTO was upon inhibition of C. albicans growth, 
morphogenesis  and  biofilm  formation.  Given  that  morphogenesis  is  pivotal  to     
C.  albicans  biofilm  formation  (Ramage  et  al.,  2002b),  preventing  hyphal 
development would potentially help in the management of oral candidosis. In line 
with other TTO studies (D'Auria et al., 2001; Hammer et al., 2000), T4-ol at these 
non-toxic  concentrations  was  effective  at  inhibiting morphogenesis  and biofilm 
formation.  The  implications  of  this  are  that  T4-ol  has  the  potential  to  be 
incorporated within oral formulations of mouthwashes and toothpastes that would 
act as a preventative management strategy. However, it may be the case that the 
TTO mixture is a more effective treatment due to the different properties of the 
molecules in the mixture. In addition, development of microbial resistance to this 
mixture may be less likely than for an individual derivative. 
Little is known about how the T4-ol molecule interacts with salivary proteins and 
whether substantivity is relevant, as is the case with chlorhexidine (Tomas et al., 
2009).  It  was  shown  that  the  molecule  acted  in  a  time-dependant  manner, 
therefore, it may be that T4-ol may be more appropriate in relation to denture 
cleansers  that  have  a  longer  contact  time  with  the  denture  and  retained 
microorganisms. Moreover, it would be useful to investigate whether T4-ol could 
be incorporated within denture lining materials, PMMA [poly methyl methacrylate 
acrylic resin] or other dental materials, as has been previously investigated with 
other antimicrobial agents (Amin et al., 2009; Chandra et al., 2005; Douglas & 
Walker,  1973;  Tallury  et  al.,  2007;  Wilson  &  Wilson,  1993).  Preliminary 
experiments in this study showed that a 1 hour treatment of denture material with 
0.5%  T4-ol  could  inhibit  C.  albicans  morphogenesis  and  hence  block  biofilm 
formation. The widespread use of this compound as an oral chemotherapeutic is                                                                                 Chapter 7: General Discussion 
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of less concern than for azoles. This study showed that repeat TTO exposure, 
whilst  in  a  limited  time-frame  (10  exposures),  did  not  alter  the  sensitivity  of         
C.  albicans  to  TTO.  Furthermore,  in  this  limited  study  the  sensitivity  towards 
azoles and other antifungal agents was not altered over the same time-frame. 
Induced in vitro resistance to TTO has been reported in Staphylococcus aureus 
(Nelson, 2000), and reductions in TTO sensitivity and antibiotic sensitivities were 
also  detected  in  staphylococci  after  repeated  exposure  to  sub-lethal 
concentrations of TTO (McMahon et al., 2008). Antibiotic sensitivities reverted to 
normal when cells were sub-cultured in the absence of TTO, but TTO sensitivity 
remained lower. The stress of the TTO treatment may slow down cell growth and 
metabolism,  causing  reduced  activity  of  the  antimicrobial  agent,  or  upregulate 
efflux pumps to remove any drug molecules from the bacterial cells more rapidly. 
Hence, it is inadvisable to have widespread use of TTO or any other drug at 
ineffective levels, as there is the potential for selection of less-sensitive strains 
(McMahon et al., 2007). In contrast, it was demonstrated that induction of TTO 
resistance in C. albicans could not be achieved (Mondello et al., 2003). Further 
detailed studies using T4-ol opposed to TTO would have to be performed, but the 
preliminary evidence is positive.  
 
Combinations of chlorhexidine (CHX) with essential oils have been investigated 
as alternative mouthwashes (Filoche et al., 2005). Bacterial biofilm inhibition was 
achieved  using  lower  concentrations  of  chlorhexidine  when  cinnamon  oil, 
Leptospermum  morrisonii  oil,  manuka  oil  and  Listerine
®,  were  included  in  the 
treatment.  This  paper  suggested  that  CHX  had  a  bacteriostatic  effect  on 
Streptococcus  mutans  biofilms  at  the  concentrations  used.  Chlorhexidine  is 
thought to have bacteriostatic activity in vivo (Beighton et al., 1991); therefore 
use of a CHX / essential oil mixture may improve the bacteriocidal activity. Use of 
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and tissue irritation, while also preventing the potential selection and persistence 
of  bacteria  with  reduced  antibiotic  sensitivities  (Russell,  2002;  Russell,  2004). 
These lower concentrations may also provide opportunity for immunomodulation, 
as these non-toxic concentrations are likely to induce cellular responses without 
killing the oral cells. However, the evidence in  this study for the use of TTO-
based  oral  products  in  control  of  inflammation  is  inconclusive,  partly  due  to 
reproducibility  problems.  The  effect  of  TTO,  T4-ol  or  other  components  on 
epithelial cells may well be significantly anti-inflammatory, if these cells respond 
in a similar way to other in vitro cells (Brand et al., 2001; Caldefie-Chezet et al., 
2006;  Hart  et  al.,  2000).  TTO  may  reduce  inflammation  caused  by  invasive 
strains  of  C.  albicans,  but  it  remains  to  be  seen  whether  this  is  a  positive 
outcome, as the pathogen may continue to spread when unchecked by innate 
immune  factors  and  cause  more  serious  problems.  These  studies  were 
performed in cell culture conditions, so the translation of the data is limited. To 
improve  this  the  effects  of  TTO  on  cytokine  production  could  be  studied  in 
organotypic  cell  models,  which  are  more  representative  of  the  oral  mucosa 
(Dongari-Bagtzoglou & Kashleva, 2006).  
 
Convincing  evidence  for  the  immunomodulation  from TTO,  or  its  constituents, 
may strengthen the case for its use in many conditions, including eczema, burns 
and periodontal disease. It could well be the case that the complex combination 
of chemicals in the TTO affects multiple immuno-modulatory processes, and by 
only concentrating on a single molecule, like T4-ol, subtle effects may be missed. 
Further work is required on TTO and its components to determine their effects on 
immune  responses  and  the  overall  clinical  result  of  TTO-based  interventions. 
Nevertheless,  T4-ol  does  offer  potential  as  a  bioactive  molecule  that  merits 
further study.                                                                                                            
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Conclusion 
Candida  albicans  is  the  predominant  yeast  associated  with  oropharyngeal 
candidosis (OPC), characterised by formation of multispecies biofilms on the oral 
epithelium  or  artificial  denture  surfaces.  Current  antifungal  treatments  have 
limited success due to various resistance mechanisms and patient compliance 
issues,  with  recurring  infections  common.  Therefore,  alternative  methods  for 
suppressing or eradicating biofilms are desirable. The aims of this study were to 
evaluate the efficacy of tea tree oil (TTO) and key derivatives against biofilms 
formed by a diverse panel of clinical C. albicans isolates, and to assess their 
effects on a clinically relevant oral cell line, both in terms of their toxicological and 
immunomodulatory properties. TTO components have powerful activity against 
C. albicans biofilms, with terpinen-4-ol (T4-ol) and α-terpineol exhibiting greater 
anti-biofilm activity than TTO. TTO and T4-ol were significantly less toxic than 
chlorhexidine  at  therapeutic  levels.  TTO  did  not  exhibit  any  clear 
immunomodulatory  effect  at  non-toxic  levels,  whereas  T4-ol  showed  possible 
anti-inflammatory effects. The use of a single TTO component has advantages 
over the complete oil in terms of product safety and consistency. Therefore, T4-ol 
could be developed for use in both prophylactic oral hygiene products, such as 
mouthrinses  and  denture  cleansers,  and  as  a  novel  treatment  for  established 
OPC  infections,  as  it  has  potent  antifungal  activity  and  is  minimally  toxic. 
Preclinical and clinical trials of mouthwashes or denture cleansers, containing the 
range of T4-ol concentrations (0.125 - 0.5%) investigated in these studies would 
be required to validate the clinical use of such a product. Future work is required 
to determine if T4-ol has an anti-inflammatory effect in the oral environment, both 
in vitro and in vivo, and if so, whether this is beneficial to the patient. It is also 
important to investigate the potential for development of resistance to T4-ol after 
multiple exposures. Finally, more robust clinical studies are required to provide 
evidence for the use of TTO-based oral products.                                                                                                           Bibliography   
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Poster  Presentation:  Society  for  General  Microbiology,  Dublin, 
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Novel tea-tree oil based treatment of Candida biofilms. 
Steven  Milligan,  Shauna  Culshaw,  Jeremy  Bagg,  Petrina  Sweeney, 
Gordon  Ramage.  Section  of  Infection  and  Immunity,  Glasgow  Dental 
School, Faculty of Medicine, University of Glasgow, UK. 
 
Candida albicans is the predominant yeast associated with oropharyngeal 
candidosis  (OPC),  which  presents  clinically  as  thrush  or  denture 
stomatitis.  These  infections  are  characterised  by  multispecies  biofilms 
forming  on  the  oral  epithelium  or  artificial  denture  surfaces.  Current 
antifungal  treatments  have  limited  success  due  to  resistance,  with 
recurring  infections  common.  Therefore,  alternative  methods  for 
suppressing or eradicating biofilms are desirable. The aim of our study 
was  to  evaluate  the  efficacy  of  tea  tree  oil  (TTO)  and  key  derivatives 
against biofilms formed by 100 oral Candida albicans isolates. These were 
formed  in  microtitre  plates,  treated  with  individual  components  and  the 
fungicidal activity evaluated using a metabolic dye to evaluate killing. It 
was  shown  that  although  generic  TTO  was  effective  against  planktonic 
cells,  it  was  poorly  active  against  sessile cells  (MFC90  >2%).  However, 
terpinene-4-ol and α-terpineol exhibited anti-biofilm activity (MFC90 = 1%). 
In addition, lower concentrations (0.25%) of these two agents were able to 
inhibit filamentous growth. Overall, TTO-based mouthwashes may offer a 
suitable alternative to conventional azole treatment. 
 
                                                                                                  
 
   
   
 
 
 
                                                                                                  
 
   
   
 
Oral  Presentation:  British  Society  for  Dental  Research,  Glasgow, 
September 2009. 
 
Candidosis  Management:  Antifungal  and  Immuno-modulatory 
Properties of Tea tree oil. S. G. Milligan, G. Ramage, S. Culshaw,  M. P. 
Sweeney, J. Bagg. University of Glasgow Dental School, Glasgow, Scotland.    
 
Candida  albicans  is  the  predominant  yeast  associated  with  oropharyngeal 
candidosis  (OPC),  which  presents  clinically  as  thrush  or  denture  stomatitis. 
These infections are characterised by multispecies biofilms forming on the oral 
epithelium  or  artificial  denture  surfaces.  Current  antifungal  treatments  have 
limited success due to various resistance mechanisms, with recurring infections 
common. Therefore, alternative methods for suppressing or eradicating biofilms 
are desirable.  
 
Objectives: The aims of this study were to evaluate the effectiveness of tea tree 
oil  (TTO)  and  key  derivatives  against  biofilms  formed  by  a  panel  of  oral               
C.  albicans  isolates,  and  to  assess  the  cytotoxic  and  immuno-modulatory 
properties of TTO and its derivatives in a clinically relevant oral cell model.  
 
Methods:  Biofilms  were  formed  on  microtitre  plates  and  treated  with  various 
concentrations of individual TTO components. Fungicidal activity was evaluated 
using  the  metabolic  dye  XTT.  The  most  efficacious  components  were  then 
applied  to  a  human  oral  epithelial  cell  line  (OKF6-TERT)  and  the  toxicity 
evaluated  using  a  commercially  available  assay.  Cells  were  stimulated  with 
zymosan A (yeast cell wall polysaccharide) and treated with TTO components, 
and cytokine profiles analysed using a commercially available kit. Real-time PCR 
was also used to measure gene expression changes for selected cytokines.  
 
Results:  It was shown that terpinen-4-ol (T4-ol) and α-terpineol exhibited greater 
anti-biofilm  activity  (MFC90  =  0.5%)  than  TTO  (1%).  TTO  and  T4-ol  were 
significantly  less  toxic  than  chlorhexidine  at  therapeutic  levels.  TTO  reduced 
stimulatory effects of zymosan on pro-inflammatory cytokines.  
 
Conclusions:    TTO-derived  mouthwashes  may  offer  a  suitable  alternative  to 
conventional  azole  treatment,  as  they  exhibit  potent  antifungal  activity,  are 
minimally toxic and can modulate inflammatory mediators. 
 